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ABSTRACT
The majority of malaria-associated deaths occur in children less than 5 
years of age and severe malaria accounts for up to 90% of such deaths. We are 
interested in dissecting why some children develop either one of the severe 
malarial syndromes or the uncomplicated Malaria (UM). We studied a total of 
1,622 plasma and 519 DNA samples from our pediatric Nigerian cohort. By 
monitoring and comparing the differences in the plasma proteome in the UM group 
to each of the severe syndromes at both onset and through convalescence we 
found that congenitally low plasma Haptoglobin (Hp), low/stable plasma level of 
sCD163, sub-optimal plasma Hemopexin (HPx) level and low plasma clusterin 
(CLU) levels could be put forward as predictors of acute/insidious onset of severe 
malarial anaemia (SMA) and Cerebral Malaria (CM). We show that low plasma 
CLU is a very specific marker of CM at acute onset and propose a mechanism 
through which high CLU levels can protect from CM. We also propose that 
circulatory HPx level is useful as both diagnostic and prognostic biomarkers of 
severe malaria as its level varies among the severe malaria forms at acute onset 
and also increases sensitively with response to treatment in all the malaria groups.
We show that Hp phenotypes could be linked to the pathological differences 
that underlie the acute onset of UM, severe malaria and disease progression 
among subjects: Hp phenotypes seem to modulate response to malarial infection 
and might be responsible for contradictory reports on the pathophysiology of 
severe malaria. We also show for the first time that Hp gene sequence 
variants/deletions at sites in both the distal and proximal upstream region are 
significantly associated with protection from and susceptibility to malaria, whether 
or not they are associated with plasma Hp levels.
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CHAPTER ONE 
1.0 INTRODUCTION
1.1 The History of malaria
The scourge of malaria has co-existed with the human race since antiquity. 
A suspected malaria illness was reported in a Chinese document as early as 
2700BC and in an ancient Egyptian Papyri from about 1570BC (Cox, 2010). 
During the time of Hippocrates (460-370BC), malaria was known as paroxysms of 
fever, it was known to progress from chills to fever to sweats and then further 
exacerbation. Hippocrates trying to describe malaria symptoms said, “When 
paroxysms fall on even days, the crisis will be on even days; and when paroxysms 
fall on odd days, the crisis will be on odd days.... There may be relapse and it 
could be deadly” (Cunha and Cunha, 2008). From the ancient time, the 
incidence of malaria has been linked to poverty and poor environment such as 
marshy areas (Cox, 2010). However, the causative agent was unknown. Insight 
into the study of malaria began when Charles Louis Alphonse Laveran discovered 
the malaria parasite while working in Algeria in the year 1880 (Cox, 2010). 
Furthermore, Ronald Ross in 1897 discovered the mosquito as a vector for avian 
malaria and about the same time, other scientists also reported the mosquito as a 
vector for human malaria (Cox, 2010).
Malaria was thought to originally affect all continents except the Antarctic 
(Cox, 2010, Carter and Mendis, 2002). In 1955, the WHO launched a global 
eradication of malaria programme through the use of DDT and other insecticides 
that brought about total eradication of malaria in Europe and other developed 
countries in 1967 (Majori, 2012, Trigg and Kondrachine, 1998). This also brought 
about a significant eradication of malaria in Asia and Latin America. Unfortunately, 
Africa did not benefit from the campaign before it ended in 1969 (Majori, 2012, 
acentalNajera, 2001, Trigg and Kondrachine, 1998). Other subsequent control
23
measures adopted by the WHO have not been very effective. Hence, the scourge 
of malaria in sub-Saharan Africa remains very critical (Majori, 2012, Trigg and 
Kondrachine, 1998, Teklehaimanot and Mejia, 2008).
This scourge of malaria in sub-Saharan Africa remains unresolved due to 
absence of active surveillance; lack of improvement in the health services; lack of 
development in both urban and rural areas (Majori, 2012); antimalarial drug 
resistance (Talisuna et al., 2004, Ng et al., 2015); difficulty in access to research 
funding in recent years (Talisuna et al., 2015), funding often appearing out of tune 
with political statement (Najera, 2001); absence of an effective vaccine (Tran et 
al., 2015, Owens, 2015); inadequate parasite and vector-based studies (Talisuna 
et al., 2015, Stone et al., 2015); poverty (Ricci, 2012, Teklehaimanot and Mejia,
2008, Kaler, 2008, Sylvester and Ivan, 2006, Worrall et al., 2005, Kmietowicz, 
2000, 1992); lack of rapid and specific diagnosis (Singh et al., 2014, Okiro et al.,
2009, Drakeley and Reyburn, 2009); lack of proper legislation on drug production, 
distribution and usage (Lalani et al., 2015, Chaccour et al., 2015) and emerging 
resistance of the vector to insecticides (Mnzava et al., 2015, Lindblade et al., 
2015, Weetman and Donnelly, 2015).
Outside of Africa, wherever malaria is or has been endemic, the female 
mosquito vectors of malaria are reported to be zoophilic rather than anthropophilic 
(Carter and Mendis, 2002). This predilection of female anopheles mosquitoes to 
feed on humans might partly account for their selective advantage in the region 
(Carter and Mendis, 2002).
1.2 Malaria infection
Malaria illness is caused by Plasmodium species that infect the female 
Anopheles mosquito. The parasite is transmitted to the vertebrate host through 
this mosquito bite. Infection has also been reported through other means such as
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blood transfusion, organ transplant, sharing of blood contaminated sharp objects 
and even congenitally (McGuire et al., 1994). However, the most prevalent method 
of transmission is through the bite of an infected Anopheles mosquito.
The five species of Plasmodium (P) implicated in humans are, P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi (Kantele and Jokiranta, 
2010). The genus Plasmodium includes over 120 species with particular host 
restrictions and predilections to certain geographical locations. Severe cases in 
humans are largely caused by P. vivax and P. falciparum and are responsible for 
most of the infection in sub-Saharan Africa (Manning et al., 2011). Knowlesi 
malaria was originally recognized as the disease of the macaque monkey but has 
been reported to affect humans in Malaysia (Singh et al., 2004, Moon et al., 2013).
The most virulent of malaria parasites is P. falciparum. It causes most 
malaria-related death in humans. The infection is unique in that the parasites 
infected cell binds to the endothelium during the blood stage and can be 
sequestered in organs including the brain, liver and the placenta (Rogerson et al., 
2007). It is common in Africa, particularly in Nigeria (Olivar et al., 1991).
Unlike falciparum, P. vivax is not prevalent in Africa as the majority of 
Africans lack the duffy antigen on the surface of erythrocytes, a receptor for P. 
vivax (Carter and Mendis, 2002), but it is common in other tropical areas outside of 
Africa (Moon et al., 2013). Both P. vivax and ovale infection can be difficult to 
eradicate because of their ability to form hypnozoites that remain dormant in 
hepatocytes in the liver. On the other hand, P. malariae does not form hypnozoites 
but exhibits an asymptomatic blood stage that can persist for decades 
(Greenwood et al., 2008a).
The malaria parasite undergoes a multistage transformation in a complex 
life cycle (Fig. 1.1). The sporozoites are released into the host through the bite of a 
female Anopheles mosquito. These sporozoites head to hepatocytes about 45
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minutes after the bite and undergo asexual reproduction forming a schizont, 
containing numerous merozoites (Fig. 1.1). The hepatic or exoerythrocytic phase is 
largely without physical clinical manifestations or symptoms.
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Figure 1.1 Malaria parasite life cycle
The parasite life cycle is divided into 3 major phases, the exoerythrocytic cycle, the erythrocytic 
cycle and the sporogonic cycle as depicted. The entire life cycle is divided into 12 stages; 1. The 
mosquito injects sporozoites during blood meal; 2. The sporozoites migrate to the liver; 3.
Sporozoites form exoerythrocytic schizont; 4.The schizont ruptures releasing numerous 
merozoites; 5. The merozoites invade Red Blood Cells (RBCs) and develop through both immature 
and mature trophozoites to form erythrocytic schizonts. 6. The schizont ruptures releasing 
merozoites for continuous RBC destruction in the asexual erythrocytic phase; 7. Some merozoites 
form sexual gametocytes, which are picked up during mosquito blood meal and develop within the 
mosquito into 8. Exflagellated microgametocytes; 9. Macrogametocytes; 10. Ookinete; 11. Oocyst; 
and 12. Ruptured Oocyst releasing sporozoites, which are injected by the mosquito during blood 
meal. Source: adapted from blog; http://zitandraw.bloqspot.co.uk/2011/12/life-cycle-of-plasmodium-
vivax.html
The duration of the exoerythrocytic phase depends on the Plasmodium 
species; 6 days for P. falciparum, 8 days for P. vivax, 9 days for P. ovale, 8-9 days 
for P. knowlesi and 13-15 days for P. malariae (Vaughan et al., 2008). During the 
erythrocytic phase, the merozoites invade erythrocytes and develop through 
trophozoite and schizont phases in erythrocytes (Fig. 1.1). A small proportion of 
these asexual parasites do not undergo schizogony but differentiate into sexual 
stages, the male and female gametocytes (Fig. 1.1). Gametocytes are non- 
pathogenic but are important in the transfer of infection to another host through the 
bite of the vector (Fig. 1.1). The development to the gametocyte stage in P. vivax 
starts just after merozoites are released from hepatocytes and in P. falciparum it is
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at about 7 days at the peak of asexual erythrocytic schizogony (Pukrittayakamee 
etal., 2008, Miller etal., 2002).
The clinical symptoms observed in malaria start when the first generation of 
merozoites invades erythrocytes during the erythrocytic cycle. The rupture of the 
schizont to release merozoites also releases parasitic products that contribute to 
the cause of clinical symptoms. It is also at this stage that the complex network of 
inflammatory cytokines begins their action (McGuire et al., 1994, Autino et al., 
2012). The erythrocytic cycles occur every 24 hours in P. knowlesi, 48 hours in P. 
falciparum, P. vivax and P. ovale and 72 hour in P. malariae.
Successful parasitic invasion and survival requires a complex network of 
specialized proteins (Florens et al., 2002, Holder et al., 1994, Blackman et al., 
1990). Each stage is associated with changes in protein expression and metabolic 
pathways that enable Plasmodium to escape immune clearance (Florens et al., 
2002).
Malaria is usually associated with fever but also mimics a range of other 
illnesses. In areas where malaria is holoendemic, differential diagnosis of malaria 
is necessary to rule it out or confirm its presence due to overlapping symptoms 
with other diseases. Malaria usually mimics flu-like symptoms, gastroenteritis, 
typhoid fever, Pneumonia, meningitis, encephalitis and viral infection like hepatitis 
especially in children (McGuire et al., 1994, Schumacher and Spinelli, 2012). 
These similarities in symptoms are common to all malaria parasites but are mostly 
observed in P. falciparum malaria (Bartoloni and Zammarchi, 2012).
In Africa, there are challenges in differentiating malaria from endemic 
typhoid fever, particularly in areas without laboratory and trained microscopists. 
Osier, attempting to differentiate malaria from typhoid fever observed that despite 
the similarity between them such as chills, fever, headache and splenomegaly, 
malaria begins with multiple chills while typhoid fever begins with a single morning
27
chill and that chills do not characterize typhoid fever except for this initial one. 
Chills in malaria are accompanied by spiking fever followed by sweating, profound 
malaise and then complete recovery between attacks (Cunha and Cunha, 2008). 
However, these clinical observations have led to misdiagnosis and attempts to 
improve on it have been unsuccessful (Smith et al., 1994, Redd et al., 1992)
It was also observed that malaria fever is periodic depending on the length 
of the asexual cycle and synchronizes with the release of the erythrocytic schizont 
(McGuire et al., 1994, Cunha and Cunha, 2008). The time to the onset of 
symptoms or the detection of parasites in the blood depends on age, use of 
antimalarial prophylaxis, route of infection such as blood-induced infection during 
blood transfusion and host immunity. Strong immunity can suppress the onset of 
clinical symptoms; migrants from malaria holoendemic regions have been reported 
to have P. falciparum infection and remained asymptomatic for 2-8 years (Krajden 
et al., 1991, Greenwood et al., 2008b, Szmitko et al., 2009).
1.3 Epidemiology of malaria in sub-Saharan Africa, Nigeria.
Malaria is a global threat, particularly in Africa (Murray et al., 2014). Malaria 
is a major cause of ill health globally. Nearly half of the world population spanning 
108 countries is exposed to malaria. The global annual malaria associated death 
was reported to be more than a million from 2006 to 2012 (Birhanie, 2016, Chen et 
al., 2016, Schumacher and Spinelli, 2012, Srivastava et al., 2015), however, some 
have reported about 0.6-0.5 million deaths per year between 2013 to 2015 (Kang 
et al., 2016, Tan et al., 2016).
While progress seems to have been made on the global platform within the 
last decade, much still needs to be done in sub-Saharan Africa. About 80-90% of 
global malaria associated deaths occurs in the Sub-Saharan Africa (Tan et al., 
2016), hence not much progress seems to have been made in this region. More
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than 0.6 million children that are less than 5 years of age are reported to die from 
malaria in sub-Saharan Africa (Schumacher and Spinelli, 2012, Huang et al., 
2015) and this is mostly due to Severe Malaria Anemia (SMA) and Cerebral 
Malaria (CM), which account for about 90% of these deaths (Gunst et al., 1998, 
Delanghe et al., 1998b). SMA is the major cause of death particularly in children 
that are less than five years of age, pregnant women and the immune- 
compromised (Burte et al., 2013).
Malaria transmission is endemic and stable in Nigeria. A total of 110 million 
cases of malaria are clinically diagnosed per year in Nigeria (Han and Peng, 
2015). Others reported that malaria accounts for up to 60% of outpatient visit in 
Nigeria, with about 25-30% mortality in under 5 years of age (Singh et al., 2014). 
Children under the age of 5 in Nigeria can have up to four malaria attacks in a year 
(Singh et al., 2014). Malaria is the most common cause of hospital attendance in 
Nigeria with an estimated annual economic loss of over US$ 835 million from the 
cost of treatment and other malaria associated losses (Han and Peng, 2015). 
About 96-98% of malaria infections in Nigeria are caused by Plasmodium 
falciparum while infections due to Plasmodium malariae are rare and are as low as 
2-4% (Olivaretal., 1991).
While CM is the most common severe form of P. falciparum malaria in the 
northern part of Nigeria, SMA is more common in the south (Anumudu et al., 
2007). A six-year (2000-2005) review show that out of 16,031 children admitted at 
the University College Hospital (UCH), Ibadan showed that severe malaria cases 
constituted 11.3% with 89.1% being children less than 5 years old and CM 
accounted for 19.7% of all severe malaria cases. The yearly morbidity rate from 
severe malaria in Ibadan, Nigeria ranged from 8.7% to 13.2% with a significant 
continuous increase from 2000 to 2004 (Orimadegun et al., 2007).
The epidemiological factors that enhance the development of SMA in
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Nigerian children include lack of prompt response at the onset of the disease; 
misinterpretation of symptoms at onset; excessive use of home remedies; 
inappropriate use of drugs; fake drugs and non-adherence to antimalarial drug 
prescription refusal to attend hospital owing to tedious protocol and long waiting 
time; attendance at the hospital is only when symptoms seem to aggravate. This 
was particularly observed in the southern part of Nigeria where herbal home 
remedies for malaria are practiced widely and attendance at hospital is only when 
such home remedies have failed; (Anumudu et al., 2007).
CM is more prevalent in children between the age of 3 to 6 years while 
SMA is more prevalent in younger children of 0.6 to 2 years of age (Biemba et al., 
2000). Age is an important predisposing factor in the development of SMA (Imbert 
et al., 1997). However, the intensity of transmission was thought to influence the 
age at which severe malaria develops; the median age of 1, 3 and 5 years was 
observed in regions with high, moderate and low transmission, respectively.
Reports concerning the association of age and severe malaria 
manifestation are contradictory. While one study reported that age and intensity of 
transmission are both independent variables in severe malaria (Reyburn et al.,
2005), another group reported that increasing intensity of transmission caused a 
shift in the burden of CM but not SMA and respiratory distress towards a younger 
age (Roca-Feltrer et al., 2010). Plasma falciparum-specific antibody to malaria did 
not show any disparity in the different age groups (Erunkulu et al., 1992). The 
onset of CM is drastic and dramatic unlike the more mild and subtle onset of SMA. 
As a result, the appropriate management of SMA is often delayed and initially 
overlooked, and is a contributing factor to its prevalence.
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1.4 Clinical manifestation of malaria
Just the fever cycle in the presence of parasitaemia is commonly 
categorized as mild or uncomplicated malaria. However severe complications of 
malaria constitute anaemia, and in severe anaemia the indicated haemoglobin 
level is less than 5g/dl; convulsion; respiratory distress; hypoglycemia; 
haemoglobinuria; lactic acidosis; renal failure; hypotension; shock and jaundice. 
Most of these complications are manifest in Severe Malarial Anaemia (SMA), 
Severe Malaria (SEVM) and Cerebral Malaria (CM) (Trampuz et al., 2003, 
Njuguna and Newton, 2004, Okeyo et al., 2013).
1.41 Anaemia in malaria
Anaemia is one of the complications of malaria due to cycles of Red Blood 
Cell (RBC) destruction by the parasites. Lower levels of haemoglobin 
concentration in people living in tropical countries compared to those in temperate 
regions are mostly attributed to malaria. The intensity of anaemia is usually 
associated with parasite density (Everaert et al., 1998c). A haemoglobin 
concentration lower than the mean by two standard deviations (2 SD) when 
adjusted for age, sex and the state of an individual including pregnancy could be 
considered as anaemia (McGregor et al., 1966). Generally, a haemoglobin 
concentration less than 11-8g/dl is regarded as anaemia. Hb levels that are less 
than 8g/dl or a haematocrit of less than 24% have been reported in the presence 
of parasitaemia (Crawley, 2004). In severe cases of malaria, the haemoglobin 
concentration could be less that 5g/l or a haematocrit of 15% (Okeyo et al., 2013). 
The presence of parasitaemia is used to differentiate malarial anaemia from 
anaemia of other aetiology such as poor nutrition, haemoglobinopathies (Abdalla 
and Pasvol, 2004), and infectious diseases (Crawley, 2004).
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Anaemia in malaria, particularly P. falciparum malaria can occur even 
without obvious clinical symptoms in the patients (Kurtzhals et al., 1999). 
Haemoglobin concentration could be lower in a P. falciparum-infected 
asymptomatic individual by 1.0-2.0g/dl compared to healthy parasite-negative 
individuals. Pregnant women with asymptomatic malaria have recently been 
reported to have anaemia (Nega et al., 2015).
1.42 Parasite density and anaemia
The fall in haematocrit sometimes does not parallel the parasite biomass 
particularly during convalescence. The degree of anaemia is sometimes not equal 
to the severity of the infection. In acute intense infection, the Hb level might be 
normal despite high parasite biomass (White et al., 1992, Mackintosh et al., 2004). 
However, the discrepancy between Hb level and parasitaemia was suspected to 
be due to the sequestration of parasites in the microvasculature of vital organs. As 
a result, it was thought that the lower parasite levels in peripheral blood are not 
representative of the total body parasite biomass (White et al., 1992). As a result, 
it was suggested that the parasite biomass should only be computed by 
multiplying parasitaemia by blood volume only when sequestration is not 
suspected, as with benign malaria (White, 1997).
A more recent study has indicated that the accurate way of quantifying the 
total parasite biomass is to measure the P. falciparum Histidine Rich Protein 2 
(PfHRP2) (Karl et al., 2015); Higher sequestration index, total parasite burden but 
not circulating biomass have been reported to be associated high plasma PfHRP2 
(Huang et al., 2015, Karl et al., 2015).
The periodicity of both schizogony and merogony, which are characterized 
by the presence of numerous newly invaded ring forms could affect the number of 
circulating parasites in the peripheral blood (Sherman, 1998, White and Ho, 1992).
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Sequestration may not be suspected when mature parasites are predominant in 
the peripheral blood. Therefore, assessing the stage of parasite maturity on the 
slide during admission could also be an indicator of malaria severity (Silamut and 
White, 1993, Sherman, 1998). The removal of non-infected erythrocytes 
carrying parasite antigen (Balia et al., 1991, Molitor et al., 1991) could also explain 
the disparity between Hb level and parasite density. However in some individuals, 
the haematocrit can be normal at the peak of infection, as earlier mentioned 
(White et al., 1992, Mackintosh et al., 2004). Therefore, the mechanisms behind 
anaemia are poorly understood and raise many questions on the pathophysiology 
of SMA in particular.
1.43 Severe malaria anaemia (SMA)
SMA is defined as Hb concentration that is less than 5-6g/dl in the presence 
of the asexual form of the parasite, without any specified parasite density 
(Mackintosh et al., 2004, Cox et al., 2013, Okeyo et al., 2013). P. falciparum 
malaria is the major cause of SMA, but other studies have also implicated P. 
knowlesi and P. vivax (McGuire et al., 1994). However, P. falciparum has a higher 
mortality rate because the parasite has a predilection for erythrocytes of all ages 
unlike P. wVax and P. ovale (Weatherall and Abdalla, 1982). While 1 in 7 young 
red blood cells (RBCs) might be available for P. vivax, all RBC are equally 
susceptible to P. falciparum invasion (White et al., 1992).
Various possible mechanisms have been proposed to underlie the 
pathophysiology of SMA, but none of them has been properly studied due to the 
absence of appropriate models that could be used to dissect these mechanisms 
(Craig et al., 2012). A higher rate of erythrocyte destruction than the rate of 
erythrocyte production is thought to be a possible cause of SMA (Mackintosh et 
al., 2004). A proportion of Hb as high as 70% was thought to be digested by the
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parasite prior to their removal (Abdalla and Pasvol, 2004). The rigid membrane 
of parasitized RBC is also thought to enhance their clearance by the reticulo­
endothelial system (Poschl and Linderkamp, 1992, McCullough, 2014, Deng et al., 
2015). The spleen is very effective in removing rigid RBC as well as sequestration 
of the parasitized cells. Furthermore, a substantial amount of RBC are also 
removed by intravascular haemolysis (Weatherall and Abdalla, 1982).
The deposition of parasite proteins on surfaces of both infected and 
uninfected cells as a result of unsuccessful parasite invasion attempts causes 
complement mediated lysis or uptake by macrophages (Sterkers et al., 2007), an 
immune mediated erythrocyte destruction (Molitor et al., 1991).
The presence of IgG and complement factors on the surface of erythrocytes 
as detected by means of the direct Coombs test (DAT) is associated with 
macrophage activation and erythrophagocytosis (Goka et al., 2001). A high rate of 
positive DAT is known to occur in anemic patients (Jeje et al., 1983b, Facer et al., 
1979).
Immune mediated erythrocyte clearance is thought to account for 
continuous and partial erythrocyte removal after parasite clearance as sensitized 
erythrocytes are not immediately removed from the circulation (Facer et al., 1979).
Not all types of IgG on the infected erythrocyte surface can induce cell 
clearance. The presence of lgG1 and 3 is associated with higher haemolysis while 
lgG2 and 4 are associated with low-grade haemolysis (van der Meulen et al., 
1980, Stratton et al., 1983), however, the amount of IgG was not reported. Another 
study showed that there is no correlation between the level of IgG on the 
erythrocyte surface and parasitaemia (Jeje et al., 1983a), hence the rate of 
immune mediated RBC destruction does not necessarily equate with the parasitic 
load and could partly explain the disparity between parasite density and anaemia.
Decreased RBC production results from marrow hypoplasia seen in acute
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infections. Malaria induced dyserythropoiesis is a morphological observation, 
which in functional terms results in ineffective erythropoiesis (Zwadlo et al., 1987). 
Severely impaired bone marrow function is suspected in SMA cases with low 
parasitaemia; Children with SMA and low-grade parasitaemia are reported to have 
dyserythropoiesis and excessive growth of immature erythrocytes compared with 
those with acute malaria (Weatherall and Abdalla, 1982).
As parasites disappear from the blood either by therapy or host 
mechanisms, both haemoglobin level and bone marrow morphology return to 
normal (Abdalla, 1990), within 3 weeks in the convalescence phase (Phillips et al., 
1986). This is an indication that malaria parasite clearance marks the onset of the 
recovery phase.
There has been controversy regarding the relationship between 
erythropoietin level and anaemia. Some groups reported that erythropoietin (EPO) 
level sometimes appears to be normal in SMA patients (Skorokhod et al., 2010, 
Mackintosh et al., 2004) while others have claimed that reduced erythropoietin 
level is associated with anaemia (Etzerodt et al., 2010, Van Gorp et al., 2010, Giha 
et al., 2010, Yu et al., 2011, Koda et al., 1998a). Other studies seem to resolve 
this controversy by reporting that normal levels of erythropoietin in the face of 
inadequate erythropoiesis could be caused by the accumulation of haemozoin in 
the bone marrow (Koda et al., 1998b, Rougemont et al., 1988) and the activities of 
cytokines (Font et al., 2001).
A product derived by lipid peroxidation catalyzed by haemozoin called 4- 
hydroxylnonenal (HNE) was reported to have an inhibitory role in erythropoiesis 
(Skorokhod et al., 2010). Haemozoin could induce cytokine imbalance through 
overproduction of IL-10 and IFN-a. Both IL-10 and IFN-a suppresses 
erythropoiesis via IL-12 (Font et al., 2001, Burte et al., 2013), a major cytokine that 
directly enhances erythropoiesis (Mohan and Stevenson, 1998). It is thought that
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HNE directly influences erythroid progenitor cells and indirectly alters the 
production of inflammatory mediators such as TNF-a and Nitric Oxide (NO). 
Reduced NO might decrease the rate of parasite clearance and hence reduce 
erythropoiesis (Font et al., 2001).
1.44 Pathology of cerebral malaria and other clinical malaria syndromes
Cerebral Malaria (CM) is a clinical complication of malaria in humans with 
P. falciparum infection. It is characterized by convulsion and unarousable coma 
that persist for more than 30 minutes in the presence of asexual stage 
parasitaemia. The metric for the coma includes a Glasgow Coma scale <11 or 
Blantyre coma scale <3 (McGuire et al., 1994). The strict definition of CM allows it 
to be differentiated from other forms of malaria and encephalopathies and to allow 
the comparability of clinical investigation (Warrell et al., 1982, Taylor and 
Molyneux, 2015, McGuire et al., 1994, Polimeni and Prato, 2014).
CM occurs when the cerebral capillaries are blocked due to sequestration 
of parasite-infected RBC, RBC and residual bodies containing haemozoin 
(Mackintosh et al., 2004). A post-mortem study carried out on pediatric CM 
patients revealed different patterns of sequestration (Taylor and Molyneux, 2015), 
and a generalized multi-organ sequestration is a major feature of CM (Milner et al., 
2015). Sequestration is thought to involve principally RBC infected with late 
trophozoites and schizonts, parasites in the second half of their intra-erythrocytic 
growth (Mackintosh et al., 2004).
Hypoxia is known to enhance parasite sequestration to the endothelial cell 
via parasite proteins such as PfEMP-1 binding to receptors such as ICAM-1, CD31 
and CD36 (Turner, 1997, Idro et al., 2005, Brown et al., 1999, Storm and Craig, 
2014). Sequestration is also enhanced through resetting (the binding of infected to 
non-infected erythrocytes), auto-agglutination (the binding of infected erythrocytes
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to each other) and platelet-mediated clumping of infected erythrocytes (Mishra and 
Newton, 2009). The sequestered parasites and RBC coupled with rigidified 
erythrocytes limit microvasculature flow and metabolic supply to the brain.
Severe haemolysis has also been reported in CM (Eisenhut, 2015, Poh et 
al., 2014), indicating that anaemia may be implicated in the pathology of CM. This 
anaemia accompanied by hypoglycemia causes seizure (Idro et al., 2005, Mishra 
and Newton, 2009).
Inflammation and permeability of the Blood Brain Barrier (BBB) are also 
implicated in CM. The permeability allows parasite molecules to get to the brain 
(Recuenco et al., 2014, Polimeni and Prato, 2014) and induce severe neurological 
dysfunction. Both CD8+ T cells (Polimeni and Prato, 2014) and Matrix 
Metalloproteinase (MMP) proteolytic enzymes are involved in the disruption of the 
inter-endothelial tight junction. MMP inhibitors are believed to prevent BBB 
dysfunction, reduce the inflammatory role of pro-inflammatory cytokines, reduce 
the high mortality rate in CM and ameliorate CM-associated neurological sequelae 
(Polimeni and Prato, 2014).
CM is thought to result in neurological impairment and sequelae, which may 
be transient or prolonged. Epilepsy was reported to be one adverse outcome of 
CM (Christensen and Eslick, 2015, Serghides et al., 2014). Sequelae of CM such 
as neurological impairments that are usually associated with intracranial pressure 
enhance mortality. Intracranial pressure is a fatal complication in CM and a major 
cause of death (Idro et al., 2005, Newton et al., 1997, John et al., 2008, Seydel et 
al., 2015). Increased brain volume was observed in some children with CM and it 
is strongly associated with neurological morbidity (Postels et al., 2014).
The cause of coma in children with CM is unclear; there is abrupt 
development of coma following seizure in children, however, in adults the 
development of coma is gradual and seldom follows seizure (Idro et al., 2005,
37
Mishra and Newton, 2009). A recent study reported that a high level of EPO is 
associated with prolonged coma and mortality in children of about 2 years-of-age 
and above and correlates with markers of endothelial and platelet activation and 
the presence of histidine-rich protein-2 (Shabani et al., 2015).
Cytokines also play a role in the pathogenesis of CM. High levels of Tumour 
Necrosis Factor-Alpha (TNF-a), IL-6 and IL-10 are associated with CM (Gimenez 
et al., 2003, Day et al., 1999). High levels of TNF-a, interleukin-1 (IL-1) and 
Transforming Growth Factor (TGF) were found localized in post-mortem analyses 
of brain tissue from CM patients (Mishra and Newton, 2009). On the other hand, 
anti-inflammatory cytokines such as IL-10 and IL-12 have been proposed to have 
regulatory and protective roles (Polimeni and Prato, 2014).
Studies show that bioavailability of NO might also improve disease outcome 
in children with CM (Xu et al., 2015, Trovoada Mde et al., 2014), while endothelial 
Protein C receptor was reported to be an early biomarker of poor prognosis and 
mortality in CM patients (Moussiliou e ta l., 2015). Furthermore, a high level of 
CRP might worsen the severity of CM and might play a role in human malaria; 
CRP deficient mice were reported to be more resistant to experimental CM (Szalai 
et al., 2014).
Other complications of malaria include respiratory distress that can occur at 
high parasitaemia or during convalescence following parasite clearance (McGuire 
et al., 1994). Malaria can also affect the blood sugar level because of the demand 
of the parasite for glucose, inducing a condition called hypoglycemia. This was 
observed in 8% of adults and 30% of children with CM (McGuire et al., 1994). 
Proteins that are involved in various aspects of glucose metabolism such as 
insulin-glucagon metabolism, and glycolytic enzymes are reported to be elevated 
in SMA and CM compared to UM groups (Bachmann et al., 2014). However, long 
treatment with quinine can stimulate insulin production leading to hypoglycemia.
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Malaria induced hypoglycemia should be suspected when a patient with malaria 
shows altered behavior, impaired consciousness, tremor and breathlessness 
(McGuire etal., 1994).
Jaundice or hepatic dysfunction is more common in adults than children. 
While unconjugated hyper-bilirubinemia in jaundiced patients is an indication of 
extensive haemolysis of infected and non-infected erythrocytes, conjugated 
bilirubin is more likely to be the result of hepatocytic dysfunction (McGuire et al., 
1994).
The passage of dark urine or black water fever occurs in acute malaria. It is 
thought to be a good prognosis in malaria. However, a few patients may develop 
acute renal failure following necrosis of the glomerulus tubules (Lange, 1992, 
Quaye, 2008, McGuire et al., 1994).
There is multi-organ damage in malaria because its pathology affects 
virtually all of the organs of the body (Krishnan and Karnad, 2003).
1.5 Extravascular and Intravascular haemolysis
Any removal of erythrocytes prior to their normal life span of 120 days is 
termed haemolysis. Intravascular haemolysis is characterized by the release of 
erythrocyte cellular components into the plasma. Extravascular haemolysis entails 
erythrocyte removal largely by the spleen without the release of erythrocyte 
components into the plasma (Dhaliwal et al., 2004).
Hemolysis may be asymptomatic until erythrocytosis no longer matches 
erythrocyte destruction. Clinical manifestations of haemolysis include either acute 
or chronic anaemia, reticulocytosis, dark urine and jaundice. The diagnosis is 
established by increased unconjugated bilirubin, elevated lactate dehydrogenase, 
decreased haptoglobin and peripheral blood smear and staining to detect 
reticulocytosis. The causes of haemolytic anaemia include immune-mediated
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mechanisms, microangiopathy, hereditary RBC disorders and infections (Dhaliwal 
etal., 2004).
Immune-mediated haemolytic anaemia includes Autoimmune Hemolytic 
Anaemia (AIHA), transfusion induced or alloimmune haemolytic anaemia, and 
drug induced haemolytic anaemia. Antibodies directed against antigen on the 
erythrocyte induce haemolysis. The deposition of complement factor C3 on the 
surface of RBC leads to slow clearance by macrophages in the spleen and the 
liver while deposition of the membrane attack complex (C5b to C9) results in 
intravascular haemolysis (Dhaliwal et al., 2004, Engelfriet et al., 1992).
Drugs such as high doses of penicillin induce the expression of IgG 
antibody and causes extravascular haemolysis. Quinine could form a complex with 
IgM and could also induce haemolysis (Dhaliwal et al., 2004, Petz, 1993, Adner et 
al., 1968, Gottschall et al., 1991).
Endothelial damage within small blood vessels such as microangiopathy 
can cause an obstruction through the aggregation of platelets and fibrin. This 
obstruction within the vascular endothelium produces shearing force on the 
erythrocytes in circulation leading to intravascular haemolysis (Schrier, 2000, 
Maedel L and Sommer S, 1993). Disorders of erythrocyte enzymes such as 
glucose-6-phosphate dehydrogenase deficiency (G6PD) (Beutler and Luzzatto, 
1999, Beutler, 1994, Steensma et al., 2001); the erythrocyte membrane such as 
hereditary spherocytosis (Konca et al., 2015, Comite Nacional de et al., 2015, 
Bolton-Maggs et al., 2012, Dhaliwal et al., 2004) and haemoglobin such as sickle 
cell anaemia and thalassaemia enhance haemolysis (Dhaliwal et al., 2004).
Malaria is both an inflammatory and haemolytic disease characterized by 
cycles of erythrocyte destruction. Cellular invasion by the parasite and its 
metabolic products enhance erythrocyte removal either intravascularly or 
extravascularly (Imrie et al., 2012). Intravascular haemolysis is an intrinsic feature
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of severe malaria (Imrie et al., 2006) and it causes the release of free haem (fHb) 
into the plasma (Mendonca et al., 2012, Ferreira et al., 2008). Diverse and 
complex physiological pathways are normally deployed in mammals to control the 
oxidative effect of fHb when released from RBCs. There are specific proteins in 
circulation whose function is to ameliorate the toxic effect of fHb and its byproducts 
such as haem and iron. Control mechanisms start during erythropoiesis and 
extend through to haem and iron metabolism. Examples of a few proteins that 
drive these processes include Haptoglobin; CD163 receptors on macrophages; 
and Alpha Haemoglobin Stabilizing Protein (AHSP), an important protein 
implicated at an early stage of erythropoiesis (Imrie et al., 2012). AHSP functions 
as a chaperone, providing protection against oxidative damage to a-Hb subunits 
through specific binding (Kihm et al., 2002, Santiveri et al., 2004, Dickson et al., 
2013, Mollan et al., 2013, Favero and Costa, 2011).
During intravascular haemolysis, fHb, haem and reactive oxygen or 
nitrogen species (ROS/RNS) are released into the plasma (Mendonca et al., 2012, 
Ferreira et al., 2008). There is further oxidation of fHb by actions of ROS and RNS 
to methaemoglobin (MetFe3+), releasing more haem as well as exposing the haem 
prosthetic group. Further oxidation of both a(3 subunit of the MetFe3+ is possible 
yielding MetFe4+ which is a transient intermediate molecule and a potent inducer 
of pro-inflammatory cytokine (Ferreira et al., 2008).
Oxidation of fHb transfers highly toxic free haem to the endothelial cell and 
to low-density lipoprotein (LDL) that can convert Lactate Dehydrogenase (LDH) to 
a cytotoxic oxidized product making the cell more prone to oxidative cellular injury 
(Balia et al., 2005). The iron moiety of fHb can also be oxidized by nitric oxide 
(NO) and this can further induce oxidative damage through mediators such as lipid 
and hydrogen peroxides (Han et al., 2002, Zukin et al., 2013, Fowkes et al., 2006). 
The fHb dimers that are released into the plasma during intravascular haemolysis
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are thought to accumulate in malaria, particularly in SMA (Mendonca et al., 2012).
Both Hp and CD163 are involved in the metabolism of fHb dimer during 
haemolysis (Mendonca et al., 2012, Ferreira et al., 2008). Hp scavenges fHb and 
forms a complex with it (Quaye, 2008). This prevents the oxidation of fHb, nitric 
oxide damage, renal excretion of iron and any further oxidative damage (Sertorio 
et al., 2013). Once the complexes are internalized in macrophages, haem- 
oxygenase-1 (HO-1) enzymes degrade haem released from Hb into iron, bilirubin 
and carbon monoxide (CO) (Quaye, 2008, Mendonca et al., 2012, Sertorio et al., 
2013, Schaer et al., 2006).
At low Hp plasma level, the plasma level of fHb increases following 
haemolysis (Delanghe et al., 1998c, Delanghe and Langlois, 2001). Hence, Hp is 
considered as a marker of haemolysis (Delanghe et al., 1998b, Gupta et al., 2011, 
Imrie et al., 2006, Kim et al., 2012a, Ko et al., 2013).
Similarly, LDH is known to be abundant in erythrocytes and its plasma level 
is elevated in the event of erythrocyte lysis. Elevated plasma level of LDH is also a 
surrogate marker of haemolysis in vascular pathophysiology (Balias, 2013, Shah 
et al., 2014, Kato et al., 2006, Tabbara, 1992).
Hp has several biologic functions apart from its main role in fHb scavenging 
and its association with malaria has been widely reported (Langlois and Delanghe, 
1996, Atkinson et al., 2014, Nyakeriga and Troye-Blomberg, 2013, Mendonca et 
al., 2012, Quaye, 2008, Delanghe et al., 1998c, Fowkes et al., 2006, Imrie et al.,
2006).
1.6 The human Hp
Haptoglobin (Hp) is an acute phase protein. It’s widely known as the 
scavenger of fHb, thereby preventing renal excretion of iron and oxidative damage 
as earlier mentioned. It is synthesized mainly in hepatocytes in response to
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Interleukin 6 (IL-6), which is also synthesized in response to IL-1 and TNF-a 
(Quaye, 2008, Nielsen and Moestrup, 2009). IL-6 responsive regions on the Hp 
gene promoter include A-157, B-111 and C-61 (Quaye, 2008), while the A-165 to 
A-147 on Hp were found to be crucial for all hormone regulatory functions 
(Baumann et al., 1990). These cytokines and hormones were reported to promote 
Hp gene transcription (Quaye, 2008).
The plasma concentration of Hp increases with age and is measurable from 
3 months to adulthood. Lower Hp level could be expected at 3-6 months of age. A 
concentration of 30-200 mg/dL is reached at about 20 years of age (Shinton et al., 
1965). However, Hp level is dependent on location, Hp genotype, splenomegaly, 
a+-thalassaemia genotype, parasitaemia and age. There is a suspected negative 
correlation between Hp level and age at low parasite densities and a positive 
correlation at higher densities (Fowkes et al., 2006).
1.6.1 The structure of Hp protein and gene
The Hp gene is comprised of two alleles that are co-dominant; both Hp1 
and Hp2 alleles are located on the long arm of chromosome 16 (Smithies, 1955, 
Smithies and Walker, 1956, Robson et al., 1969). The Hp1 allele has five exons 
and the Hp2 allele has seven (Fig. 1.3). The 5th exon of Hp1 and the 7th exons of 
Hp2 constitute the p-chain (Fig. 1.3 and 1.2). Both exon 3 and 4 of the Hp1 allele 
were duplicated to form the Hp2 allele such that the Hp2 allele is about 1.7kb 
longer (Yang et al., 1983, Wobeto et al., 2008b).
The Hp monomer is made up of two a and two p chains (Fig. 1.2). The a 
and p loci are linked such that a single mRNA generates the pro-Hp. The pro-Hp 
then undergoes proteolysis at position 161 (arginine) to yield the a and P-chains of 
Hp (Fig. 1.2). The a-chain represents 19% and the p-chain represents 81% of the 
total Hp molecule (Bier, 1967). Each p-chain is joined to an a-chain with a
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disulphide bond (Fig. 1.2). The a-chains are also joined together with a disulphide 
bond (Fig. 1.2). There are also some disulphide bonds along each polypeptide 
within the a- and the (3-chains (Kurosky et al., 1980, Raugei et al., 1983), which 
are suspected to be involved in the stabilization of the protein (Fig. 1.2).
The a-chains are classified as a1-chain and a2-chain and are present in the 
protein as either a1 or a2 or both (Koch et al., 2003). The Hp'\ allele and Hp2 
allele are so named due to the presence of a1 and a2 chains respectively. The 
Hp2-2 phenotype consists of two a2-chains (Fig. 1.2), Hp1-1 has two a1-chains 
and the Hp2-1 phenotype has one each of a1- and a2-chains.
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Figure 1.2 The structure of Hp2-2 protein dimer
The 406 amino acid precursor; PreproHp (black) has an N terminal signal peptide (residues 1 to 
18), a proteolytic cleavage site at residue 161, and forms a dimer. Following removal of the signal 
peptide each protein in the dimer is cleaved into two fragments, the a2 chains (red) and the (3 
chains (blue), which are held together by interchain disulphide bonds. The S-S represents 
disulphide bond. There are also intrachain disulphide bonds between cysteine residues as 
indicated, which are taught to stabilize the polypeptide. The numbers written in black on both the (3 
and the a2 chains indicate other glycosylation (CHO) sites. The a1 chain of Hp1 is shorter than the 
a2 chain of Hp2 but the (3 chain is identical. Hp2-2 has two a2 chains, Hp1-1 has two a1 chains
while Hp2-1 has one a1 and one a2 chain.
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Figure 1.3 Diagram of Hp gene showing the difference between the Hp1 and
the Hp2 allele
The Hp2 and Hp7alleles are comprised of seven and five exons, respectively. The first six exons in 
the case of Hp2 and the first four exons in the case of Hp1 code for the a chain. Exons 5 and 6 of 
Hp2 are thought to have arisen by an internal duplication of exons 3 and 4, as indicated with the 
red and yellow colouring. The 3’ exon (coloured green) codes for the (3 chain in both cases.
The a1-chain contains 83 amino acids while the a2-chain contains about 
142 amino acids (Maeda, 1991, Wobeto et al., 2008b), so the a1 chain has a 
molecular weight (MW) of about 9kDa while the a2 MW is about 17kDa. 
Electrophoretic mobility on a gel after chemical reduction of Hp showed that the a- 
chains are sub-classified as slow (S) or Fast (F). The a1-chain is easily identified 
on a gel as a1S (alpha 1 slow) and a1F (alpha 1 fast). The difference between the 
a1S and a1F or a2S and a2F lies in the amino acid at positions 52 and 53 in the 
a i Chain and positions 111 and 112 in the 0 2  Chain. Asparagine and glutamic acid 
at these positions gave rise to the “slow” form while aspartic acid and lysine at 
these positions gave rise to the “fast” forms (Connell et al., 1966, Koch et al., 
2003).
The (3-chain is heavier than the a-chain with a molecular weight o f about 
37kDa and is comprised of about 245 amino acids in all Hp types. The Hp |3-chain 
is highly glycosylated. About 20% of the weight is carbohydrate present on the 
protein and sialic acid accounts for about 5% of this (Bier, 1967).
While the (3-chain was not reported to be polymorphic (Wobeto et al., 
2008a, Kurosky et al., 1980), the alpha chains are, resulting in 3 major
phenotypes, Hp1-1, 2-1 and 2-2 (Maeda et al., 1984, Langlois and Delanghe, 
1996). The ‘F and S’ subtypes associated with both Hp1 and 2 alleles give rise to 
further phenotypes within the population. The possible allele combinations for 
Hp1-1 are Hp1F-1S, Hp1S-1S, and Hp1F-1F (Wobeto et al., 2008a). Possible sub­
phenotypes associated with the Hp2-1 genotype include Hp2FS-1S, Hp2FS-1F, 
Hp2FF-1F, Hp2FF-1S, Hp2SS-1S and Hp2SS-1F while that of Hp2-2 include 
Hp2FS-2FS, Hp2SS-2FS, Hp2FF-2FS, Hp2FS-2SS and Hp2FS-2FF phenotypes 
(Koch et al., 2003).
Hp is known to bind free haemoglobin (fHb) in the ratio of 1:1 with a very 
high stability and affinity; 1X1 O'15 mol L'1 (Wobeto et al., 2008a). However, there 
are contradictory reports regarding the regions on both Hb and Hp that are 
involved in the binding. While some authors have suggested that it is the (3-chain 
of Hp that binds the a-chain of Hb (Bier, 1967), other suggested that both the a|3 
chains of Hb and Hp are involved in the binding (Langlois and Delanghe, 1996); 
the p-chain of Hb binds to Hp at two specific sites, amino acids p11-25 and P131- 
146, while the a-chain binds Hp at position 121-127 (McCormick and Atassi, 
1990).
The p-chain is heavier than the a-chain with a molecular weight of about 
37kDa and is comprised of about 245 amino acids in all Hp types. The Hp p-chain 
is highly glycosylated. About 20% of the weight is carbohydrate present on the 
protein and sialic acid accounts for about 5% of this (Bier, 1967).While the p-chain 
was not reported to be polymorphic (Wobeto et al., 2008a, Kurosky et al., 1980), 
the alpha chains are, resulting in 3 major phenotypes, Hp1-1, 2-1 and 2-2 (Maeda 
et al., 1984, Langlois and Delanghe, 1996). The ‘F and S’ subtypes associated 
with both Hp1 and 2 alleles give rise to further phenotypes within the population. 
The possible allele combinations for Hp1-1 are Hp1F-1S, Hp1S-1S, and Hp1F-1F 
(Wobeto et al., 2008a). Possible sub-phenotypes associated with the Hp2-1
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genotype include Hp2FS-1S, Hp2FS-1F, Hp2FF-1F, Hp2FF-1S, Hp2SS-1S and 
Hp2SS-1F while that of Hp2-2 include Hp2FS-2FS, Hp2SS-2FS, Hp2FF-2FS, 
Hp2FS-2SS and Hp2FS-2FF phenotypes (Koch et al., 2003).
Hp is known to bind free haemoglobin (fHb) in the ratio of 1:1 with a very 
high stability and affinity; 1X1 O'15 mol L'1 (Wobeto et al., 2008a). However, there 
are contradictory reports regarding the regions on both Hb and Hp that are 
involved in the binding. While some authors have suggested that it is the p-chain 
of Hp that binds the a-chain of Hb (Bier, 1967), other suggested that both the ap 
chains of Hb and Hp are involved in the binding (Langlois and Delanghe, 1996); 
the p-chain of Hb binds to Hp at two specific sites, amino acids p i 1-25 and p131- 
146, while the a-chain binds Hp at position 121-127 (McCormick and Atassi, 
1990).
1.6.2 Ahaptoglobinaemia/hypohaptoglobinaemia
Hp is elevated in a wide variety of inflammatory diseases. However, its level 
decreases to an undetectable level in illness associated with haemolysis, 
(Blumberg et al., 1963). About 30% of the African population has an insufficient Hp 
level to permit phenotyping. This null/low Hp level in circulation is referred to as 
ahaptoglobinaemia/hypohaptoglobinaemia and is designated as HpO (Blumberg et 
al., 1963).
Studies on hypohaptoglobinaemia in malaria have provided conflicting 
views regarding its aetiology in childhood malaria: on one hand, a low level of 
plasma Hp in malaria was proposed to have a genetic cause, while on the other 
hand it was attributed to the disease causing intravascular haemolysis (Delanghe 
etal., 1998b).
There is slight variation in the frequency of hypohaptoglobinaemia in 
different populations within the same country (Constans et al., 1981). Its average
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frequency in Africa was reported to be 40% (Teye et al., 2004), whilst that of 
ahaptoglobinaemia was reported to be 1 in 1,000 Caucasians. The average 
frequency of hypohaptoglobinaemia in Nigeria and Cameroon was 30% and that of 
central part of Nigeria alone was reported to be within 65-76%, however, the 
frequency in persons under constant anti-malarial drugs was reported to be 30% 
lower (Allison et al., 1958, Giblett, 1959, Langlois and Delanghe, 1996). The 
frequency of hypohaptoglobinaemia in North Americans of African descent was 
reported as 2-4% and is generally lower in Africans not residing in malaria 
holoendemic regions (Giblett, 1959, Langlois and Delanghe, 1996), As a result, 
ahaptoglobinaemia was reported to be a consequence of malaria infection 
(Boreham et al., 1979) and it’s acquired in areas where malaria is endemic and 
untreated (Boreham et al., 1979). In spite of this, it is still not clear whether 
a/hypohaptoglobinaemia is a consequence of, or a predisposing factor to malaria.
A 5.2 kilobase (kb) deletion of the Hp gene, spanning from upstream of 
exon 1 to between 52 and 53 base pairs (bps) upstream of exon 5 of the adjacent 
haptoglobin-related (HPR) gene, was reported to be associated with null Hp level. 
The frequency of this deletion was 0.051, 0.031, and 0.060 in Koreans, Japanese, 
and Chinese respectively. However, no such deletion was present in 101 Africans 
and 100 Europeans of African decent (Koda et al., 2000).
The homozygous genotype deletion results in complete absence of serum 
Hp; heterozygous deletion such as the deletion of only the Hp1 allele (Hp2/Hp1del 
genotype) is associated with extremely low Hp level and the deletion of Hp2 allele 
(Hp2del/Hp1 genotype) is associated with an Hp level that is approximately 50% of 
that observed in normal genotype. The frequencies of these heterozygous 
deletions in Japanese, Chinese and Korean populations is within 15-30% (Wobeto 
et al., 2008a). No gene deletion or re-arrangement was found in a Vanuatu (Hill et 
al., 1987); southern and western Asian; European; and African (Gambian)
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populations (Soejima et al., 2007).
Three previously known base substitutions (A-55G, A-61C and T-104A) 
together with three new ones (C-101G, T-191G and C-242T) within the 5' flanking 
region of the Hp gene were identified. The A-61C base substitution was reported 
to significantly decrease transcriptional activity and was associated strongly with 
the Hp2 allele and ahaptoglobinaemia. The C-101G substitution was found to be 
similar in transcriptional activity to the wild type and was associated with Hp1S 
allele and hypohaptoglobinaemia (Teye et al., 2003).
A heterozygous T—>C substitution at codon 247 in the (3-chain of the Hp2 
allele in the Ghanaian population caused reduced expression of the protein when 
transfected into COS7 cells. This base substitution resulted in a missense change 
of the non-polar amino acid isoleucine to the polar amino acid threonine. Aside 
from the A -61C  mutation, which leads to low Hp expression, this codon 
substitution could be another etiologic cause of ahaptoglobinaemia, possibly in 
African population (Teye et al., 2004).
1.6.3 Geographical Frequency distribution of Hp
Hp phenotypes are known to show marked frequency variation with 
geographical location and race. There is a general increase in the Hp2 allele 
frequency among Korean, Indian, Afghanistani, Australian and European 
populations. The frequency of the Hp1 allele is higher in African populations. West 
Africa has the highest frequency of the Hp'l allele. The frequency of Hp1 and Hp2 
alleles in Southern Africa is approximately the same but the Bushmen in South 
Africa and Botswana have a lower Hp1 allele frequency of about 20-30%  
compared to the rest of the population. The Hp1 allele frequency in regions 
representing the North Eastern borders of Africa decreases, ranging from 30% in 
Djibouti, 40% in Ethiopia and 21% in Egypt. The northern part of Algeria has a
lower Hp 1 frequency than the southern part (Teye et al., 2006, Elagib et al., 1998, 
Mavondo et al., 2012, Carter and Worwood, 2007, Constans et al., 1981, Buettner- 
Janusch et al., 1973, Hashem et al., 1966, Giblett et al., 1966, Buettner-Janusch 
and Buettner-Janusch, 1964, Pllitzer, 1963, Goldschmidt et al., 1962). A wide 
range in the frequency of the Hpl allele exists in India, China, Indonesia and 
Russia as well as in Australia. The aboriginal Australian population have the 
lowest frequency of the Hp'l allele (Wobeto et al., 2008a, Pllitzer, 1963, 
Goldschmidt etal., 1962).
Unlike in Africa, the frequency of the Hp1 allele in Europe is fairly stable, 
around 35-40%. The Sami people in the north region of Finland, Sweden and 
Norway have an Hp\ allele frequency of 31-32%. However, wide variations in Hp 
allele frequencies exist from the southern to the northern part of Italy (Goldschmidt 
et al., 1962, Carter and Worwood, 2007). The Hp1 allele frequency in the Middle 
East and Asia is fairly stable between 20-35%. Jewish people have a very stable 
frequency of 30-33% across the globe.
Diverse ethnic groups characterize the American population and therefore 
the Hp1 allele in Americans was considered based on race. The black American 
has the highest frequency of Hp1, although it is about the same as in those of 
Hispanic origin. The frequency of the Hp1 allele among native Americans in 
Canada and the USA ranges from 41-54%. The indigenous peoples in South 
America have a higher percentage of Hp1 allele that is about the same as those in 
West Africa (Wobeto et al., 2008a, Pllitzer, 1963, Goldschmidt et al., 1962, 
Langlois and Delanghe, 1996).
The frequency of the various subtypes is not usually ascertained; however, 
a study in England indicated that the frequency of Hp2FS is the highest while 
Hp2FF is the lowest. The Hp1S is about 24-28%, Hp1F is about 11-15%, Hp2FS is 
about 54-63%, Hp2SS is about 5-6% and Hp2FF is about 0-1%. An extreme
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variation exists in the frequency of the Hp1F allele, particularly in India and Nigeria 
and there is a gradually increasing gradient in the frequency of Hp2FS, particularly 
from the West to the East. (Mastana et al., 1994, Mastana and Fisher, 1994).
1.6.4 Biological significance of Hp
Hp is involved in a number of biological actions such as the immune 
response, regulatory effects on nitric oxide (NO), prostaglandins, angiogenesis, 
antibody-like function, antibacterial-like function and antioxidant functions 
(Kasvosve et al., 2010, Wobeto et al., 2008a).
Table 1.1 Summary of the biologic function of Hp
S/N
BIOLOGIC FUNCTION OF Hp
1. Protection against 
oxidative stress
Hp protects against oxidative stress by protecting 
the iron moiety of haem from free radicals such 
as superoxide and hydroxides by binding to fHb.
2. Inhibition of nitric 
oxides
Nitric oxide (NO), originally referred to as 
endothelium-derived relaxing factor (EDRF). 
Free Hb and Hp bound to free Hb inactivate 
NO/EDRF, whereas Hp does not.
3. Angiogenic function Hp stimulates tissue repair and compensates for 
ischemia by promoting the growth of collateral 
vessels.
4. Immunomodulation Hp phenotypes are associated with response to 
vaccination. Hp2-2 produces higher antibody titre
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than Hp1-1 and Hp2-1 individuals. The complex 
formed between Hp and fHb produces anti­
inflammatory cytokines on binding to CD163. Hp 
also binds with neutrophils as well as B-cell 
receptors via CD22.
1.6.4.1. Hp protection against oxidative stress
Oxidative stress has been suggested to be involved in pathophysiology of 
malaria. The imbalance between oxidant and antioxidant has been reported to 
cause severe damage (Tiyong Ifoue et al., 2009, Araujo et al., 2008).
Oxidative stress is when the pro-oxidant exceeds the antioxidant (Araujo et 
al., 2008). Hp protects against free radicals such as superoxide and hydroxyl by 
binding to fHb thereby shielding the iron moiety of haem within the porphyrin ring 
of fHb. The presence of fHb causes the accumulation of these free radicals, 
particularly hydroxyl radicals that are formed between biological hydroperoxides 
and Fe2+ in the haem moiety (H2O2 + Fe2+ = 20H - + Fe3+). These Free radicals 
cause damage by lipid peroxidation, for example, haem iron catalyzes the 
oxidation of low-density lipoprotein (LDL), making it capable of damaging 
endothelial cells (Balia et al., 1991) The Hb binding capacity (HBC) of Hp as well 
as the affinity of the Hp-Hb complex for CD163 is dependent on the Hp phenotype.
The HBC measures the capacity of an Hp phenotype to protect against
haemolysis and oxidative stress. The HBC of Hp is ranked in the order
Hp1-1>Hp2-1>Hp2-2, while the binding of their respective complex to CD163 is
ranged in the order of Hp2-2>Hp2-1>Hp1-1 (Kasvosve et al., 2010, Quaye, 2008).
This is because though all Hp phenotypes have enough binding capacity for Hb,
their ability to scavenge fHb is associated with the protein’s size, Thus, Hp2-2
being the largest moves fHb to the extravascular space more slowly, allowing
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greater oxidative stress due to the presence of more fHb in circulation. Hp1-1 on 
the other hand is more protective against oxidative damage (Koda et al., 1998b). 
Higher circulatory levels of fHb bind and scavenge NO. Therefore, Hp2-2, which is 
thought to leave more fHb in the circulation is associated with high plasma haem, 
increased NO consumption and low plasma nitrite compared to Hp1-1, which on 
the other hand is thought to have a protective role in this regard (Sertorio et al., 
2013).
The addition of Hp to RBC during storage prior to transfusion helps to 
improve the quality of stored RBC by preventing loss of NO through scavenging of 
fHb (Wang et al., 2014c). The movement of Hp/fHb complex into the macrophage 
is not applicable in this regard, as Hp is only required to bind fHb and prevent it 
from depleting the NO. In this case, Hp1-1 with the highest affinity to fHb will best 
maintain the quality and NO content of stored RBC.
1.6.4.2 Hp effect on endothelial vasodilation
Many cells including macrophages produce NO through the activities of 
appropriate cytokines. The biologic function of NO is a double-edged sword and 
complicated. Large amounts of NO could act against parasites and 
microorganisms but they are also cytotoxic. On the other hand, small amounts of 
NO are involved in maintenance of vascular tone, affecting the contractile state of 
the smooth muscle cells found in the vessel wall. Decreased tone means larger 
diameter of the vessel, decreased resistance and more supply to the appropriate 
organ. Increased tone implies smaller diameter and more resistance to the flow. 
NO is also described as an Endothelial Derived Relaxing Factor (EDRF) (Langlois 
and Delanghe, 1996, Edwards et al., 1986) and plasma fHb inhibits endothelial 
vasodilation through direct interaction with EDRF. Hp and fHb have opposing 
effects on the endothelial vessel; while both fHb and Hp/fHb complex prevents its
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dilation, Hp prevent relaxation; decrease in tone (Langlois and Delanghe, 1996, 
Edwards et al., 1986).
1.6.4.3 Angiogenic effect of haptoglobin
Angiogenesis is an important process in recovery from inflammation and a 
number of pathological conditions. Purified Hp has been reported to stimulate 
angiogenesis in a dose dependent manner in patients with vasculitis. Increased 
Hp during inflammation and ischemia plays an important role in tissue repair and 
vessel development. Anti-haptoglobin antibody inhibits angiogenesis. Furthermore, 
a correlation between angiogenic activity, disease and serum level of Hp have 
been reported (Cid et al., 1993). The human Hp2 gene transfected into Endothelial 
Progenitor cells (EPC) induced the expression of pro-angiogenic factor genes.
While the Hp2 allele is important in angiogenesis, the Hp1 allele 
suppresses angiogenesis (Park et al., 2009). Other reports indicated that Hp2-2 
has more angiogenic function than both Hp2-1 and Hp1-1 (Langlois and Delanghe, 
1996). The levels of serum angiogenic factors are higher in Hp2-2 compared to 
both Hp2-1 and Hp1-1 (Weissgerber et al., 2012).
1.6.4.4 Immuno-regulatory function of Hp
The role of inflammatory mediators in directing host immune functions in 
relation to infectious and non-infectious disease is becoming an intensively studied 
process. Hp is a glycoprotein that regulates the immune response (Mandato et al., 
2012, Abdullah et al., 2009), ranging from immunosuppression (Oh et al., 1990b), 
to inhibition of lymphocyte reactivity or inducing the biosynthesis of IgG (Lange, 
1992) and Hp2-2 has a stronger effect than the two other Hp types in this regard. 
The tight correlation between inflammation and induction of Hp expression by 
cytokines further led to the notion that Hp may play a regulatory role in immune
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function.
Aside from the proposed anti-inflammatory activity of plasma Hp during the 
course of an acute phase reaction (Huntoon et al., 2008), Hp also inhibits 
prostaglandin synthesis and protects against harmful oxidation processes (Lange, 
1992).
CD22 is a receptor of resting mature B-cells that recognizes a2-6 sialylated 
glycoprotein on Hp and other sialylated proteins in the plasma (Powell et al., 1993, 
Hanasaki et al., 1995). Sialylated Hp could therefore bind to B-cells through CD22 
and modulate lymphocyte antigen recognition (Law et al., 1994, Stamenkovic and 
Seed, 1990). Hp affects the proliferation and cytokine production of stimulated T 
cells and B cells (Galicia et al., 2009). For example, 2mg/ml Hp concentration 
inhibited B-cell proliferation while 0.5-1 mg/ml enhanced it (Baseler and Burrell, 
1983).
Hp suppresses secretion of TNF-a, IL-10, and IL-12p70 from macrophages 
(Galicia et al., 2009). This regulatory function of Hp on cytokine secretion could 
also be linked to its ability to bind human mast cells via interaction with 
Macrophage-1 (MAC-1) or CD11b/CD18 (El-Ghmati et al., 2002). This binding via 
MAC-1 present on neutrophils, NK and mononuclear phagocytes like 
macrophages (Galicia et al., 2009) could modulate both MAC-1 and mast cell 
functions (El-Ghmati et al., 2002, El Ghmati et al., 1996). Human Mast cells are 
known to induce production of pro-inflammatory cytokines, histamines, growth 
factors and proteases (Jung et al., 2013) and also play a role in allergic reactions 
such as rhinitis and urticaria (El-Ghmati et al., 2002).
Hp may modulate both innate and adaptive immune responses; it is 
reported to have two binding sites on neutrophils and inhibits several of their 
functions (Galicia et al., 2009), including neutrophil respiratory burst activity (Oh et 
al., 1990b). Hp as a product of tumour cells interferes with innate and adaptive
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immune function and its elimination in cancer patients may serve as an 
immunotherapy (Oh et al., 1990a).
The Hp/fHb complex is also known to modulate the immune system; 
binding of Hp/fHb complex to CD163 could induce Th-1 pro-inflammatory cytokine 
or Th-2 anti-inflammatory cytokine (Van Gorp et al., 2010). Hp1-1 complexed with 
fHb and bound to CD 163 stimulated the secretion of IL-6, IL-10 and TNF-a (Guetta 
et al., 2007). The binding of Hp/fHb complex to CD163 activates an anti­
inflammatory response via IL-10, which in turn increases the expression of CD163 
and further enhances Hp/fHb scavenging via a positive feedback mechanism (Van 
den Heuvel et al., 1999, Van Gorp et al., 2010). While fHb/Hp1 complex bound to 
CD163 receptor induces the secretion of anti-inflammatory cytokines, fHb/Hp2 
bound to CD163 is not known to induce anti-inflammatory cytokines (Guetta et al., 
2007, Strauss and Levy, 2008). The modulation of the balance between pro/anti­
inflammatory cytokine by Hp genotypes exposed to fHb explains partly the inter­
individual response to haemolysis associated inflammatory disease (Guetta et al.,
2007).
Hp interacts with both resting and activated CD4+ and CD8+ T-cells, 
leading to the suppression of T-cell activation. Hp inhibits the production of Th-2 
cytokines; both IFN-y and IL-2 production are slightly inhibited at high Hp level. Hp 
deficient mice could not produce IFN-y. Hp therefore is an acute phase protein that 
could play an immunoregulatory role particularly in the balance between Th-1 and 
Th-2 cytokines (Arredouani et al., 2003).
Hp isoforms are associated with antibody titre response to Salmonella typhi 
vaccine (Nevo and Sutton, 1968). Individual with Hp2-2 are reported to have the 
highest anti-type O titre after immunization with S. typhii vaccine (Nevo and 
Sutton, 1968). However, Hp2-2 individuals produced lower antibody titres following 
influenza and hepatitis B vaccination but stronger antibody responses with tetanus
56
(Kasvosve et al., 2010, Delanghe et al., 1998c).
Hp phenotype is related to the titre of agglutination against streptococci 
carrying a T4-antigen (Prokop et al., 1979, Gunther et al., 1979). Higher 
agglutination titre was observed in pregnant Hp2-2 women. The agglutination 
properties of both Hp2-2 and Hp2-1 were inhibited by addition of Hp1-1 anti-sera. 
Also, absorption of Hp by affinity chromatography decreased the agglutination titre 
for T4 streptococci (Prokop et al., 1979, Gunther et al., 1979). The agglutination 
might have been mediated via a lectin-like binding since both Hp2-2 and 2-1 do 
not have the variable antigen-binding sites that characterize an IgG and more so 
that the agglutinations do not induce complement activity (Langlois and Delanghe, 
1996).
The association between Hp and IgA in allergic rhinitis has also been 
reported (Khazaei et al., 2012).
1.6.5 Haptoglobin phenotypes in infectious and non-infectious diseases
As earlier mentioned, Hp is an important immunomodulator; Hp suppresses 
T-cell proliferation and cytokine release. Th2 cytokines are more suppressed than 
Th1 cytokines and therefore the concentration of Hp is important in determining 
the ratio of both cytokines which are important in disease susceptibility (Kasvosve 
et al., 2010).
The binding between fHb and Hp makes iron unavailable for microbial 
growth, and therefore it’s protective against bacterial and non-bacterial infections 
that requires iron such as HIV (Kasvosve et al., 2010), and particularly HIV-1 
(Quaye et al., 2000a).
Association between Hp phenotypes and various infections have been 
reported. Individuals with Hp1-1 are prone to Streptococcus pyogenes infection. 
Hp1-1 is also associated with Epstein bar virus, Hepatitis B and C and malaria
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infection. On the other hand, Hp2-2 has a protective role in Streptococcus 
pyogenes infection but it’s associated with higher risk of mortality in tuberculosis 
and HIV. Hp2-2 is prevalent in individuals with trypanosomiasis while Hp2-1 is 
prevalent in those with legionella disease.
1.6.5.1 Haptoglobin polymorphism and malaria
Hp1-1 is reported to be associated with susceptibility to severe malaria in 
Africa (Elagib et al., 1998, Quaye et al., 2000b) in spite of its higher frequency in 
the region. This frequency of the phenotype in the region is probably sustained by 
conferring protection from other diseases. The Hp2 is thought to have spread 
under the influence of a strong selection pressure but its unclear whether it arose 
as a result of protection from malaria or another disease. Children with Hp2-2 are 
reported to have 30-50% reduction in clinical malaria episodes while children with 
Hp1-1 have a reduced rate of non-malarial fever but a high rate of malarial fever 
(Atkinson et al., 2007).
There are conflicting reports in the literature on the role of Hp polymorphism 
in malaria (Kasvosve et al., 2010); while some authors reported that Hp1-1 is 
associated with susceptibility (Elagib et al., 1998, Quaye et al., 2000b, Minang et 
al., 2004, Atkinson et al., 2007), others did not find any association (Idro et al., 
2008, Aucan et al., 2002, Bienzle et al., 2005), Some authors thought that the 
contradiction is due to an A-61C (rs5471) mutation found in the promoter region of 
the Hp gene. It was reported that this SNP is associated with low circulatory Hp 
level and protects from malaria as much as the sickle cell trait (Cox et al., 2007), 
and was reported to be of higher frequency in the Hp2 than the Hp1 allele (Cox et 
al., 2007). It was reported that the low plasma Hp level associated with the A-61C  
could be reversed following malaria treatment (Cox et al., 2008, Quaye, 2008), 
however, it is very unlikely to reverse a genetic effect as was reported. Low Hp
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levels due to a genetic effect could not be reversed; hence, the low Hp levels 
observed with A-61C could be haemolysis or disease associated rather than 
genetic.
We propose that while low Hp levels as a consequence of malaria could be 
reversed, low levels due to a genetic effect cannot be reversed. A study has 
reported that Hp levels recovered in 75% of the study population following anti- 
malarial treatment but not in the remaining 25% (Joshi et al., 2002). The etiologic 
cause in those 25% was likely to be genetic. Defining the aetiology of Hp is very 
important to understand its effect in the pathophysiology of malaria.
1.6.5.2 Hp association with non-infectious diseases;
Cancer
Hp is a serum protein biomarker for Non-small Cell Lung Cancer (NCLC) 
(Ayyub et al., 2015, Wang et al., 2014a) and is important in evaluating the 
histological type of lung cancer (Ayyub et al., 2015, Hoagland et al., 2007). A high 
level of Hp is associated with NCLC such as squamous cell carcinoma and 
adenocarcinoma compared to controls (Ayyub et al., 2015, Abdullah et al., 2009). 
Levels in squamous carcinoma are higher than in adenocarcinoma (Wang et al., 
2014a).
High levels of Hp were reported in small cell lung cancer (Shah et al., 2010, 
Everaert et al., 1998b). A more detailed study identified Hp a-chain as the specific 
biomarker for NCLC (Park et al., 2013) and ovarian cancer (Delanghe et al., 
1998a). Hp p-chain is reported to be a non-specific biomarker for early detection of 
prostate cancer (Saito et al., 2008). The association of Hp polymorphism and 
development of cancer depends on the type of cancer. A high frequency of Hp1-1 
and family history have been reported to be important in breast cancer (Awadallah
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and Atoum, 2004, Wobeto et al., 2008a). Serum level of Hp increases with the 
stages of lung cancer (Fedorovych et al., 1995) and Triple Negative Breast 
Cancer (TNBC). Higher Hp level is associated with grade 3 compared to grade 2 
TNBC in young women (Tabassum et al., 2012).
A higher frequency of the Hp1 allele, particularly in the heterozygous Hp2-1 
is associated with ovarian cancer, oesophageal cancer, and leukaemia. The Hp2 
allele, particularly in the homozygous Hp2-2 phenotype is associated with lung, 
oesophageal and gastric cancer. Hp2-2 patients have a better prognosis for 
epithelial ovarian cancer and also elicit better immune responses than those with 
Hp1-1 and 2-1 phenotypes (Mandato et al., 2012, Zhao et al., 2007).
A reduced risk of cervical cancer is associated with Hp2-2 (Quaye et al.,
2009) while Hp polymorphism is not associated with the development of prostate 
cancer and does not determine the disease outcome (Mavondo et al., 2012). 
However, some reported the use of fucosylated Hp as a novel prognostic 
biomarker for prostate cancer (Fujita et al., 2014, Fujimura et al., 2008), distant 
and liver metastasis in colorectal cancer (Takeda et al., 2012, Sun et al., 2012), 
colon cancer (Park et al., 2012), pancreatic cancer (Lin et al., 2011, Miyoshi et al., 
2010, Nakano et al., 2008, Miyoshi and Nakano, 2008, Okuyama et al., 2006) and 
in cancer treatment using a peptide vaccine (Pang et al., 2013). The level of 
fucosylated Hp is high during the disease and low on recovery (Thompson et al., 
1992b, Thompson et al., 1992a, Thompson et al., 1991).
Glycosylated forms of Hp are also a marker for monitoring disease 
progression in a number of cancers including lung cancer (Tsai et al., 2011, Shah 
et al., 2010, Bresalier et al., 2004, Thompson et al., 1992a); The Hp/fHb complex 
has also been shown to be cytotoxic to human hepatocellular carcinoma cells by 
inducing apoptosis and DNA fragmentation (Kim et al., 1995).
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Diabetes
Hp1-1 may delay the onset of diabetes while Hp2-2 poses a microvascular risk 
(Goldenberg-Cohen et al., 2011). Diabetic patients with Hp2-2 are under increased 
oxidative stress as compared with those expressing Hp1-1 or Hp2-1 (Awadallah et 
al., 2013).
Individuals with Hp2-2 develop more complications or sequelae such as 
cardiovascular complications than those with Hp1-1 while an intermediate risk is 
associated with Hp2-1 (Wobeto et al., 2008a). Hp1-1 protects diabetic patients 
from narrowing of blood vessels (restenosis) following the implantation of a 
coronary stent and it is associated with a smaller size of infarct in myocardial 
infarction (Wobeto et al., 2008a). The Hp1-1 genotype is associated with lower 
coronary artery disease risk in diabetes, protects from diabetes-associated 
nephropathy (Wobeto et al., 2008a) and an increased risk of stroke incidence in 
type-1 diabetes (Costacou et al., 2014).
Diabetics with Hp2-2 are more predisposed to developing microvascular 
complication and retinopathy. Type-2 diabetes individuals with Hp2-2 develop 
more cardiovascular complications than those with Hp1-1 while an intermediate 
risk is associated with Hp2-1 (Wobeto et al., 2008a, Adams et al., 2013, Vardi and 
Levy, 2012, Vardi et al., 2012, Shi et al., 2012, Kurosky et al., 1980, Ryndel et al.,
2010).
The cardiovascular complication associated with Hp2-2 is due to impaired 
antioxidant function. Hence, vitamin E supplementation in Hp2-2 diabetics is 
clinically effective and can prolong life (Blum et al., 2010, Nakhoul et al., 2009).
Hp2-2 also predisposes to atherosclerosis (Wobeto et al., 2008a) and it is 
associated with lower arterial elasticity, vascular resistance, microvascular 
complications, poor endothelial function in diabetics compared to controls (Dayan 
et al., 2009), refractory hypertension in type-2 diabetes mellitus (Wobeto et al.,
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2011), and retinopathy (Wobeto et al., 2008a).
Hp modulates glycemic control and cognitive function in type-2 diabetes. 
Hp1-1 patients with type-2 diabetes and poor glycemic control have impaired 
cognitive ability (Guerrero-Berroa et al., 2015). People with type-1 diabetes 
develop renal disease despite good metabolic control. A greater risk of renal 
disease is associated with Hp2-2 (Orchard et al., 2013).
Cardiovascular disease and atherosclerosis
Hp2-2 is a risk factor for coronary atherosclerosis and peripheral arterial 
occlusive disease (Delanghe et al., 1999). Hp2-2 patients are 5-6 times more likely 
to suffer from subclinical atherosclerosis than Hp1-1 and Hp2-1 patients 
respectively, (Ragab et al., 2014). Furthermore, Hp is a significant predictor of 
premature atherosclerosis in children with (3-thalassaemia major.
Hp is an independent risk factor for the development of cardiovascular 
disease (CVD) particularly when there is an underlying diabetes (Levy et al., 2002, 
Levy, 2004, Blum et al., 2008, Costacou and Levy, 2012, Adams et al., 2013). It is 
also a risk factor for obstructive sleep apnea (Lavie et al., 2003) and chronic 
kidney disease (CKD) (Strandhave et al., 2013); Hp2-2 negatively correlates with 
decreased heart rate variability and high CRP protein in patients with CKD 
(Strand have et al., 2013).
1.6.6. Other inflammatory and haemolysis associated defence proteins
1.6.6.1 CD163
Macrophages and their progenitor cells, the monocytes are part of the 
immune system with a variety of functions displayed via the different molecules 
expressed at their surface. They are distinguished by such signals, secretory
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products and expressed biomarkers. One such molecule is the scavenger receptor 
CD 163 that was used to detect a specific macrophage phenotype associated with 
the healing phase of the inflammatory process (Zwadlo et al., 1987, Etzerodt et al., 
2010, Van Gorp et al., 2010). The expression of CD163 is restricted to cells of the 
monocyte/macrophage lineage. CD163 is present on resident tissue macrophages 
such as red pulp macrophages in the spleen, Kupffer cells in the liver, and 
interstitial and alveolar macrophages in the lung (Van den Heuvel et al., 1999, Van 
Gorp et al., 2010). CD163 is a 130kDa membrane protein that is extensively 
glycosylated; its size could be significantly reduced by treatment with glycosidase 
(Van Gorp et al., 2010). It has a cytoplasmic tail, and trans-membrane and 
extracellular domains. The phenotypes of CD163 are differentiated based on the 
length of its cytoplasmic tail. The extracellular domain consists of about nine 
cysteine-rich scavenger receptors (CRSR) motifs of about 110 amino acid 
residues (Fig. 1.4) and is similar to other scavenger receptor superfamily proteins 
(Etzerodt and Moestrup, 2013, Graversen et al., 2002). CD163 plays a role in
the resolution of inflammation and is more expressed at the site of chronic 
inflammation (Sulahian et al., 2004, Moestrup and Moller, 2004). However, its 
principal function is to serve as a receptor for scavenging fHb/Hp complex into the 
macrophages (Schaer et al., 2006).
The binding of fHb/Hp complex to CD163 is dependent on physiological 
calcium concentration; there is no binding at low calcium concentrations (Madsen 
et al., 2004). As mentioned, the internalized fHb is degraded to iron and bilirubin 
(Fig. 1.4), particularly in liver macrophages thereby curbing the toxic effect of fHb 
(Sulahian et al., 2004). Furthermore, the fHb/Hp-CD163 pathway only functions 
when the plasma Hp level is high in relation to Hb. In the event of low/null Hp 
levels, a direct uptake of fHb by CD163 is possible. Uptake of fHb without CD163 
is also possible (Schaer et al., 2007).
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Following the internalization of fHb/Hp by CD163, the intact CD163 is shed 
from the surface of the macrophage as soluble CD163; sCD163 (Sulahian et al., 
2004, Adly et al., 2015), through the actions of inflammatory mediators (Fig. 1.4) 
and both TNF-a Converting Enzymes and a Disintegrin Metalloproteinase-17 
(TACE/ADAM17) that are thought to be responsible for the cleavage (Thomsen et 
al., 2013) by an as yet unknown mechanism. The binding of Hp/fHb complex to 
CD163 produces anti-inflammatory cytokines such as IL-10 (Perdijk et al., 2013). 
Secondly, haem metabolites such as bilirubin resulting from the degradation of 
scavenged fHb also have potent anti-inflammatory effects (Fig. 1.4).
Evidence from mass spectrometry analysis showed more than 94% identity 
between both sCD163 and the CD163 extracellular domain (Moller et al., 2010, 
Van Gorp et al., 2010). Hence, sCD163 could also bind fHb/Hp complex and 
prevent the toxic effect of fHb. However, its scavenging function is limited because 
its circulatory level is approximately 1000-fold lower compared to Hp (Madsen et 
al., 2004).
Both sCD163 and CD 163 are also receptors for erythroblast adhesion, 
Tumour necrosis factor-like weak (TWEAK) inducer of apoptosis and some 
pathogens. These interactions could result in receptor-mediated endocytosis and 
are capable of triggering the production of signaling molecules and that makes 
them function as immunomodulators and potential targets for cell-directed immune 
therapy (Van Gorp et al., 2010). The sCD163 can also act like an anti­
inflammatory, exhibiting cytokine-like function by decreasing T-lymphocyte 
activation and proliferation (Frings et al., 2002, Davis and Zarev, 2005).
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Figure 1.4. fHb-Hp Scavenger-Receptor Mechanism
IL-6 induces the expression of Hp, which binds to fHb in the plasma. Both Hp and fHb forms a 
complex that binds to CD163. This binding is mediated by the presence of physiological calcium. 
fHb internalized into the macrophage is degraded in the lysosomes, the haem moiety is released 
to be degraded by HO-1 to biliverdin that is then converted to bilirubin; Fe2+; and CO. The binding 
of Hp/fHb complex to CD163 activates TACE/ADAM17 through inflammatory mediators to cleave 
CD163 as sCD163. sCD163 has 110 amino acids and is very related to CD163. The diagram was 
adapted with modification from Moestrup and Moller (Moestrup and Moller, 2004) and Etzerodt and
Moestrup (Etzerodt and Moestrup, 2013)
In a clinical setting, sCD163 is of significance because it is being used as a 
biomarker of macrophage activation during inflammation (Adly et al., 2015).
Clearance of sCD163 could be through its binding with TWEAK, a secreted 
cytokine belonging to the TNF-a superfamily. TWEAK is also capable of stopping 
the biological actions of sCD163 (Etzerodt and Moestrup, 2013).
1.6.6.2 Hemopexin
HPx is a plasma glycoprotein that is produced primarily in the liver and 
other secondary sites such as the nervous system, skeletal muscle, and kidney. It 
is regulated during haemolysis, haem overload and inflammatory events and has 
been considered as an acute phase protein (Fiorito et al., 2013, Tolosano et al.,
2010). It is known to bind haem with the highest affinity during haemolysis with 
systemic haem overload (Tolosano et al., 2010, Fiorito et al., 2013, Dong et al.,
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2013).
The human HPx gene is 12kb in size with 10 exons and 9 introns and is 
located on chromosome 11p15.4-p15.5. The protein, HPx is a 60kDa glycoprotein 
with about 20% of carbohydrate. HPx consists of two homologous domains of 
about 200 residues each, joined by 20-residue non-covalent link. The two domains 
combine to bind a haem molecule. On separation of the two domains, the N- 
terminal domain retains its ability to bind haem like intact HPx while the C-terminal 
domain could not but retains its ability to bind to HPx receptor. Both the N-terminal 
and C-terminal domains contain a beta-propeller and show about 25% homology 
in their amino acid sequence.
HPx is a fully sialylated glycoprotein with 4-5 bi-antennary carbohydrate 
chains depending on the species. Human HPx is differentiated by its O- 
glycosylated threonine at the N-terminus. The carbohydrate moiety is apparently 
not involved in haem binding (Delanghe and Langlois, 2001). The only known 
receptor for the haem-HPx complex is the scavenger receptor, the Low Density 
Lipoprotein Receptor-related Protein-1 (LRP) also known as CD91. This receptor 
is expressed in many cell types, indicating multiple sites of haem-HPx complex 
recovery. The major sources of haem are haemoglobin (Hb) from ruptured 
erythrocytes, myoglobin and enzymes with haem prosthetic groups including 
peroxidases and cytochromes from damaged tissues or secreted myeloperoxidase 
from neutrophils.
HPx binding of Hb-derived haem is especially important when Hp is 
depleted or absent (Delanghe and Langlois, 2001, Schaer et al., 2014). The 
normal host response to intravascular haemolysis is an important scavenger- 
receptor-enzyme system (Hp-CD163-HO-1) that prevents the fHb/free-haem- 
induced toxicity. It is a homeostatic mechanism that increases the expression of 
Hp, CD163 receptors and Haem-oxygenase 1; HO-1 (Mendonca et al., 2012).
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However, the plasma concentration of Hp is a limiting factor in some 
circumstances (Thomsen et al., 2013).
The depleted level of Hp could induce the accumulation of free-haem. This 
could occur when fHb is oxidized by Reactive Oxygen and Nitrogen Species (ROS 
and RNS) to methaemoglobin or by spontaneous breakdown of fHb (Ferreira et 
al., 2008). Free-haem is highly cytotoxic particularly to endothelial cells (Ferreira et 
al., 2008, Quaye, 2008). The toxicity induced by free-haem is believed to activate 
the second scavenger-receptor-enzyme system; HPx-CD91-HO-1, whereby the 
HPx scavenges free-haem to the hepatocyte through the CD91 receptor for further 
degradation by the haem-oxygenase-1 enzyme; HO-1 (Ferreira et al., 2008, 
Thomsen et al., 2013). The binding of haem to HPx in the plasma is in the ratio of 
1:1 (Shipulina et al., 2000). About 90% of the HPx-haem complex is internalized in 
the parenchyma cells of the liver by receptor-mediated endocytosis within 2 hours 
(Immenschuh et al., 1995). This uptake of haem-HPx further stimulates 
intracellular protective mechanisms, including the induction of HO-1 (Paoli et al., 
1999), which further degrade the haem in the cytoplasm of the liver. Free-haem 
when bound to HPx could influence the pathological process through gene 
expression, cellular signalling and nervous/immune-modulation (Fiorito et al., 
2013).
HPx is widely involved in the modulation of a variety of physiological and 
pathological processes; studies indicated that HPx plays a role as an anti-oxidant, 
anti-apoptosis, immune regulation, and organic protection, and participates in the 
regulation of cell differentiation and extracellular matrix reconstruction (Dong et al., 
2013). HPx provides neuroprotection in mouse models of stroke and intra-cerebral 
haemorrhage. It protects neurons in vitro against haem or ROS toxicity via haem 
oxygenase-1 (H01) activity (Hahl et al., 2013, Vinchi et al., 2013).
HPx has been shown to have an anti-inflammatory function by suppressing
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macrophages from releasing excess proinflammatory cytokines (Lin et al., 2012, 
Hahl et al., 2013). A correlation was also found between HPx level and the 
potential of sera to block the invasion of the hepatocytes by Plasmodium 
falciparum sporozoites (Pied et al., 1995, Delanghe and Langlois, 2001).
Despite the lack of an international reference range as a standard for HPx 
levels (Delanghe and Langlois, 2001), its circulatory plasma concentration is 
approximately 0.4 to 1.5g/l but fluctuates in certain pathological conditions such as 
haemolytic anaemia (Muller-Eberhard et al., 1968, Kamboh and Ferrell, 1987). 
The normal level in children was reported to be about 20% lower than that of 
adults (Kanakoudi et al., 1995). About 2mg/l of HPx is reported to be present in the 
urine of normal individuals (Lizana and Blad, 1983). The level detected in 
cerebrospinal fluid (CSF) is 1.8-3.4mg/l (Schuller et al., 1971).
HPx depletion is not as pronounced as that of Hp. Low levels of HPx 
therefore signify a severe or chronic degree of haemolysis (Langlois and 
Delanghe, 1996). Determination of HPx in tandem with Hp has potential 
applications in the laboratory assessment of intravascular haemolysis, particularly 
in populations characterized by lower reference values of plasma Hp (Delanghe et 
al., 1998b, Kasvosve et al., 2000, Delanghe and Langlois, 2001) because HP 
x allows monitoring of severe haemolysis when Hp is depleted. This is because 
HPx is recycled; released back into the circulation unlike Hp, which is not recycled 
(Delanghe and Langlois, 2001).
Hp usually has a higher level of acute phase responsiveness compared to 
HPx (Delanghe and Langlois, 2001).
1.6.6.3 Haem oxygenase-1
Haem oxygenase-1 (HO-1) is an inducible enzyme that degrades haem to 
carbon monoxide and biliverdin (Schluesener et al., 2001). It is an important
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enzyme in the host response to intravascular haemolysis and also prevents the 
deleterious effect of haem (Mendonca et al., 2012), (Fig. 1.4).
HO-1 is induced by the release of haem (Schluesener et al., 2001) 
complexed with its scavenger receptor proteins as earlier mentioned. 
Prostaglandin D2 is also known to induce the expression of HO-1 (Kuesap and 
Na-Bangchang, 2010) as well as NO. NO protects against CM by inducing the 
production of HO-1 (Jeney et al., 2014).
Mice deficient in HO-1 had complete hepatic failure. HO-1 is cytoprotective 
in that it suppresses the pro-oxidant effect of free haem, which sensitizes the 
hepatocyte to undergo TNF-a mediated self-death (Seixas et al., 2009, Gozzelino 
and Soares, 2014); protects against inflammation; oxidative stress and restores 
liver function during and after parasite clearance (Dey et al., 2014). High levels of 
HO-1 expression reduce hyperglycemia, improve glucose metabolism, and partly 
protect renal tissue from hyperglycemic injury, possibly through its anti-oxidant role 
(Ptilovanciv et al., 2013).
The role of CD163, HO-1 and Hp in haem metabolism needs further 
investigation. The validation of their roles in malaria within a larger cohort might 
provide useful resources for the development of future targeted therapies that will 
be of importance in alleviating the malaria burden (Hansson et al., 2015).
1.6.6.4 C-reactive protein (CRP)
CRP is a major acute phase protein (Ansar et al., 2006) whose 
concentration increases significantly in infectious disease (Pied et al., 1989). It is 
secreted by the hepatocyte following stimulation by IL-1 (Nussler et al., 1991).
CRP is often present in general infection and trauma (Gillespie et al., 1991, 
Upragarin et al., 2005) but its presence in malaria in the absence of other ailments 
is indicative of the pathological process. A positive correlation has been reported
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between plasma Hp, CRP and parasitaemia (Saad et al., 2013).
The plasma level of CRP is a surrogate marker of the degree of 
parasitaemia and malaria pathology (Taylor-Robinson, 2000). This is because its 
level correlates positively with parasitaemia unlike that of Hp (Hurt et al., 1994a).
CRP inhibits the development of sporozoites at an early stage of the 
infection (Pied et al., 1989). It prevents the parasite’s hepatic development by 
preventing its movement in hepatocytes and by blocking parasite division through 
an antibody mediated process (Nussler et al., 1991). CRP is known to have a 
direct binding capacity for infected cells mediated by calcium and 
phosphorylcholine in pathological conditions.
In disease, CRP binding to infected erythrocytes is 2-3 fold stronger than to 
normal erythrocytes (Ansar et al., 2006). The effector function of the strong CRP 
binding to infected erythrocytes is demonstrated by its potency in activating the 
complement pathway (Ansar et al., 2006). The binding of CRP to erythrocytes also 
prevents the activities of some complement regulatory proteins such as CR1, 
CD35, CD55 and CD59, and enhances haemolysis that accounts for the 
pathogenesis of anaemia (Ansar et al., 2006).
There is lower level of CRP in children recovering from SMA than CM in 
areas of high transmission and this has been implicated as a risk factor for SMA in 
lower aged children (Waitumbi et al., 2004). On the other hand, the higher level of 
CRP in malaria was reported to be associated with death, hence the protein is a 
marker for malaria associated mortality (Paul et al., 2012).
Both CRP and parasitaemia are metrics for measuring the effects of 
intervention programmes like the deployment of insecticide treated nets (Hurt et 
al., 1994b). People using insecticide treated nets have lower levels of CRP and 
parasitaemia than people not utilizing insecticide treated nets (McGuire et al., 
1996).
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It appears that the development of partial immunity to malaria reduces the 
expression of CRP. Higher CRP levels were associated with parasitaemia in 
children under 1 year of age while lower levels were associated with parasitaemia 
in older children (Hurt et al., 1994a).
Recent studies showed that CRP levels negatively correlate with amounts 
of Zn and positively correlate with amounts of Cu in Sudanese patients with severe 
falciparum malaria (Saad et al., 2013), bringing to light the likely pathological role 
of mineral elements in malaria.
A (-286) C>T>A SNP in the promoter region of the CRP gene is known to 
influence CRP level and susceptibility to malaria. A significant number of malaria 
episodes and high parasite density are associated with the A allele but not the C 
and T allele (Giha et al., 2010).
1.7 Oxidative stress in malaria
The role of oxidative stress during malaria infection is still unclear. Oxidative 
stress plays a crucial role in the development of systemic complications in malaria. 
Malaria infection induces the generation of the hydroxyl radical (OH*), which most 
probably is the main reason for the induction of oxidative stress and apoptosis. 
Twice as much hydroxyl radical is produced by falciparum infected erythrocytes 
compared with normal erythrocytes (Atamna and Ginsburg, 1993).
A potential source of free radical production is the Hb molecule, since the 
parasite uses it as a source of amino acids for its own nutrition during the 
erythrocytic stage of the disease. This results in free haem release, which induces 
further intravascular oxidative stress, changes in erythrocytes, endothelial cells 
and parasite sequestration in tissues and organs such as the liver and the brain 
(Kumar and Bandyopadhyay, 2005).
Large amounts of ROS and RNS are products of macrophages and
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neutrophils that are elicited in response to the infection. However, their continuous 
release offsets the balance between the oxidants and the antioxidants (Cabrales 
et al., 2011, Percario et al., 2012). During a malaria episode, a high level of 
oxygen radical is being produced as superoxide anions, which can kill the parasite 
but also cause tissue damage. To prevent this damage the antioxidant enzyme, 
Zn/Cu superoxide dismutase (SOD-1) converts these radicals into hydrogen 
peroxide, which can then be removed by catalase and the glutathione system. 
SOD-1 level has been related to tissue damage and is also a marker for oxidative 
stress (Andrade et al., 2010).
Malarial infection may be associated with oxidative damage and reduced 
alpha-tocopherol reserves in the erythrocyte membrane, suggesting that local 
antioxidant depletion may contribute to erythrocyte loss in severe malaria (Griffiths 
et al., 2001). Increased production of ROS by the parasite may deplete the 
erythrocyte of its defense mechanisms namely, SOD, catalase, glutathione 
peroxidase, NADPH, NADH, glutathione (GSH) and glutathione reductase (Mishra 
et al., 1994).
1.8 Cytokines in malaria
So far, the role of cytokines has been mentioned in several contexts. It is 
not possible to discuss infection without mentioning the role of cytokines that 
participate in cellular signaling. Cytokines are released from White Blood Cells 
(WBC), particularly T-lymphocytes expressing CD4 on their surface called T- 
helper cells (Th-cells) and classified as Th-1 and Th-2 (Berger, 2000).
Th-1 cells tend to produce pro-inflammatory cytokines such as IL-1, IL-6, IL- 
2, IL-12, IL-8, IL-18, TNF-a, and IFN-Y. Excessive production of these pro- 
inflammatory cytokines may lead to tissue damage or disease progression and 
needs to be countered by the anti-inflammatory cytokines of Th-2 cells such as IL-
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4, IL-10, IL-5, IL-9, IL-1 ra, TNF-a binding protein, slL-1R and IL-13 (Berger, 2000, 
Goncalves et al., 2010). Other molecules within the above groups such as IL-2, 
IL-3, IL-7, IL-10, IL-11, IL-12 and Granuloma-Monocyte Colony stimulating Factor 
(GM-CSF) can also act as positive or negative growth factor in a number of cells 
(Gruys et al., 2005).
An early pro-inflammatory cytokine response helps in limiting the infection 
by inhibiting the growth of malarial parasites at low concentrations. On the other 
hand, if these pro-inflammatory responses are not down-regulated they result in 
disease progression and complications (Clark et al., 2006). IL-10 is an anti­
inflammatory cytokine produced mostly by monocytes and T-cells in response to 
increasing levels of pro-inflammatory cytokines. It is responsible for the switching 
from a Th-1 to a Th-2 cytokine response; the biologic function of IL-10 is to inhibit 
the activity of Th-1 cells, natural killer cells and macrophages to counter the effect 
of pro-inflammatory cytokines (Goncalves et al., 2010).
Th-1 cells and their cytokines are important in parasite clearance but induce 
severe tissue damage at the same time. The action of IL-10 on these cells and 
also on the production of chemokines (MCP-1, and 5, IL-8, IP-10 and MIP-2) may 
prevent them from enhancing the pathological process (Couper et al., 2008). The 
biological functions of IL-10 are similar in various infections irrespective of its 
source of production (Goncalves et al., 2010).
The balance between the pro- and anti-inflammatory cytokines is important 
in malaria (Mackintosh et al., 2004, Naik et al., 2000). The ratio of IL-10 and TNF- 
a or IL-6 has been a parameter for measuring the balance between pro- and anti­
inflammatory cytokines. This balance is proposed to exacerbate or ameliorate 
pathology. The induction of acute phase protein by IL-6 should down-regulate the 
actions of pro-inflammatory cytokines such as TNF-a and IL-1 (Gadient and 
Patterson, 1999). As a result, IL-6 appears to act both as a pro- and an anti­
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inflammatory cytokine. Circulatory level of TNF-a, IL-6, and IL-10 and the ratio of 
IL-6:IL-10 were higher in dead patients than in survivors. Survivors have stable 
levels of both IL-6 and IL-10 but in most cases the level of IL-6 is lower (Day et al., 
1999). Raised IL-10 and IL-6 have been associated with hyperparasitaemia, 
shock, and jaundice (Day et al., 1999).
Low IL-10 has been reported to be associated with SMA (Day et al., 1999). 
A study in a Nigerian cohort reported a very high level of IL-10 in UM and a lower 
level in SMA groups (Burte et al., 2013). In contrast, a study in Mali showed that 
both IL-10 and IL-6 are significantly higher in SMA compared to UM and healthy 
individuals (Lyke et al., 2004). Due to the disparity in these reports, it was 
considered that something else may account for the low level of IL-10 in the SMA 
group. In this study, it was hypothesized that Hp phenotypes are accountable for 
the disparity. Therefore, the relationship between Hp phenotypes and plasma 
cytokines level were investigated further.
1.9 Aims and objectives
This study is to investigate changes in the levels of plasma proteins with 
convalescence in P. falciparum malaria infected child cohort, living in the malaria- 
holoendemic city of Ibadan, Nigerian.
The human proteome is central for disease diagnosis, prognosis and 
therapeutic monitoring. The blood plasma contains a huge number of proteins 
derived from organs and tissues. Hence, it’s a reflection of both the physiological 
and pathological state of cells (Saffer et al., 2002) and a good reservoir of disease- 
specific biomarkers (Liu et al., 2014). A unique characteristic of the plasma 
proteome is that the proteins are present in unique amounts; they are in a dynamic 
range to one another; their levels in a pathological condition differ from one 
ailment to another and they are more useful for objective assessment of the
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disease state than clinical observation (Gillespie et al., 1991). All of these features 
made the plasma a very good sample for clinical investigation (Yu et al., 2011).
This study was initially a discovery-based project with the overall aim of 
looking into the differences in the levels of plasma proteins as well as proteins that 
are specific to each malaria syndromes and which could possibly explain the 
development of severe forms of malaria. It is not clear why some children develop 
severe malaria complication while the infection is restricted to the mild or 
uncomplicated form in others.
Specifically, the study aims;
1. To investigate and validate changes in the plasma proteins of children 
recovering from SMA in order to further understand the pathophysiology of 
SMA and how it differs to other syndromes and to search for and/or validate 
proteins associated with clinical malaria syndromes that could be useful as 
biomarkers for malaria diagnosis or prognosis. Monitoring the changes in 
the plasma protein through convalescence in comparison with the control 
will both help to understand the pathology of the disease and to identify 
potential biomarkers. The problem is that malaria in the sub-Saharan Africa 
is still poorly diagnosed due to lack of trained physicians and scientists; 
symptom overlap with other diseases and the absence of biomarkers that 
can discriminate among the clinical malaria phenotypes. Some of the 
clinical observations used to establish the diagnosis of malaria are not 
specific. For example, cerebral malaria is often defined with the presence of 
asexual form of the parasite, convulsion and coma. However, coma and 
convulsion are associated with other encephalopathy-like syndromes such 
as meningitis. Also, the presence of the parasite in the blood is not 
uncommon in these subjects as malaria is holoendemic. Lack of definitive 
diagnosis could leads to a high rate of antimalarial drug abuse; drug
resistance and high mortality rate, particularly among children less than 5 
years of age. Therefore, the search for proteins that could effectively 
discriminate among the malaria syndromes and between malaria and other 
causes of fever at acute onset is important.
2. Following preliminary investigations on pool samples, we found that the 
levels of Hp, clusterin (CLU) and HPx were differentially expressed in the 
malaria groups relative to the levels in the healthy community controls (CC) 
and need to be investigated further on individual crude samples. This 
further led to a hypothesis-based study to address some specific questions 
such as;
❖ Are low levels of Hp in malaria a risk factor or a consequence of the malaria 
infections?
❖ How do the levels and isoforms of Hp in malaria affect the clinical outcome 
of the disease?
❖ Do individuals with different Hp phenotypes but presenting with the same 
malaria syndrome elicit the same response to the disease?
❖ Are there any genetic variants that are associated to both the disease and 
Hp levels.
❖ Are there significant changes in the plasma CLU and HPx levels in malaria 
syndrome between acute onset and convalescence?
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CHAPTER TWO 
2.0 MATERIAL AND METHODS
2.1 Total Protein Estimation Assay
Protein estimation assay was performed using bicinchoninic acid (BCA) and 
the manufacturer’s (Pierce™) manual. Briefly, the BSA standard and the samples 
were diluted in lysis buffer (7.5mM Tris, 2M urea and 1% CHAPS), samples were 
diluted 1 in 200 in the buffer. Working reagent was prepared by mixing 50 part of 
BCA reagent A with 1 part of BCA reagent B. Standard and samples (25pL) were 
added to the plate followed by 200pL of working reagents. Reagents and samples 
were mixed on a plate shaker for 30 seconds and plates were incubated at 37°C 
for 30 minutes. Thereafter, plates were left at room temperature for 10 seconds 
and the absorbance was read at 560nm in a FLUOstar Omega plate reader (BMG- 
Labtech). Blank corrected values were plotted against concentrations in a 
standard curve and the unknown total protein concentrations were determined 
from the standard curve (linear regression fit) and multiplied by the dilution factor.
2.2 Two-Dimensional-Difference-Gel Electrophoresis (DIGE)
For the preliminary investigation, we performed plasma proteome profiling 
both crude and immunodepleted plasma samples. Briefly, thirty plasma samples 
collected from children between 6 and 156 months of age were pooled based on 
the clinical groups (disease versus control). The Seppro lgY14 spin column 
immunodepletion method was to remove the most plasma-abundant proteins 
including Albumin and Immunoglobulins (Igs). Typically, 120pg protein was 
resuspended at a final concentration of 10pg/pl in lysis DIGE buffer (30mM Tris, 
8M urea, 4% CHAPS, pH8.5) and left on ice for 10 minute. A total of 960pmol 
CyDye (GE Healthcare reconstituted in DMF) was added and incubated 30 
minutes at 4°C. The reaction was stopped within 10 minutes of adding 10mM
L-Lysine. Cy5 and Cy3 were used to label two different disease groups, whilst Cy2 
was always used to label a pool of all disease groups (namely CC, UM, SMA and 
CM) to allow comparison between gels. For each gel, all three labeled samples 
were mixed together and buffered in DIGE isoelectrofocusing (IEF) buffer (8M 
urea, 4% [w/v] CHAPS, 0.4% [v/v] carrier ampholyte, 0.0004% [w/v] bromophenol 
blue, 130 mM DTT) to a total of 200pl. Samples were applied onto ReadyStrip IPG 
strips (pH 3-10, 11 cm, Bio-Rad, UK) and actively rehydrated for 13 hours 40 
minutes at 50 V  followed by the IEF (250 V  for 15 min linear, 8,000 V  for 2 hours 
linear, 8,000 V  for 35,000 V/hour rapid) using a PROTEAN IEF cell (Bio-Rad, UK).
After IEF, the IPG strips were immediately equilibrated: strips were 
transferred to 2% (w/v) DTT in equilibration buffer (6M urea, 2% (w/v) SDS, 20%  
(v/v) glycerol, 50 mM Tris pH 8.8) for 15 minutes followed by another 15 minutes in 
2.5 % (w/v) iodoacetamide in equilibration buffer. Thereafter, strips were then 
processed to SDS-PAGE.
2.2.1 SDS-PAGE: Second Dimension Electrophoresis
Bio-Rad precast Criterion gels that accommodates 11cm strips and running 
buffer (1x Tris/Glycine/SDS) were used in the second dimensional gel. The IPG 
strip was held gel side up and the plastic backing was placed against the back of 
the gel cassette. The strip was centered at the middle of the gel and pressed 
slightly with the aid of the forceps until it firmly touched the gel.
Paper dipped in Precision Plus Protein standard ranging from 10kDa to 
250kDa was placed into the designated well on the right side of the gel with the aid 
of forceps. Overlay agarose (Bio-Rad) was used to seal the precision plus 
standard and the strip. After the agarose has solidified, the electrophoresis was 
performed in the criterion cell, connected to power supply at 200V (constant) for 
an hour.
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2.2.2.Two-Dimensional (2D) Gel electrophoresis (2DE)
120pg plasma protein containing a pooled sample of all disease groups 
was resuspended in 125pL of sample IEF rehydration buffer (8M urea, 4% [w/v] 
CHAPS, 2% [v/v] carrier ampholyte, 0.0002% [w/v] bromophenol blue, 65 mM 
DTT) and shaken for 2 h at room temperature. Samples were applied onto 
ReadyStrip, 11 CM IPG strips (Bio-Rad, U.K.) and actively rehydrated for 13 h and 
40 min at 50 V. Thereafter, the IEF (250 V  for 15 min linear, 4000 V  for 2 h linear, 
4000 V  for 10 000 V/h rapid) was performed in a PROTEAN IEF cell (Bio-Rad, 
U.K.).
After the IEF, strips were either stored at -8 0  °C or processed immediately. 
For equilibration, strips were transferred to 2% (w/v) DTT in equilibration buffer 
followed by 15 min in 2.5% (w/v) iodoacetamide in equilibration buffer. The 
proteins were further fractionated by SDS-PAGE (as described above). The gel 
was rinsed trice in water for 10 minutes to remove the SDS and then stained for an 
hour in Coomassie, CooBlue stain (Interchim) The Coomassie stained gel was 
then destained in water until a clear background was achieved.
2.2.3 Gel Analysis
The gels were analyzed with Bio-Rad PDQuest. Differentially expressed 
spots were selected if showing a change of more than 1.5-fold expression 
between two groups; disease versus control as quantified by the PDQuest (Bio- 
Rad). The Coomassie stained gel was aligned to DIGE images to select spots for 
excision. The PDQuest (Bio-rad) software was also used to excise spots of 
interest using EXQuest spot cutter.
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2.2.4 Mass Spectrometry Analysis
Excised spots were washed in 200mM ammonium bicarbonate in 50% 
acetonitrile (ACN) for 30 minutes at 37°C. This step was repeated 3-5 times until 
spots were completely de-stained. The spots were incubated in 20mM DTT 
(prepared in 200mM ammonium bicarbonate in 50% ACN) for an hour at 37°C 
followed by a wash without DTT. Spots were then incubated in 5mM 
iodoacetamide (prepared in 200mM ammonium bicarbonate in 50% ACN) for 20 
minutes at 37°C. Spots were further washed twice in 20mM ammonium 
bicarbonate in 50% ACN and supernatant removed. ACN (100%) was added for 
15 minutes until spots were shrunk opaque, the supernatant was again removed 
and spots were left to dry.
In-gel digestion was performed by adding 2ug/ml Trypsin Gold (Promega) 
and then left at 32°C for 16 hours to recover the spot. Trypsin supernatant was 
then processed to LC-MS/MS analysis using the OrbiTrap LC-MS 
(ThermoScientific). Peptide profile was extracted and transferred to the Mascot 
database for protein identification.
2.3 Immuno-probing Assays for Hp
Western blotting and immuno-probing were performed in order to determine 
the different Hp phenotypes in the population. After the initial separation of the 
proteins using the SDS-PAGE, the proteins were transferred to a nitrocellulose or 
PVDF membrane by western blotting before the immuno-probing assay.
2.3.1 SDS-PAGE
The volume of plasma sample corresponding to 20pg of total protein or 
10,000ng/ml_ of Hp as determined from ELISA was diluted in lysis buffer (7.5mM  
Tris, 2M urea and 1% CHAPS) and further diluted 1:1 in Laemmli buffer (Bio-Rad)
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containing the recommended volume of (3-mercaptoethanol (BME). The proteins 
were then denatured in the heat block at 98°C for 5-10 minutes. Thereafter, tubes 
were briefly centrifuged before loading the protein into the gel. A 16% gel made 
from both resolving gel [30% acrylamide stock, resolving buffer (1.5M Tris buffer, 
pH 8.8 and 10% (w/v) SDS), distilled water, 10% or 50pl of ammonium 
persulphate; APS and 10pL TEMED] and stacking gel [30% acrylamide, stacking 
buffer (0.5M Tris buffer, pH6.8, 10% SDS w/v), distilled water, 50pL APS and 10pL 
TEMED] was used. The electrophoresis was performed in 1X Tris/glycine/SDS 
buffer (geneflowR) at 120V for the first 20 minutes and 150V for the second 25 
minutes.
2.3.2 Western Blotting
Blotting to PVDF or nitrocellulose membrane was performed in a Bio-Rad 
trans-blot cell using electro-blotting buffer (39mM glycine, 48mM Tris-base, 
0.0375% SDS, 20% methanol and distilled water). The sandwich was prepared in 
a gel holder cassette. Briefly, a pieces of fiber presoaked in the electro blotting 
buffer is placed on the clear panel of the cassette followed by pre-soaked pieces 
of filter paper that is about the size of the gel. A PDVF or nitrocellulose membrane 
was soaked briefly in methanol and in the electro-blotting buffer and was placed 
on top of the pre-soaked filter paper, taking care to avoid air bubbles. Thereafter, 
the gel was placed on the nitrocellulose or PVDF membrane. The sandwich was 
completed by placing a piece of filter paper on top of the gel followed by another 
pre-soaked fiber pad. The sandwich cassette was then closed and placed in the 
buffer tank with the clear panel facing the red anode. Electro-blotting buffer was 
added up to the recommended mark on the tank. The cell was connected to the 
power supply at a constant voltage of 30V overnight (approximately 15-16 hours). 
Thereafter, the nitrocellulose was removed and stained with ponceau S prior to the
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blocking step in order to briefly visualize the transferred protein.
2.3.3 Immuno-probing for Hp
The membrane was placed in 10mL blocking solution [2-3% marvel milk in 
PBS-tween (1X PBS and 0.1% Tween 20)] for an hour. Thereafter the membrane 
was incubated in polyclonal rabbit anti-human Hp (Dako-Cytomation) primary 
antibody (diluted 1 in 10,000 in blocking solution) with mild shaking for 1 hour at 
room temperature or 4°C overnight. Thereafter, the nitrocellulose was washed 
thrice in PBS-tween for a minimum duration of 20 minutes at room temperature 
and was incubated at room temperature for 2 hours in fluorescent goat anti-rabbit 
IgG secondary antibody (Alexa FlourR 488) diluted 1 in 5000 in PBS-tween. 
Another washing step was performed and the nitrocellulose was rinsed in water. 
The Pharos FX™ Plus Molecular Imager (Bio-Rad) was used to scan the blot for 
the protein (Hp) bands.
Alternatively, goat anti-rabbit IgG HRP-conjugated secondary antibody 
solution was used. The membrane was incubated for an hour at room temperature 
with gentle shaking in HRP-conjugated secondary antibody diluted 1 in 10,000 in 
blocking solution. Thereafter, the blot was rinsed in fresh wash buffer for 5-10 
minutes with gentle agitation.
For chemi-luminescent detection; an equal volume of HRP-substrate 
solution, 3mL luminol reagent and 3mL peroxide solution mixed in a clean 
container and allowed to stand for 10 minutes in the dark was used to incubate the 
membrane for 5 minutes at room temperature. Thereafter, the blot was removed 
and was covered in a clean plastic wrap avoiding air bubbles. It was then exposed 
to X-ray film in the dark for 10-30 seconds and the film was developed for band 
visualization.
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2.4 Enzyme-Linked Immunosorbent Assays (ELISA)
ELISA was used for the accurate quantification of some plasma proteins of 
interest. All the standard curves for the assays described below are found in the 
Appendix 1.
2.4.1 Quantitative Determination of Plasma Hp
Hp level in the plasma samples were quantified using an Human Hp 
Sandwich Enzyme-Linked Immunosorbent Assay (sandwich ELISA; sELISA) kit 
(Genway) and manufacturer’s procedure with slight modification. Plasma samples 
were diluted 1/20, 1/500, 1/1000, 1/10,000 and 1/20,000 in phosphate buffered 
saline (PBS) to ensure the detection of any Hp present either at low or high 
concentrations in the plasma. Affinity purified Chicken IgY against Human Hp was 
diluted in coating buffer (0.05M sodium carbonate-bicarbonate, pH 9.6) to working 
concentration of 5pg/mL and was used to coat the plate by adding 100pL to each 
well of 96 well plates.
The plates were then incubated at room temperature for 1 hour or overnight 
at 4°C. Thereafter, 400pL of blocking solution (50 mM Tris-HCI, 140 mM NaCI, 1% 
BSA, pH 8.0) was added to each well and incubated for an hour at room 
temperature. Affinity purified human Hp used, as the standard was diluted 1 in 10 
in PBS to a concentration of 200ng/mL as the stock. Serial dilutions at 1:3 were 
then made from the stock to give the lowest standard concentration of 0.27ng/mL.
One hundred microlitre (100pL) of both standard and samples were added 
to the respective wells excluding blank. The plates were incubated at room 
temperature for an hour. Thereafter, wells were washed five times with washing 
buffer (0.05% Tween 20 in PBS, pH 7.4). For each washing step, the wells were 
filled with washing buffer, swirled on the table and allowed to stand for a minute. 
Thereafter, the detection antibody (100pL), HRP conjugated chicken IgY anti­
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human Hp diluted 1:2000 in conjugate diluent (50mM Tris, 0.14M NaCI, 1%BSA, 
0.05% Tween 20, pH 8.0) were added to each well and incubated at room 
temperature for an hour. Another washing step was performed as described 
above. Thereafter, OPD substrate was prepared at 1 mg/mL by dissolving one 
OPD tablet (Acros Organics) in 20ml_ citrate-phosphate buffer (50mM citrate- 
phosphate with 30% of H2C>2 in distilled water) and 100pL of it was added to the 
respective wells and the plate was incubated for 10-30 minutes.
A stop solution, 2M H2SO4 (1 OOjjL) was added to stop the OPD reaction 
after a considerable colour formation within 15-20 minutes. Plates were read for 
absorbance at 490nm with a FLUorStar-Omega ELISA plate reader (BMG- 
Labtech). A MasterPlex ReaderFit v2.0 software (MiraiBio Group, Hitachi Solutions 
America, Ltd.) was used to generate a five to four parameter logistic (5/4-PL) 
standard curve-fit and the concentrations of the unknown were determined from 
the standard curve.
2.4.2 Quantitative measurements of plasma Hp1-1, Hp2-1 and Hp2-2
All the samples were separated based on their Hp genotypes or 
phenotypes. Sandwich ELISA was performed to quantify the level of each 
phenotype of the protein. Human Hp containing the appropriate amount of its 
entire sub-units (a1, a2-chains and the p-chain) was used as the standard. All 
other procedures were the same as those of Hp sELISA described above. The 
phenotypes were randomly quantified together in order not to introduce variation.
2.4.3 Quantitative measurement of plasma Hemopexin (HPx) levels
Plasma levels of HPx were measured using the human HPx sELISA kit 
(Genway) and the manufacturer’s instruction. The anti-human HPx antibody was 
adsorbed to the surface of polystyrene microtitre wells. Standards or calibrators
84
diluted 1 in 2 from 200ng/mL to 6.25ng/mL and samples diluted 1 in 40,000 were 
added to the designated wells. After the washing steps, anti-HPx-HRP conjugate 
was added for 2 hours and was followed by another washing steps. The enzyme 
bound to the immunosorbent was assayed by adding 3,3,5,5, tetramethylbenzidine 
(TMB). The amount of bound enzyme varies directly with the concentration of HPx 
in the samples. The absorbance was read at 450nm. The standard curve and the 
concentration of unknown were determined as mentioned in section 2.4.1.
2.4.4 Measurement of human plasma free Haemoglobin (fHb) levels
Plasma fHb was assayed using Human-fHb ELISA kit (MyBioscience) and 
manufacturer instruction. The standards were diluted 1 in 2 from 1000ng/mL as 
the highest concentration to 15.625ng/mL as the lowest concentration. Samples 
were diluted 1 in 800 in the same diluent. The assay employed direct competitive 
inhibition enzyme immunoassay technique. Briefly, antibody specific to 
haemoglobin (Hb) was coated to the plate. 50pL of standards, samples and biotin- 
conjugated Hp were pipetted into the wells and incubated at 37°C for 40 minutes. 
A competitive inhibition reaction was then launched between Hb (standard or 
samples) and biotin conjugated Hb for the precoated Hb antibody. After the 
washing steps, 100pL of avidin conjugated HRP was added and incubated at 37°C 
for 40 minutes and was followed by another washing step. A substrate solution, 
90pL of TMB was added and incubated at 37°C for 20 minutes. Thereafter, 50pL 
of stop solution was added and the absorbance was read at 450nm with 
wavelength correction at 540nm. The colour formed was inversely proportional to 
the amount of fHb bound in the initial step. Unknown concentrations were 
determined from the standard curve as earlier mentioned in section 2.4.1.
This assay was designed to avoid the measurement of free haem in the 
plasma, as free haem does not have the globin moiety that is the target of the
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monoclonal antibody.
2.4.5 Quantitative measurement of Plasma Lactate Dehydrogenase (LDH)
The level of LDH was measured by sELISA using human LDH ELISA kit 
(Cloud-clone Corp) and the manufacturer instructions but with slight modifications. 
Plasma samples were diluted 1:200 in PBS while the standard was diluted 1 in 2 
ranging from 10ng/mL to 0.156ng/mL. Plates were read at 450nm and the 
concentrations were calculated from the standard curve as earlier described in 
section 2.4.1.
2.4.6 Quantitative measurement of sCD163 by ELISA
Mouse anti-human CD163 (360pg/mL) reconstituted in PBS to 2pg/mL was 
used as the capture antibody and the biotinylated mouse anti-human antibody 
(180pg/mL) reconstituted in reagent diluent (1%BSA in PBS) to 1pg/mL was used 
as the detection antibody while the human CD163 (520ng/mL) was used as the 
standard. Both the antibodies and the standard were purchased from R&D. The 
standard was diluted 2-fold in reagent diluent with concentration ranging from 
20,000pg/mL to 312.5pg/mL and the samples were diluted 1 in 100 in the same 
diluent. Tween 20 (0.05%) in PBS, pH7.2 was used as the wash buffer, TMB 
reagents (R&D) and H2O2 mixed 1:1 was used as substrate solution and 2N 
H2SO4 was used as the stop solution. The ELISA was performed following the 
manufacturer instruction. The concentration of the unknowns was determined 
from the standard curve as described in section 2.4.1.
2.4.7 Quantitative measurement of Plasma Clusterin (CLU)
The human plasma CLU levels were quantified using human CLU ELISA kit 
(Ray Biotech. Inc.) and the manufacturer’s manual. The plasma samples were
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diluted 1 in 50,000 in 1X assay diluent. A 2-fold dilution was performed for the 
standard with concentrations ranging from 20,000pg/mL to 19.53pg/mL. Both 
standard and samples (100pL) were added to the designated wells of the 96 wells 
plate that have been coated with human anti-CLU antibodies. The plate was then 
incubated at 4°C overnight with gentle shaking. Unbound analytes were removed 
in the washing steps. Biotinylated antibody (1x) was added to the plate and 
incubated for 1 hour at room temperature. After another washing steps, the HRP- 
streptavidin solution was added for 45 minutes followed by another subsequent 
washing steps to remove the unbound anti-CLU-HRP. The amount of CLU bound 
to the enzyme-labelled antibody was assayed by adding TMB. After 15-20 
minutes, the reaction was stopped with 50ul of the stop solution. The 
concentration of the unknowns was determined from the standard curve as 
described in section 2.4.1 above.
2.4.8 Quantitative measurement of Plasma C-reactive protein (CRP)
The plasma level for CRP was quantified using CRP human ELISA kit (Invitrogen) 
and the manufacturer’s instruction to measure the acute phase responsiveness. 
The plasma was diluted 1 in 50,000 and the standard was diluted in 2-fold with 
concentrations ranging from 1200pg/mL as the highest standard to 18.75pg/mL as 
the lowest. The concentration of unknown was determined from the blank 
corrected absorbance and the standard curve as described in section
2.4.9.Quantitative measurement of plasma SOD-1 levels by ELISA
The plasma levels of soluble superoxide dismutase-1 (SOD-1) were 
measured by the method of ELISA using a commercialized human SOD-1 ELISA 
kit (Cloud-clone Corp) and the manufacturer instructions. Polyclonal antibody 
against human SOD-1 was used as the primary antibody. The plasma samples
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were diluted 1 in 500 in PBS. A stock of 4,000pg/mL was made from the standard 
(32,000pg/mL as supplied) and was further diluted 1 in 2 in PBS to the lowest 
standard concentration of 62.5pg/mL. The absorbance measurement and 
determination of unknown concentrations were as described in section 2.4.1.
2.5 Human Free-haem Assay
The free-haem was measured by colorimetric assay using haemin 
colorimetric assay kit purchased from BioVision Inc. and the manufacturer’s 
manual. The kit utilizes peroxidase activity in the presence of free-haem, even in 
trace amount, to produce colour change measurable at 570nm. Briefly, the plasma 
samples were diluted 1:1000 in the haemin assay buffer. Hemin standard was also 
diluted in haemin assay buffer to 40, 80, 120, 160, and 200nM. Both sample and 
standard were incubated with the kit reaction mix (prepared from enzyme mix, 
haem substrate, Assay buffer and probe in the DMSO as supplied) for 30-60 
minutes. The amount of free haem in the plasma was quantified from the blank 
corrected absorbance and the standard curve.
2.6 Cytokine Multiplex Assay
Human plasma cytokines were measured using the human cytokine 17Bio- 
plex beads immunoassay kit (Bio-Rad) and the manufacturer’s instructions. 
Samples were diluted 1 in 5 prior to mixing with magnetic beads. The machine 
was calibrated prior to the measurement and plates were read using the Bio-Plex 
200 Systems (Bio-Rad). The amounts of analytes as assayed in each of the 
samples were analyzed using the Bio-Plex Manager 6.0 software (Bio-Rad 
Laboratories) or the MasterPlex ReaderFit v2.0 software (MiraiBio Group, Hitachi 
Solutions America, Ltd).
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2.7 Hp Genotyping by PCR
Genotyping was performed particularly when there was null to low level of 
plasma Hp, for those subjects without plasma samples but only DNA samples and 
to confirm the phenotypes that was determined by western blotting in case of 
antibody cross-reactivity with Haptoglobin Related Protein (HPR).
A forward primer, Sa5 (5’ GAGGGGAGCTTGCCTTTCCATTG 3’) and 
reverse primer, Sa6 (5’ GAGA l l l I IGAGCCCTGGCTGGTG 3’) were designed 
for both Hp1 and Hp2 alleles (Fig.2.1).
Other primers, such as the forward, LS1 (5’ TGAGCACTTAAGAGAGCAGGC 3’) 
and reverse, LS2 (5’ CTTCACATTCAGGAAGTTTATCTCC 3’) were designed for 
the specific genotyping of only the Hp2 allele (Fig.2.1).
The PCR mix used for LS1 and LS2 primers is as follows; Kapa HiFi HS 
DNA polymerase (0.5pL); 10mM Kappa DNTP mix (0.75pL); Kapa HiFi fidelity 
buffer (0.5pL); forward and reverse primers (10pM each); template DNA (50ng) 
and distilled water to a total reaction volume of 25pL.
The PCR was performed at initial denaturation, 95°C, 3 minutes and 35 
cycles of second denaturation (98°C, 20 seconds), annealing (61.5°C, 15 
seconds), and extension (72°C, 2 minutes). A final extension step was performed 
at 72°C for 2 minutes.
The PCR reaction for Sa5 and Sa6 is similar to that of LS1 and LS2 but with 
100ng of template DNA, an additional 2mM of MgCI2 and at an annealing 
temperature of 69.2°C or 71.5°C depending on the PCR machine (Eppendorf 
Mastercycler).
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Figure 2.1 Primer mapping for Hp genotyping
The positions for the pairs of primers Sa5 and Sa6 are as indicated by the red arrows and the LS1 
and LS2, which are specific for only Hp2 allele are indicated by the yellow arrows. Ex=exons, 
labeled 1 to 7. Both exon 3 and 4 are duplicated in the Hp2 allele. The Hp2 allele is 1.7kb longer 
than the Hp1 allele due to the duplication. The combinations of these primers were used for 
specific genotyping of Hp among subjects.
2.7.1 Gei Electrophoresis
To check for the right size of PCR products (amplicon), gel electrophoresis 
was performed with 1.0-0.7g of Agarose melted in 100mL 1X TAE running buffer. 
Ethidium Bromide (1pL) was added to the melted agarose and the running 1X TAE 
buffer. PCR product (12pL) mixed with loading dye (either Bioline or prepared) 
together with 1kb hyperladder (Bioline) was loaded into designated wells on the 
gel. The electrophoresis was performed mostly at 98V (higher voltage was 
dependent on the size of the tank, the distance between the electrodes of the tank, 
~8-10V/cm) until the dye front reached the desired point depending on the size of 
the PCR product. The DNA was then visualized at 302nm using a UVP 
transilluminator.
2.8 High Throughput Hp gene sequencing
The Hp gene was sequenced using amplicon-based Nextera lllumina 
sequencing on a MiSeq machine. Overlapping amplicons covering the entire 
length of the Hp gene extending to 3.34kb upstream of the first exon were 
designed (Fig. 2.2) and generated by monoplex PCR. Both the promoter and the
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distal upstream region of the promoter were covered in the design of the 
amplicons (Fig. 2.2).
In order to generate these amplicons per sample, monoplex PCRs was 
performed for each amplicon specific primer that was used (Table 2.1). This was 
because multiplex PCR failed due to differences in the Tm of the primers and the 
regions of the Hp gene; some regions were more difficult to amplify. A validated 
control was introduced into each set of PCR reaction to check for optimum 
performance of the PCRs.
2.8.1. DNA quantification assay
The concentration of DNA was quantified using the picoGreen fluorescence 
assay (Invitrogen), a more sensitive assay than the UV absorbance method. The 
assay utilizes a cyanide dye that fluoresces upon binding to dsDNA. Briefly, DNA 
standard was prepared in a 1x TE buffer (10mM Tris, 1mM EDTA, pH7.5) in a two­
fold dilution to final DNA concentration of 2000ng/mL to 25ng/ml_ and containing 
200-5ng of DNA per well. The DNA samples were diluted 1:100 in 1x TE buffer. 
Picogreen reagent (lOOpL) diluted 1:200 in the same buffer was mixed with both 
standard and samples and incubated 2-5 minutes at room temperature prior to 
measuring the fluorescence at 420nm excitation and 525nm emission 
wavelengths. The amount of DNA was quantified from the standard curve.
2.8.2 Preparation of Hp amplicon by monoplex PCR
Overlapping primers specific to different regions on the Hp gene were 
designed to produce overlapping fragments (amplicons) of the entire Hp gene 
(Fig. 2.2) in a series of monoplex PCRs. PCRs were performed for each of the 9 
primers to generate 9 amplicons for each sample or patient. A total of 63 different 
PCR reactions were performed as earlier mentioned.
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The amplicons from each pair of primers were pooled per well or samples 
after the right sizes of the amplicons were visualized by gel analysis; 
electrophoresis (as described in 2.7.1). The pooled amplicons were further used in 
the library preparation for Nextera Next Generation lllumina Sequencing on MiSeq.
16:72083574 16:72095400
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3 34kb 1 6kb 1.77kb
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Figure 2.2 Primer mapping for amplicon amplification
Primers specific to the different regions of the Hp gene were designed to produce overlapping 
amplicons across the entire Hp length as indicated by dotted upward arrows, which indicate the 
start and stop position on chromosomes 16 covered by our primers. Short single arrows indicate 
the respective positions of primers. Ex1= Exon 1 etc, Single arrowheads indicate primers positions.
As mentioned earlier, the primers were designed to cover the Hp gene from 
3.4kb upstream of the start codon to beyond exon 7 with the Hp2 allele and exon 5 
with the Hp1 allele, and covering 16:72083574-72095400 in the GRCh37 or hg19 
version of the human genome database (Fig. 2.2). The Hp2 allele from the 
GRCh37 version of the human genome database was used as the reference gene 
for the primer design. The primer recognizes corresponding regions of the Hp1 
allele but shorter PCR products were produced for those primers covering the 
regions of difference/duplication between Hp1 and Hp2 alleles (Fig. 2.2).
The PCRs, particularly the annealing temperatures were determined after 
series of optimization for each primer in a gradient PCR. KAPA HiFi HotStart 
ReadyMix (2.5mM MgCI, 0.3mM of each dNTP, 1U of KAPA HiFi HotStart DNA 
polymerase per 50pl_ reaction volume) PCR kit (KK2502; KapaBiosystems) was
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used in most cases except for LS1, LS2 and Sa5, Sa6 primers (KK2501; 
KapaBiosystems). Template DNA (50-1 OOng) was used for the PCR. The Tmo of 
both forward and reverse primers were designed to be as close as possible. There 
were no secondary structure formations by the primers. The %GC of the primers 
used ranges from 50-57.8.
All the designed primers were purchased from Sigma-Aldrich. On arrival, 
the lyophilized primers were reconstituted in distilled water (dH20 )  by adding the 
recommended volume to make 100pM. The primers were then further diluted 1:10 
to a working concentration of 10pM. The final concentration of the primer in the 
PCR mix was 0.3pM in a 25pL reaction volume on adding 0.75pL of 10pM working 
concentration. Table 2.1 shows the list of primers, PCR mix and reaction.
2.8.4 NexteraR XT DNA library preparation
The DNA quality and quantity was checked before commencing the process 
of library preparation. The minimum amount required for Hp sequencing on MiSeq 
is 1 ng of DNA. The library was prepared as discussed below.
2.8.4.1 Amplicon quality and quantity check
Each amplicon (5pL) corresponding to each patient were pooled together 
following the working template. At the end, each well of the 96 well plates 
contained fully amplified overlapping fragments of Hp for each sample. The 
concentrations and quality of the pooled amplicons (DNA) were examined on a 
Glomax and Bioanalyzer prior to library preparation. All samples were of a good 
quality with concentrations between 22-100ng/mL on the average.
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2.8.4.2 Nextera XT DNA library preparation
For library preparation, a Nextera XT DNA sample preparation and index 
kits (lllumina) were purchased according to the total number of samples. The 
sample preparation kit include the Amplicon Tagment Mix (ATM), Tagment DNA 
buffer (TD), Nextera PCR Master mix (NPM), Resuspension buffer (RSB), Library 
Normalization Additivel (LNA1), Library Normalization W ashl (LNW1), 
Hybridization Buffer (HT1), Neutralize Tagment buffer (NT), Library Normalization 
Bead-1 (LNB1), Library Normalization Storage buffer 1 (LNS1), index primers 
S501-S508 and N701-N712. Prior to the onset of library preparation, the kits were 
stored as recommended. The recommended user supplied consumables were 
also supplied for the assay.
The Nextera sample preparation kits enable up to 24 or 96-library 
preparation with unique indexes to ensure a library with proper index combination 
in the multiplex pool. The Nextera XT DNA Sample Preparation Kit uses an 
engineered transposome to simultaneously fragment (enzymatic DNA 
fragmentation to ~300-500bp) and tag input DNA, adding unique adapter 
sequences in the process. A limited-cycle PCR uses these adapter sequences to 
amplify the insert DNA. The PCR also adds index sequences on both ends of the 
DNA, thus enabling dual-indexed sequencing of pooled libraries on lllumina MiSeq 
as diagrammatically represented below (Fig. 2.3).
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Figure 2.3 Illustrating Nextera XT assay
A. The illumina Nextera assay uses enzymes called transposomes to cut DNA into short segments 
and (B) at the same time adding adapters. (C) A reduced cycle PCR is used to add unique index.
The overall process produces a sequencing ready fragment.
The libraries were prepared following the nextera XT DNA library 
preparation guide.
Briefly,
1. Tagmentation of DNA was performed with 5pl (1ng) input DNA, 10pl TD 
and 5pl ATM to allow amplification by PCR in subsequent step.
2. A limited PCR amplication step was performed with 15pl of NPM and 5pl of 
index primers S501-508 (i5) and N701-712 (i7) arranged on column A-H 
and row 1-12 respectively on illumina index plate fixture such that each 
sample had unique index sequences. The PCR was performed at 72°C for 
3 minutes, 95°C for 30 seconds, and 12 cycles of: 95°C for 10 seconds, 
55°C for 30 seconds, 72°C for 30 seconds, and 72°C for 5 minute and then 
held at 10°C. This step ensured the amplification of tagmented DNA and 
addition of index i5 and i7 required for cluster formation.
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3. A PCR clean-up step was performed with RSB, AMPure XP beads and 
80% freshly prepared ethanol. This procedure was performed to purify the 
library and to remove very short library fragments from the population.
4. The LNA1, LNB1, LNW1, LNS1 and freshly prepared 0.1 N NaOH and 
illumina procedure were used to normalize the library to ensure equal 
library representation in the pooled samples.
5. To generate sequence ready fragments, equal volumes of normalized 
libraries were combined, diluted in HT1 and heat denatured prior to MiSeq 
sequencing. Briefly, 5pL of each library to be sequenced were transferred 
column by column to a PCR 8-tube strip. Pipette tips were changed at each 
point to avoid sample cross-contamination. The content of the 8-PCR tubes 
were further combined into a single Eppendorf tube and labeled as Pooled 
Amplicon Libray (PAF), which was further diluted with 576pL of HT1 into 
another fresh Eppendorf tube labeled as Diluted Amplicon Library (DAL). A 
heat denaturation process was performed on the DAL at 96°C for 2minutes 
and was mixed and kept on an ice-water bath for 5 minutes. Thereafter, the 
DAL was loaded into the MiSeq reagent cartridge in order to ensure 
efficient loading of the MiSeq flowcell for sequencing.
6. A trained technician sequenced the library in accordance with the MiSeq 
system user guide. A phred-scale quality score >30% was used for base 
calling in the run summary.
To avoid sample DNA contamination, pre and post PCR were done on a separate 
workbench. A 0.5% sodium hypochlorite (10% bleach) was used to daily clean the 
workbench.
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2.9 Variants calling analysis
Data from the MiSeq machine were in the FASTQ file format and were used 
to call the variant as specified in the flow chart below (Fig. 2.4).
FASTQ-MISEQ O UTPUT FILE
NNHHI
Reference genome BWA
BAM file 
■■■■■■■■■■■■
SAMtools
Sorted BAM 
Index ,bai
h H h H m
Reference genom e SAMtools
VCF File IGV
Figure 2.4 Flow chart of DNA sequence data analysis
The FASTQ output files from the illumina MiSeq machine are aligned to the reference genome 
using BWA to produce an output .BAM file. The SAMTOOLs uses the .BAM output file and 
reference genome to produce the .VCF text formats that contain the genotypes used for
downstream data analysis.
Briefly, the FASTQ output file from the paired-end sequencing on MiSeq 
was aligned to chromosome (CHRM) 16: 72083574-72095400 on Fig 19 using the 
Burrows-Wheeler Alignment tool (BWA). The BWA produced an alignment output 
in the BAM format, which showed reads aligned to the reference genome. Reads 
in the BAM format were in the same arrangement as the FASTQ, a line for a read.
The SAMtools was used for finding variants based on coverage (read 
depth), number of reads containing reference and alternate bases, mapping 
quality of the reads, and the existence of nearby indels. The SAMtools produced 
an ouput file called the sorted BAM format, an indexed binary (index .bai) file that 
is smaller, faster and occupies less space than the SAM format and also arranges 
the sequences by coordinates.
The reference genome and an appropriate SAMtools command line was 
used to produce the .VCF file containing the variants. A  threshold of 20 for quality
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score and 200 reads was used as the standard for variant calling.
For visualization, both the VCF and the BAM files were uploaded into the 
IGV and the appropriate coordinate for the gene was specified.
A control measure was introduced right from the outset to check for cross­
contamination at both the amplicon and the library preparation; samples from 
mother, father, and children introduced into the assay were used as the control 
and the result indicated that there was no sample cross-contamination during the 
amplicon and library preparation. This is because the SNPs in the children were 
from either of the parents or both when visualized in the IGV. It would be highly 
unlikely for the SNPs found in the children samples to be identical to both or either 
of the parents if the samples were cross contaminated.
2.9.1 Detecting Known Variant from unknown Variant
The variation viewer in NCBI (http://www.ncbi.nlm.nih.gov/variation/view/) 
was used to search for known and unknown variants in the VCF file. The VGF file 
was uploaded to the variation viewer by clicking on the link, ‘y ° ur data’ at the 
search component. On uploading the VCF file, the coordinate of interest on the 
chromosomes was specified. The sequence viewer then displays the gene tract 
centered on the Hp gene with that of ClinVar short variation, ClinVar large 
variation and dbSNPs databases. The graphical display showed the uploaded data 
as added tracts (Fig.2.5). Clicking on the specified variant zoomed the display to 
the location of that variant/feature on the gene.
If the specified variants are known and already present in the database, 
there will be an alignment at the same position between those variant in the 
database and those in the added tract (Fig. 2.5). Unknown variants are found at a 
different position with no alignment to any variant in the databases (Fig. 2.5).
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Figure 2.5 identification of known and unknown Hp sequence variants
Any known variant in the uploaded .vcf file will align with the dbSNP variant, indicated in red colour 
and having a unique rs number (SNP ID). Unknown variant have no corresponding variant in 
dbSNP. Hp sequence corresponding to the position and region on the Hp gene where the variants
occur are as displayed.
9.2 Plasma Hp levels and Hp gene sequence variants
To observe the cause and effect between plasma Hp levels and Hp gene 
sequence variants, the plasma Hp level of healthy individuals were studied in 
association with the sequence variants. An Hp gene variant was associated with 
plasma Hp levels by considering the population with the variants and having the 
corresponding plasma Hp level. An Hp variant was said to be associated with 
normal Hp plasma levels if >70% of the population with the variant have normal 
Hp plasma levels and vice versa. The association of the variants within the 
disease groups were then computed to determine the association of the variant 
with the disease group. Plasma Hp levels was considered independent of age and 
sex. There are no significant association between plasma Hp levels and age or 
sex.
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CHAPTER THREE
3.0 DEMOGRAPHICS, STUDY DESIGN AND STATISTICAL
ANALYSIS
3.1 Background
This chapter addresses the clinical and demographic data for the cohort as 
well as the preliminary investigations that form the basis of the research focus. 
This study was part of a research cluster under the auspices of the Childhood 
Malaria Research Group (CMRG) formed between the laboratory of Delmiro 
Fernandez-Reyes at the National Institute for Medical Research; now the Francis 
Crick Institute, UK and University College Hospital (UCH), Ibadan, Nigeria. 
Members of the cluster participated in clinical examination of the patients as well 
as the sample collection.
Trained physicians and laboratory scientists at the UCH, Ibadan collected 
both the clinical and demographic data. Both Florence Burte and I carried out the 
preliminary investigation and I performed all of the statistical analysis and 
interpretation of the demographic, cohort and preliminary data.
3.2 Ethical Statement
The ethical committee at the Institute for Advanced Medical Research and 
Training (IMRAT) of the College of Medicine, UCH, Ibadan gave approval for this 
research with permit number: UI/EC/10/0130. Parents or guardians of study 
participants gave written consent in accordance with the World Medical 
Association ethical principles for research involving human subjects.
3.3 Study site
All participants in the cohort were recruited from Ibadan, the largest city in
sub-Saharan Africa with a dense population where malaria is holoendemic. All
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study participants were recruited under the auspices of CMRG at the UCH, in the 
city of Ibadan, Nigeria.
The city has a lengthy 8-month rainy season, with more than 10 rainy days 
per month between May and October. However, there is scant rainfall between 
November and April, a period that includes the Harmattan characterized by a hot, 
dry and dusty northeasterly wind. Malaria transmission and severe disease occur 
throughout the year. More than 12,000 children visiting the hospital are diagnosed 
as malaria positive each year; SMA and CM account for 11.3 and 19.7% of the 
clinical cases, respectively. Although severe malaria syndromes are predominant 
in children under 5 years-of-age, there is a significantly large burden of severe 
disease in children up to 16 years-of-age (Orimadegun et al., 2007).
3.4 Subjects and case definitions
We recruited children aged between 6 and 165 months (Table 3.1) from 
2010 to 2012. Three to four physicians examined each patient before the malaria 
positive clinical cases were defined. We define or categorize the malaria positive 
cases as the Uncomplicated Malaria (UM), Severe Malaria (SEVM), Severe 
Malarial Anaemia (SMA), and Cerebral Malaria (CM).
CM cases were defined as children with unarousable coma that persisted 
for more than one hour with generalized convulsion and the presence of asexual 
forms of P. falciparum. A Blantyre score of <2 was used to define coma status.
SMA was defined for conscious children with a packed cell volume (PCV) of 
<15% or a haemoglobin concentration <50g/L and the presence of asexual forms 
of the parasite and no other evident cause of the anaemia.
UM cases were defined as patients with fever and P. falciparum 
parasitaemia who did not require hospital admission and were recruited as part of 
a routine malaria parasite screening at the Children’s Out-patient Clinic.
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Patients with other complications of severe malaria such as respiratory 
distress, lactic acidosis, renal failure, hypoglycemia, and haemoglobinuria, and are 
without the strict definition of SMA and CM were regarded as severe malaria 
(SEVM) cases.
Bacterial blood culture positive cases and septicaemic patients with no 
manifestation of P. falciparum were excluded from the malaria groups but are 
included in the disease control; DC group. Patients with thalassaemia, sickle cell 
anaemia or G6PD deficiency were excluded from this study. The 1% of patients in 
the SMA and 10% of patients in the CM groups that died were excluded from the 
study. All participants in this study were effectively treated.
The disease control group (DC) comprised of malaria parasite-negative 
children with other forms of severe anaemia and fever of bacterial etiologies 
recruited on admission at the Otunba Tunwase Children’s Emergency Ward.
The community control (CC) group consisted of malaria parasite-negative 
healthy children who were recruited on school visits within the city of Ibadan.
Terms such as malaria groups are used to represent all the clinical malaria 
groups; UM, SEVM, CM and SMA. The severe groups represent the SMA, CM 
and SEVM. The disease group represents the entire malaria group and the DC 
while the clinical groups represent all the malaria groups and the controls, the CC 
and the DC.
3.5 Sample collection
Plasma samples were collected at hospital admission and through 
convalescence. The first sample collected on the day of admission prior to drug 
treatment and/or transfusions in the case of SMA patients were labeled as plasma 
sample day zero (PDO). Plasma samples collected at day 7 and 14 were 
designated as plasma sample day 7 (PD7) and day 14 (PD14). We collected other
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samples after the patient has been certified as fully recovered by a trained 
physician not part of this study. These samples were collected varying from day 28 
to 50 and designated as PD28, since the majority was collected at day 28. 
Samples were collected at PD28 only after the subjects were certified as parasite 
free by microscopy.
A very short needle was used to collect the blood into the blood tube firmly 
screwed to the syringe. This was to avoid dispensing blood into the tubes through 
the syringe, which might cause haemolysis of some red blood cells.
The majority of the subjects were lost in the follow up (Table 3.1), however, 
those subjects that were lost within each disease group have similar clinical 
characteristics with those subjects that remain, hence the subjects lost in the 
follow-up are unlikely to influence the result.
3.6 Clinical analysis and limitations
Clinical data were collected using a malaria-tailored questionnaire designed 
by the CMRG. Blood samples were collected in an EDTA blood tube and 
transferred on ice to the central malaria laboratory. Plasma was harvested 
following centrifugation (1000g, 10 minutes) and aliquots were frozen at -80°C  no 
later than 4 hours following collection.
Packed cell volume (PCV) was measured using the microhaematocrit 
method. Briefly, blood was collected in a capillary tube and was centrifuged at 
12,000g for 5 minutes. The cell volume as a percentage of the whole tube volume 
was calculated.
Malaria parasites were detected and counted by microscopy following 
Giemsa staining of thick and thin blood films. Malaria Parasite (MP) densities were 
calculated as: MP/pL = [(number malaria parasites/number white blood cells) x
8,000]. The microscopy criterion for a participant to be free of malaria was the
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absence of parasites in 100 high-power (1000X) fields. For validation and quality 
control, 1 in 10 thick blood films was randomly selected and examined 
independently by a local experienced microscopist not part of the research team. 
The Haemoglobinopathy screening and blood cultures were performed by HPLC 
and blood cultures respectively by scientist not part of this study. Subjects with any 
Haemoglobinopathy disorder and those with positive blood cultures were excluded 
from the malaria groups. Data for lactate/renal functions and glucose level were 
not made available but seems to have been determined locally in Ibadan for those 
in the SEVM group.
Quinine was administered intravenously to the entire group of patients in 
the CM group while quinine or artemether and lumefantrine under the trade name 
coartem in Nigeria were mostly used for subjects in other malaria groups. The 
entire SMA subject group was transfused at admission to the hospital after sample 
collection at PDO.
Certain parameters such as the Full Blood Count (FBC) including the Mean 
Corpuscular Volume (MCV), Mean Corpuscular Haemoglobin (MCH) and mean 
Corpuscular Haemoglobin Concentration (MCHC) were not available. The 
reticulocyte counts in each disease groups were not consistently recorded and are 
not reported in this study.
3.7 The cohort table
A total of 1, 622 plasma samples were collected at PDO, including samples 
collected for the DC and CC groups (Table 3.1). Subsequently, the numbers of 
samples decrease with follow-up to 249, 238 and 222 at PD7, 14 and 28 
respectively. Hence, full complement of samples was not obtained for all patients; 
some patients were missed through the convalescence phase (Table 3.1). Single 
time-point samples were collected for both the DC and the CC group.
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The age distributions in months as well as the PCV are presented as 
median with interquartile range; the lowest median age was that of the SMA and 
SEVM groups (Table 3.1). Low PCV was measured in the SMA, the CM+SMA 
groups and the DC group with severe non-malarial anaemia (Table 3.1). The DC 
group consisted of those with severe non-malarial anaemia with PCV value of 
14(8-23) and disease of other etiologies with PCV value of 32(27-35) (Table 3.1).
Though there was no significant difference (p=0.0657) in the PD among 
groups, a more detailed F-test showed slight differences in their mean values, 
F=2.219. The PD in the SMA is higher than those of other severe groups (Table
3.1). The Mann Whitney test showed that the PD in the SMA, CM and SEVM were 
statistically higher (P<0.05) than the UM.
Another study on this same cohort, measuring the plasma level of pfHRP2 
as an index of parasite biomass showed that the levels of pfHRP2 were 
significantly higher in the SMA group than the UM group (Huang et al., 2015), 
which was similar to the observed PD in the cohort. There were no differences in 
the PD when adjusted for age in both the severe and the uncomplicated malaria 
groups (data not shown). Malaria parasites were not detected in the DC and CC 
groups (Table 3.1). Individuals with overlapping CM and SMA syndromes 
(CM+SMA) are of lower age group (Table 3.1). Females and males were equally 
represented in the study (Table 3.1).
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3.81 Preliminary observation and study design
The major observation that formed the basis for this study was that the 
levels of Hp (both the (3 and a-chains) were as depleted in the CM as in the SMA 
(Fig. 3.1 C-D). Though there is some degree of haemolysis in the CM group, it is 
not known to be as severe as that of the SMA. We were therefore interested in 
why the plasma Hp level in the CM group is as depleted as that of the SMA? We 
then hypothesized that it is either Hp is congenitally low or has some yet unknown 
function in malaria syndromes that is responsible for its depleted level. To 
investigate our hypothesis, Hp levels were measured in the individual crude 
samples at acute onset and through convalescence to see if the low levels at 
acute onset will recover to normal on patients’ recovery. The basis for our 
hypothesis was that low Hp levels as the consequence of the disease will returns 
to normal on patients’ recovery after the disease causing haemolysis has been 
treated.
The levels of plasma HPx and some relevant proteins involved in malaria 
associated intravascular haemolysis were also quantified at acute onset and 
through convalescence to recovery. Plasma CLU levels were also quantified. 
Aside the preliminary experiments with 30 pooled samples; all other further 
investigations were based on crude plasma from individual samples.
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Figure 3.1 Protein spots identified on A) Crude plasma; B) Immunodepleted 
plasma; C) Hp spots; D) Hp Alpha-2 spots; E) Clusterine spots
A (Crude plasma)
Gel ana lysis: crude plasma
B (depleted plasma)
Gel Analysis; Seppro FT depleted
* * O
9o
~  i f  -o o -
Numbers represent location of protein spots; Spot 1 is a1-anti-chymotrypsin spot, spots 2-6 are 
haptoglobin spots, spots 7 and 8 are a1-acid-glycoprotein 1 and 2 respectively, spots 9 and 10 are 
haptoglobin (alpha chains spots); spots 14 and 15 are haemoglobin p and a, spots 17-20 are 
haemopexin spots, spot 29 and 30 are both apolipoprotein AIV, spot 31 is clusterin.
Only Fig. 3.1 B was performed using immunodepleted crude sample to remove excess albumin to
reveal hemopexin (HPx) at its proximity.
C (Hp Spots 2-6)
®D66
CC
•
®}56
CC
• m
®3oo
UM
%
^66
UM
CM CM
V  ' w
SMA SMA
E (CLU spot)
.
*
CC CC OU M
^  * *
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U M
•  - m W ' W
0
CM
O
CM
0
SM A
O
SM A
Figures. 3.1 C-E are two-dimensional-difference-gel-electrophoresis (2DIGE) gel pictures from 
crude plasma in the disease groups. In order to identify proteins that are depleted in the disease 
groups (Fig. 3.1 C-E), the two-dimensional-gel-electrophoresis (2DE) images from the CC (Fig. 
3.1A-B) were used to align with the 2DIGE images (Fig.3.1C-E) and corresponding spots on the 2D 
gel are excised for mass spectrometry identification.
These figures are based on 30 pool samples collected at acute onset (PDO).
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1
3.9 Statistical Analysis
Power statistic was used to determine the minimum sample size required in 
order to detect at least 20% difference with 80% power and a conventional level of 
alpha, 0.05. This standard convention was known to reduce the likelihood of 
making type 1 and 2 errors or detecting an effect in the absence of any such effect 
and vice versa (Bartko et al., 1988, Pulver et al., 1988, Sharp and Gahlinger, 
1988).
The effect sizes (d or F) were computed along-side the p-values in order to 
know the actual size (magnitude) of the statistical difference between/among 
groups as measured by the p-values.
An online computation software
(http://www.psychometrica.de/effect size.html#fvalue). the mean, the Standard 
Deviation (SD) and the sample size were used in computing the d-values. The d- 
values were interpreted in accordance with Cohen’s d guidelines (Cohen, 1988). 
The F-value detects difference in the mean values. Computed mean values were 
used for the F-test whether or not the mean values are shown in the charts. 
Outliers are not included in the computation of mean. The mean values were often 
computed using the column statistics feature of the prism software version 6.0 
(v6.0). Generally, data are presented as median and interquartile range in a 10-90 
percentile box plots, point graphs, scatter plots, tables and heat maps. Only the 
mean values were used in both the point graphs and the heatmaps. The prism 
v6.0 and the Excel spreadsheet were often used for the statistical analysis.
A one-way analysis of variance (ANOVA) and multiple comparison testing 
were performed to determine the difference among groups. ANOVA was not used 
if the computed Bartlett’s test indicated that the ANOVA assumption for 
homogeneity of variance have been violated and in such cases, the Brown- 
Forsythe tests were performed in place of ANOVA. In computing for ANOVA, the
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mean of each group were compared with the mean of every other group (multiple 
comparison testing). Outliers were not included during the computation of the 
mean as mentioned earlier; this was to avoid bias in the mean value. An unpaired 
nonparametric Mann-Whitney test was used to compare data between two non­
paired groups while a paired nonparametric Wilcoxon test was used for paired 
data within each disease group such as paired PDO and PD28 data. For results 
presented in the table format, nonparametric Spearman correlations to determine 
the 95% Confidence Interval (Cl) and/or P-value at 0.05 were performed. 
Statistical analysis was adjusted for age, sex and PD in some cases to test for 
such likely factors that could introduce variations.
Chi-square tests were performed to determine the difference between the 
observed and the expected Hp frequencies and whether the observed Hp 
frequencies in the populations were at Hardy-Weinberg equilibrium or a deviation 
from the null hypothesis.
Receiver Operator Characteristic (ROC) curves was plotted with CLU data 
in chapter 7 to determine the specificity and the sensitivity of the CLU assay in 
discriminating among the clinical malaria syndromes; the probability of a positive 
test result in the presence of the disease and the probability of a positive 
test result in the absence of the disease was computed by plotting 
sensitivity against 1-specificity in a R O C curve and the curves were  
interpreted based on the area under the curve (area) and the p-values. The  
p<0.001 was considered to be significant.
Basic descriptive statistics such as mean, median, mode, ratio and 
frequencies were also used when necessary.
The analysis of genomic data was performed with Burrows-Wheeler’s 
Aligner (BWA) and SAMtooLs. Both the .BAM and .VCF output files were viewed
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in the Integrative Genome Viewer (IGV) as earlier mentioned in Chapter 2. The 
.VCF file was for further computation.
We computed an Odds Ratio (OR) and 95% Confidence Interval (Cl) at the 
conventional level of alpha (0.05) in order to determine how strongly the presence 
or absence of a variant (SNP, indel) is associated with the disease in the 
population. Briefly, The OR is computed as 
a
O R  =  -  
c
a  x  d  
b x  c
Where a = Number of the diseased group with the variant 
b= Number of the Control group with the variant 
c = Number of the diseased group without the variant 
d = Number of the control group without the variant 
These values were imputed into the MedCalc online computation software 
(https://www.medcalc.org/calc/odds ratio.php) for the computation of the OR, Cl 
and p-Values.
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CHAPTER FOUR: RESULT 1
4.0 LOW Hp LEVELS COULD BE A RISK FACTOR FOR SMA
4.1 Background:
As discussed in the Introduction, Haptoglobin (Hp) being a scavenger of 
free-haemoglobin (fHb) is generally known to be a marker of haemolysis. 
Childhood Plasmodium falciparum Severe Malarial Anaemia (SMA) exhibits both 
haemolytic and inflammatory pathology.
Studies on hypohaptoglobinaemia (low plasma Hp) provide conflicting 
views regarding its aetiology in childhood malaria. On the one hand, the low level 
of plasma Hp associated with malaria infection was proposed to have a genetic 
cause, while on the other hand it has been attributed to the disease causing 
intravascular haemolysis (Delanghe et al., 1998c, Koda et al., 2000, Koda et al., 
1998b, Delanghe and Langlois, 2001); Low plasma Hp is also considered as a 
marker of haemolysis in the SMA group (Ouyang et al., 1998) but whether it is a 
risk factor or a consequence of this syndrome is unknown.
Differentiating between these etiological scenarios should provide insights 
into the role of Hp in the pathology of malaria. In order to ascertain this role, a 
case-control study with longitudinal follow-up to recovery of children was 
performed in the cohort (Table 3.1).
As earlier discussed in chapter three, the plasma samples were collected 
through convalescence in all the malaria groups (Table 3.1). Samples were 
collected at day of admission (PDO), and through convalescence; day 7 (PD7), day 
14 (PD14) and day 28. These samples were assayed for Hp and known markers 
of haemolysis: free haemoglobin (fHb) and lactate dehydrogenase; LDH (Balias, 
2013, Shah et al., 2014, Kato et al., 2006, Tabbara, 1992). The levels in children 
with SMA were compared to children with other malaria syndromes, malaria
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negative severe anaemia used here as the disease control (DC) and healthy 
malaria-negative community controls (CC).
The hypothesis to be tested was that a low Hp level as a consequence of 
haemolysis would return to normal (20-200mg/dl_) through Hp production after the 
underlying haemolysis had been arrested.
Studies have shown that a haemoglobin (Hb) level as low as 5.0 g/dL in 
severe malaria anaemia returns to normal 2-3 weeks after commencement of 
treatment (Raffray et al., 2014); there was a significant decrease in the level of 
total plasma haem at day 28 compared to day zero (Cunnington et al., 2012); 
reports have shown that Hp levels returned to normal within 1-2 weeks (Echeverry 
et al., 2016) and both Hb level and bone marrow morphology returns to normal as 
the parasite disappears from the blood either by therapy or host mechanism 
(Abdalla, 1990) within 3 weeks in the convalescence phase (Phillips et al., 1986). 
In line with these findings and coupled with the clinical observations by 
pediatricians, the 28-50 days recovery time-points might be sufficient for the Hp 
level and other clinical parameters to normalize. Hence, protein levels at PD28-50 
are considered as equivalent to normal prior to malaria onset and are comparable 
to those of malaria-negative healthy CC.
The results in this chapter show that the low circulatory plasma level of Hp 
observed during an acute life-threatening childhood SMA episode is not a 
consequence of haemolysis but a risk factor for acute or insidious onset of SMA.
4.2 Plasma Hp level in the SMA group is stable through convalescence to full 
recovery
At time of diagnosis (PDO), Hp level is low in the SMA group and remains 
low all through convalescence to full recovery (Fig. 4.1A). Levels in the SMA group 
at recovery are significantly lower (p=0.002) compared to malaria negative healthy
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CC (Fig. 4.1 A). Further analysis shows that there is a large proportion of non­
overlapping values; d=0.6 between Hp levels in the CC and that of the SMA at 
recovery and are not likely to be due to chance (Lakens, 2013, Cohen, 1988).
Unlike the observation with SMA patients, levels in the CM, SEVM and UM 
groups at recovery are not significantly different to the CC group (Fig. 4.1 B-D). 
Levels of Hp among all the time-points within the CM, SEVM and UM groups are 
not statistically different except for slight variation in both the medians and the 
mean values (Fig. 4.1 B-D). Levels of Hp in the SMA group are significantly lower 
at both onset and recovery compared to those of other malaria syndromes (Fig.
4.1 E-F). The levels in both the CM and the SEVM groups are significantly lower 
than levels in the UM group at onset but not at recovery (Fig. 4.1 E-F).
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Figure 4.1 Hp levels with convalescence in the disease groups, A) SMA; B)
CM; C) SEVM; D) UM and E) at PDO and F) PD28
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Graphs are presented as median interquartile range, 10-90 percentile. Outliers beyond 10-90 
percentile are indicated as round black shapes on the graph. S tatistically different to UM ($, 
p=0.01; $$, p=0.009); p= p-value; F= fvalue and it indicates the differences in mean values among 
the time points, it’s a measure of effect size. d= is also effect size but measures the difference 
between two time points, for example, d=0.6 as shown in Fig. 4.1 A implies 60% non-overlapping 
values between SMA at PDO and CC. The effect size shows the magnitude of the statistical
difference as indicated by the p-value.
Figures 4.1 A-D are based on full complements of samples at all time points, PDO, PD7 and PD28 
as shown in the general cohort table. Fig. 4.1 E and F are only at PDO and PD28. Non-parametric 
Wilcoxon test was used to compare two groups while ANOVA (Tukey multiple comparison testing) 
was used for comparison among groups across the time points. p<0.05 was considered as
statistically significant.
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Figure 4.2 Mean Hp level with age, A) 6-24 months; B) 25-60 months;
C) 61-180 months
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Mean Hp levels in subjects with full complements of samples (Table 3.1) are as presented on the 
graphs. Outliers were not included in the computation of these mean values. Non-parametric 
ANOVA was used for the statistical analysis and p<0.05 was considered as statistically significant.
p=p-value and F=f-value.
Figure 4.3 Mean Hp levels with sex, A) Male; B) Female
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Mean Hp levels in subjects with full complements of samples (Table 3.1) are as presented on the 
graphs. Outliers were not included in the computation of the mean values. Non-parametric ANOVA 
was used for the statistical analysis and p<0.05 was considered as statistically significant. 
p=p-value and F=f-value (effect size; differences in the mean values).
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4.3 Hp levels in the SMA groups are independent of age, sex and parasite 
density
The levels of Hp in the SMA group remain lower in all age groups compared 
to other malaria and the CC groups (Fig. 4.2A-C). Unlike other malaria groups, 
levels of Hp in the SMA groups are stable across the age groups through 
convalescence, particularly in children at age 25-60 and 61-180 months (Fig. 4.2A- 
C). In the CM, SEVM and UM groups, the levels of Hp recover to normal with 
patients’ recovery irrespective of both the age groups and the varying levels 
through convalescence (Fig. 4.2A-C).
The levels of Hp also remain low all through convalescence to recovery in 
both male and female subjects with SMA compared to the other malaria groups 
and the CC (Fig. 4.3A-B). Mean values of the circulatory Hp levels in male and 
female subjects with CM, SEVM and UM are not statistically different at recovery 
(Fig. 4.3A-B). The dynamics of Hp levels in the male and female subject are of 
different pattern (Figure 4.3A-B).
The significant difference observed in the entire malaria groups in both 
male (p=0.0012, F=10.42) and female (p=0.0003, F=13.97) subjects are 
influenced by the low plasma Hp level in the SMA group (Fig. 4.3A-B).
There is no significant correlation between the PD and the circulatory Hp 
level in the SMA group (Table 4.1b).
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Figure 4.4 Free-Haemoglobin levels with convalescence across the malaria
groups at A) PDO; B) PD7; C) PD14; D) PD28
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Graphs are presented as median interquartile range, 10-90 percentile. Outliers beyond 10-90 
percentile are indicated with round black dots on the graphs. Numbers within each disease groups 
at a given time point are as shown in the general cohort table 3.1. Non-parametric ANOVA was 
performed across the disease groups. p<0.05 was considered as being statistically significant.
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Figure 4.5 Levels of LDH in the malarial groups at A) PDO and B) PD28
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Graphs are presented as median interquartile range, 10-90 percentile. Outliers beyond 10-90 
percentile are indicated as round black dots on the graph. Numbers within each group are as 
shown in the general cohort table 3.1. Non-parametric ANOVA and Mann Whitney test were used 
to analyze the data. p<0.05 was considered as statistically significant. *=Statistically different to 
CC. The levels of LDH were measured only at both PDO and PD28 in tandem with that of fHb as a 
second marker of haemolysis. LDH levels at PDO agree with that of fHb at PDO in that levels are 
not statistically different across the severe malaria groups and do indicate that haemolysis in the 
SMA is not higher than other severe malaria groups.
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4.4 Plasma fHb and LDH levels in SMA are not different to other malaria 
groups
The levels of fHb at all the time points in the SMA group are not statistically 
different to that of other malaria groups (Fig. 4.4A-D). The levels of fHb in the 
entire disease groups are higher than those of CC at PDO through PD14 but not at 
PD28 (Fig. 4.4A-D). The levels of fHb within the groups do not show the wide 
differences in levels as observed with Hp (Fig. 4.1A-F and 4.4A-D).
Levels of LDH are higher in the malaria groups than the CC group at onset. 
Levels among the malaria groups are not statistically different (p=0.0795, 
F=2.549), but the SEVM group shows a slightly higher median (Fig. 4.5A). At 
recovery, the levels of LDH in the malaria groups, except the SEVM group show 
lower median compared to that of the CC; the level in both the SMA and the UM 
are statistically lower than both the SEVM and the CC (Fig. 4.5B). While there are 
no differences in the plasma LDH levels between the malaria groups at onset, 
differences exist at recovery (Fig. 4.5A-B).
4.5 The levels of both fHb and Hp in the SMA behave differently to the DC; 
non-malaria severe anaemia.
While the levels of Hp in both the SMA and the DC groups are the same 
and are both lower than the level in the CC group at acute onset, the level of fHb 
in the DC group is significantly higher than the level in the SMA group (Fig. 4.6). 
There is a positive correlation between fHb and and Hp levels in the DC group 
(Table 4.2A).
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Figure 4.6 Levels of both Hp and fHb in SMA and severely anaemic parasite
negative DC group at PDO
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The vertical axis indicates the concentrations of both fHb and Hp while the horizontal axis indicates 
the number of samples. Non-parametric Mann-Whitney test was used to make comparison 
between levels; such as level of fHb in the SMA versus the DC (SMA-fHb vs DC-fHb) as shown 
under the graph. This experiment was performed in order to check for the level of Hp and fHb in 
malaria negative severely anemic subjects (DC). A total of 35 samples were randomly picked from 
both the SMA and the DC groups at PDO; however, the numbers used in the computation are lower 
due to the removal of outliers, particularly from the Hp level in the DC group.
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4.6 Plasma fHb but not Hp correlates with PD in children with SMA
While there is a significant positive correlation between fHb and PD in the 
SMA group, there is no significant correlation between fHb and PD in the rest of 
the malarial disease groups (Table 4.1 .A).
The levels of Hp correlate negatively with parasite density only in the UM 
group (Table 4.1.b). There are significant negative correlation at both acute onset 
and at recovery between fHb and Hp in the SEVM group (Table 4.2.a-b) and a 
significant positive correlation between fHb and Hp in the DC group (Table4.2.a), 
as mentioned earlier.
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Figure 4.7; Levels of A) IL-6; and B) IL-10 in SMA subjects with normal, 
medium and null Hp levels at PD28.
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Graphs are presented as median interquartile range with 10-90 percentile. Outliers beyond 10-90 
percentile are indicated as round black dots on the graph. Non-parametric Mann-Whitney and 
ANOVA tests were used for the statistical analysis. The numbers (N) of subjects with low, medium 
and normal levels of Hp at PD28 are 20, 11 and 5 respectively. These subjects were randomly
selected from the SMA group at PD28.
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4.7 The low plasma Hp level group is associated with high IL-6 and IL-10 
level
SMA subjects with low/null Hp level have significantly higher levels of both 
IL-6 and IL-10 compared to subjects with both normal and medium Hp levels (Fig. 
4.7A-B). Both the levels of IL-6 and IL-10 are not statistically different in the 
subjects with both normal and medium Hp levels (Fig. 4.7 A-B).
4.9 Discussion
Since the discovery of Hp in 1938 (Wobeto et al., 2008b), its levels have 
been widely used as a marker of haemolysis (Gupta, 2011). However, genetic 
factors, inflammation and other yet unknown etiologies can also affect plasma 
levels of Hp (Koda et al., 1998b).
In the pathological context of clinical malaria, and in particular SMA, genetic 
associations, inflammatory responses and haemolysis-induced anaemia have 
been implicated (Casals-Pascual and Roberts, 2006, Koda et al., 1998a, Koda et 
al., 1998b), therefore the causes and consequences of low Hp plasma levels are 
difficult to dissect. A common assumption has been that low Hp levels in SMA 
patients result from parasite-induced haemolysis (Boreham et al., 1981, Langlois 
and Delanghe, 1996). However, by measuring the levels of Hp, fHb and LDH on 
hospital admission, during the convalescence and after recovery, we show that 
low Hp levels increase susceptibility to SMA, rather than being a result of the P. 
falciparum infection and its associated haemolysis.
In the present study, Hp levels on admission were lowest in children with
SMA and comparable to those in the malaria-negative DC group, an observation
that appears consistent with the haemolysis-induced hypohaptoglobinaemia
hypothesis (Gupta et al., 2011, Imrie et al., 2006, Kim et al., 2012a, Delanghe et
al., 1998b). Furthermore, the low level of Hp is not specifically restricted to children
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with SMA as the levels at the time of admission and prior to any form of treatment 
were also low in all severe disease groups compared to the levels in the UM and 
CC groups. However, the Hp levels remained low at onset and during 
convalescence to full recovery in children presenting with SMA, suggesting that Hp 
levels were already low in these patients prior to the malaria episode and the 
onset of SMA. Therefore, the low and stable level of Hp in the SMA couldn’t have 
been a consequence of the disease or higher intravascular haemolysis; our data 
show that though the level of fHb and LDH are significantly higher in children 
presenting with acute onset SMA than in malaria-negative CC, the levels of both 
fHb and LDH in the SMA group are not different to other severe malaria-positive 
groups contrary to the observation with malaria-negative severe anaemia; DC.
It would not have been possible to ascertain the aetiology of congenital 
hypohaptoglobinaemia if the level of Hp was measured only at the onset of 
malaria.
Although a/hypohaptoglobinaemia can be genetic in origin, pathological 
conditions associated with the disease can also be equally important; a null level 
of IL-6 suppresses Hp expression (Oliviero et al., 1987). But in this case, the level 
of IL-6, an inducer of Hp does not seem to be responsible for the low/null Hp levels 
in the population considering the higher IL-6 level that is associated with the low 
Hp group. We suggest that the low/null level of Hp through convalescence to full 
recovery in the SMA group is rather genetic in origin and is a risk factor for onset 
of SMA.
In acquired hypohaptoglobinaemia induced by malaria or by other 
haemolytic disease the level of Hp should return to normal after the 
commencement of treatment of the etiological cause (Saad and Geoffery, 2004, 
Trape et al., 1985, Rougemont et al., 1988). This study clearly differentiates 
acquired from congenital a/hypohaptoglobinaemia, which is worthy of note as
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a/hypohaptoglobinaemia is being used as the metrics for measuring the efficacy of 
malarial prevention or control strategies (Imrie et al., 2012, Imrie et al., 2006).
We therefore suggest that while the majority of fHb in the SMA is linked to 
parasitic destruction of RBC, direct clearance of both infected and uninfected RBC 
by the spleen rather than intravascular haemolysis could be more responsible for 
the low haemoglobin (Hb) level in the SMA.
Our data revealed that at day-of-recruitment and at full-recovery, the level 
of LDH shows similar trend to the level of fHb in all the malaria-positive cohorts. 
These findings point to the importance of the fHb and LDH turnover dynamics in 
the establishment of the major clinical malaria syndromes.
Our study provides novel insights into the Hp-Hb balance in children 
presenting with acute or insidious onset of SMA. In this context, we show that Hp 
and fHb cannot be used as indicators of haemolysis severity. The circulatory 
markers of haemolysis in the anaemia of children with SMA may be strikingly 
different to those with anaemia of non-malaria aetiology. Most importantly, we 
show that low plasma Hp level in this population is a risk factor for the occurrence 
of SMA in contrast to the other malaria syndromes studied.
In the present study we show that the longitudinal measurement of Hp level during 
convalescence and full recovery is important to differentiate congenital from 
acquired hypohaptoglobinaemia. Furthermore, our findings provide evidence that 
the hypohaptoglobinaemia phenotype can be put forward as a predictor of whether 
or not a child with uncomplicated malaria will go onto developing an acute-onset 
SMA episode in the clinic.
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CHAPTER FIVE: RESULT 2
5.0 DO HAPTOGLOBIN PHENOTYPES MODULATE RESPONSE
TO MALARIA ILLNESS?
5.1 Background
As earlier mentioned, the 3 major Hp phenotypes show marked 
geographical distribution. These phenotypes have also been associated with 
susceptibility to and protection from diseases such as diabetes, heart disease, 
cancer, HIV as well as malaria. However, the association studies on Hp 
phenotypes and malaria are contradictory and based only on their frequencies in 
malaria within given phenotypes. In addition, it has been reported that the binding 
affinity of Hp to fHb and the rate of fHb clearance by Hp via CD163 receptors are 
dependent on Hp phenotypes (Kasvosve et al., 2010, Quaye, 2008, Kristiansen et 
al., 2001), indicating their possible role in disease.
The hypothesis/question to be addressed in this chapter is that, do
individuals with different Hp phenotypes but presenting with the same malaria
syndrome and vice versa mount the same response to the illness? Since plasma
proteins are a good reflection of disease pathophysiology, plasma Hp levels and
that of markers of oxidative stress, macrophage activation, cytokines and
dyserythropoiesis were measured both at acute onset of the disease and at
recovery in individuals with different Hp phenotypes. This is with the aim to study
the possible effects of Hp phenotypes in the pathophysiology of the different
malaria syndromes. Oxidative stress, cytokine imbalance and dyserythropoiesis
were thought to be the underlying mechanisms behind SMA with no clear
definition as to which is the major mechanism. The results here show that the
plasma levels of SOD-1; a marker of oxidative stress, macrophage associated
chemokines and both pro- and anti-inflammatory cytokines differ among
individuals with different Hp phenotypes but presenting with the same malaria
132
syndrome as with different malaria syndromes but the same Hp phenotypes. The 
results spelt out here could possibly explain the differences or similarity in 
response to malaria illness and their possible associated pathophysiology among 
individuals. This chapter also reports on whether the association between malaria 
and Hp phenotype frequencies are restricted to malaria or present in other 
disease.
Results in this chapter were based on the clinical characteristics of the 
subjects in Table 5.1. In this experimental design, each disease group is further 
sub-grouped based on individual Hp phenotypes. For example, individuals with 
SMA are sub-grouped as Hp1-1, Hp2-1 and Hp2-2 SMA groups. But for the 
purpose of clarity and to avoid ambiguity, special nomenclatures such as SMA1-1, 
DC2-2 etc are used to describe the sub-groups and represent both the disease 
and Hp phenotype.
133
&o0
'£
3
0)
0JC
(0
o
wL
0
o
0
0
£O
*0O
"E
o
lO
0
JQ0
(/) T3
0 Z
? 5
Q  $  CL §
clT >
CD ~< C  
^  CO
0  o
C/3
CD
c
CD 
CO 
CDl_
(0 
Cl
.E  2
> < ?  o <
Q_ ^o w d
^  (1)5
to £  •£
-C C <DO) ■— -*-■ 
j= >  CO
=  CL ™
s i  I
.52 S 2 
™ £  ci+- 1=o
;■ * . «  K =  jt  
L" CO —
^  o c
c . S2 °  
03 TO 0
?  «  [8 
o
CO *= 
T3
_Q 
C TO 
.52 TO
L.TO
Q
CL
co TO
Cl  Cl  
> *  TO
, . S «
TO CD CO
? ■ § .£  
to a  c  
xTO "O— TO TO
=  C55 c toE. to co CT toIn  CD 203 _c Q.
C +-
—  CO ^
CO
(j; 2  W
«  o0  TO =
.. a  ^
1  CL co
3 TO
CD2 1"
=  TO 
TO ~  CD 
°  C £  
^  CD o o o _
5 TO TO “ ■ CLh- H £  O 
> 1 !n  15 O n ?  
c l £ ' £
i>'S
TO ^
£  TO
9r c 9- to< =6 
I ?
TO co 
3  TO
Z >  
ll o 
Z  CL
13
4
Figure 5.1 Hp genotyping and Phenotyping. (A) The 3.4 and 1.7 kbs DNA 
band from primers Sa5 and Sa6; B) The 1.7kb specific DNA band for primers 
LS1 and LS2 specific for Hp2 allele and C) Western blot for Hp phenotypes
Primers Sa5 and Sa6 were designed to produce the 3.4 and 1.7kb specific band for both Hp1 and 
Hp2 (Fig.5.1 A) but it hardly produce the 3.4 kb band, particularly in the Hp2-1 allele, hence, the 
Hp2 allele in both Hp2-1 and Hp2-2 was detected by a 1.7kb band from the LS1 and LS2 Hp2 
specific primers (Fig. 5.1B). Both the product of Sa5/Sa6 and LS1 and LS2 were used to determine 
the Hp genotypes. An additional band in the Hp2-2 lane less than the 3.4kb could be due to 
random deletions in the second Hp2 allele.
COCH CN■
C\l ON CNJ
5 0
4 0
2 5
2 0  
1 5
a  2  
a 1
Hp Phenotypes determined by western blot. M (kDa) = represent the molecular weight. The p, a2 
and a1 represent the beta, alpha 2 and alpha 1 chains respectively. Western blot was performed to 
determine the Hp phenotypes in subjects with only plasma samples.
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5.2 Genotyping and phenotyping for Hp
Both pairs of primers, Sa5/Sa6 and LS1/LS2 should produce distinct bands 
of the right size but Sa5 and Sa6 could not produce the 3.4kb band in the Hp2-1 
(Fig. 5.1 A) such that the presence of Hp2 in both Hp2-1 and Hp2-2 was detected 
by the 1.7kb band produced by LS1 and LS2 specific primers (Fig. 5.1 B). Sa5 and 
Sa6 produced a 1.7kb Hp1 band present in both Hp1-1 and Hp2-1 genotypes and 
a 3.4kb Hp2 band present in Hp2-2 genotypes (Fig.5.1A)..The LS1 and LS2 
primers took the advantage of the presence of an additional sequence/region on 
the Hp2 allele that is absent from the Hp1 allele (Fig. 2.1).
The western blot of Hp produces a stronger a2 band compared to a1 band 
in the presence of both a1 and a2 bands as in the Hp2-1 phenotype (Fig. 5.1C). 
However, the a1 band is as strong as the a2 band in the absence of a2 as in the 
Hp1-1 phenotype (Fig. 5.1 C).
5.3 The frequencies of Hp phenotypes in malaria are not different to DC
The frequency of Hp1-1 is higher in the entire malaria and the DC groups 
compared to the CC group while that of Hp2-2 is lower in the malaria group than 
the CC except in the SEVM group (Table 5.1). The CM and SEVM groups have 
the highest frequencies of Hp1-1 and Hp2-2 respectively (Table 5.1). The trends of 
frequencies of Hp phenotypes in malaria groups are not different to those in the 
DC group (Table 5.1).
Hp2-1 was of the highest frequency in the entire population while Hp2-2 has 
the lowest frequency (Table 5.1). The observed frequencies in all the disease 
groups are not statistically different from the expected frequencies; therefore the 
phenotypes in the populations are at Hardy-Weinberg equilibrium (Table 5.1).
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5.31: Hp phenotypes correlated differently and independent of the disease 
groups with PD, Hp, HPx and fHb.
Hp phenotypes correlated differently and independent of disease groups 
with pathological parameters such as PD, Hp, HPx and fHb. There is a significant 
negative correlation between PD and both fHb and Hp in the Hp2-1 phenotype 
(Table 5.2B). The same negative but not statistically significant correlations are 
typical of Hp1-1 phenotype (Table 5.2A). A negative and a positive but not 
significant correlation are observed between PD and both fHb and Hp respectively, 
in the Hp2-2 phenotype (Table 5.2C).
There is no correlation between PD and HPx level in the Hp1-1 phenotype 
(Table 5.2A), a significant negative correlation in Hp2-2 and a negative correlation 
in Hp2-1 (Table 5.2B-C). There are no significant correlations between fHb and Hp 
in the entire phenotypes (Table 5.2A-C). Hp positively and significantly correlates 
with HPx in the entire phenotypes (Table 5.2A-C). PD density significantly and 
negatively correlates with age only in the Hp2-2 phenotype (Table 5.2C).
Though the Hp2-1 phenotype has the highest PD, the PDs among Hp 
phenotypes are not significantly different (Table 5.2 footnote).
137
Ta
bl
e 
5.2
 
Pe
rc
en
ta
ge
 
fr
eq
ue
nc
ie
s 
of 
Hp
 
ph
en
ot
yp
es
 
in 
m
al
ar
ia
 
sy
nd
ro
m
es
CO
C/3 C/3 C/3 C/3 C/3d  d  d  d  d
CD
TO
O
d
o
03
■a
03
o
03a.x
z |m-CNI MfCO CM 03 CO
CM■CMQ_
CMCM
CM
03r^ -co
LO03
CO
CM
COOOCO
Mt“OO
X CO CO CO CO CO CO
CMa.
ooCO
03CO03-=3-
CO
CO 
|— CM OO CO 
CXD 2  mi- ^
CO co
cnj mi-LO coCNJ
co co coN  CO LO CO CO ^  '=0" 
CO CO CO
r— -*— C7D CO 03 03co iq- t— co co t—^
03 NT OO CN CNJ COO  CO T - CO N  CO
c n  \ J -  T -  's T  O OCNJ CO co ^  co CO
0 0 6 0 0 0
TO
o
r— loCNJ CO CNJ
CO CNJ CO 03
CNJ COLO
03-Q
"Oc<
>»oc
033cr
03
So I"— TT~m  CO ^
CNJ■CMa .
CNl
LO
C3CNJCNJ
CO
g  So
§  £  ■ CNJ
0  CO
— 03 CO
co" co" mF"03 03 CNJ— CO h-—
CO CO CO
CMQ .
" mj- LO CO mi- 03CO 03 CM LO CM
CO IO '3- — t--5CO OO CO r^ - CM t--100 IO T-- co OO (-->mt Ml" Mf" mj- Mj" LOCO CO co co co CO
03c o  Mi- ^ZT“ S o '
£2 .  CNl CO £2 - 
CNJ CO Q  o  CNJ COg 1 t  o  co ° °  f—
£2 SS LO X— Mf- CNJ
cnj co cq ^  <2 co
CO CO CO CO c—3 CO
too .
o1—03
TO
TO
TO
o
o LLf O
CO
<c
CO
o
o
E ■0c0 0M— 00 CL0
0 0CL C
E 0
0 03
0 0
0 O-4—*_o O03
> O1
CL
-4—<
c
CD
O
M—
O
c 0
O 0 sz
!*- 0
c 0
03 C c
'0
0
c
S Z
E
0
0
c
0
0
II 0 0
0
c
0 , .-1—»
0
0
OM—*
a3 0 c
0 O 0
E O 0
0
c c
1— 
0
1 0 s z
Z E 03
11_ 's z
O
0
Q_ 0  1_
O X 0
O 0 0  1_
O 0
0 O 0
s z r~ 003 s_ 0
O 0 c
|| 1/3 0
C/3 0
£
0
0I—
E >. CL
0 O 0
03 0
C CM
’5
cr
LU
CL
>i
O
c
1
CM
0
C
03I—
(D
0
s z
0
O CL 1CMc 0
a)
£
SZ-4—*
0
1
1 c CL
■0 0 Xi—
03
X
X
O
a.
s z
'?
03 >. 0 -*—*
a) sz 0s— 03
c
0
03 S ’
0 0
c C l 0
0 3^ -4—»M—'JI3 O O03 C s—
=3 0 0
CL 03 O
O JZ E
C l 0
<D uS Z cC/3
0 E
0
0O 0
c VI—±;--- 0 0C/3 0
0 0 0
CL
>.
s— 
0
1— 
0
O 0 CL
C 0 > 4
0 0 O
O "c C
CL 0 0
•0
C
0
0
O
CL
TO Q_ 0
> 4 -£Z-1—»O 3
C 00 0O
cr 00s—VI—
0
1-
0
0s—0
0
0 0
0 cr
0 C/3
l- 0* 0
1
3
8
Ta
bl
e 
5.3
 
C
or
re
la
tio
n 
be
tw
ee
n 
Hp
 
ph
en
ot
yp
es
 
an
d 
PD
, 
fH
b,
 H
Px
, 
Hp
 
an
d 
Ag
e 
in
de
pe
nd
en
t 
of 
di
se
as
e 
gr
ou
p
CM
CL
X
CO r>- •o CM■30 <N 3 CMCM COO o o a
CM
■2.
X
6
CMT”CM
05h-.CO
to
8
CMrCM
O o • o i aICO_CO
tCO
CM
<
Vtno
m
CO
o o o O
u
a*tocr>
a
X
•r-
lO
cr.
*
qn u
1  *  O Qj
CL
co
§
o
I
o
05
' f t
$
wr>
<MCM
o1wo
CM
O
£
0
Qa
3 CM M fO CM
o o
mQo
CT!<NO
OV
M <x> oCM t. 1 CO COO , O CM
o • 9 o
CO 1 CO COw— V r N *#"■CO • ? CO
9 9 9 9
o
>JCICM
iON.
9  9  9
— o
8 8
o  o
ID r»
8  8
o d d
to
s
o
ss^M
° l<r>
8
aco
9
° ,CM
$
d
ax
T?
CCD
D
CL
J*
r
T3
<0
Oa
CDCO
a.i
73cAS
A
£
£x
T3
C
no
CLX
o
d
<o
in 8o
q?
s?
1CM
r- <oo 9
WO
in^ CO
d 9
CM CM■o CMCM 25 r t
O O ©
oo>
aCM
9
CMO
CM
CO
o I
«r>
o
Cia
■oc
&<
O ’
05
O
COh-■
OO
CO
M"
CM
m
oincoco
ii
CMI
CM
CL
X
0i_
CD 
C/5 0 . _3
Id cp ^ > 
0 Q  
c Q-
0
§ o
s s
Q . -M-
O  ^  
9  CO 
O
t-  CO. _ °°
H °G> 05oo 
c S 
0 00
73 11 
0 
E  
0
CL
_  _  X
»  h  D  
C™ 0 0 0)II 5: r* ~  r~-* O r-
‘
■E 05 Q - co  
CD CM 
JZ CM
0
O )
C0
0
0o
70c
oou)>_
070
CX
o
ooo
M"
M-
II
73
>
0a
to
0 -#—» 
co
0 
c
0 1_____
0
QX
co
0
C/5
C
0
73
</5
0i_
0
CL
0
13
9
5.4 There are low and stable levels of plasma Hp in both 
SMA1-1 and SMA2-1 groups
The levels of Hp in the entire Hp phenotypes are not statistically different 
within the control groups. However, Hp level in the DC2-2 group has a lower 
median compared to levels in both DC2-1 and DC1-1 groups (Fig. 5.2A).
Plasma Hp level at acute onset of the disease is lower in the SMA2-2 group 
than level in the SMA2-1 and the SMA1-1 unlike with the phenotypes in the CM 
groups at acute onset (Fig. 5.2B-C). While the Hp level at recovery in the SMA2-2 
group is not different to level in the CC2-2 group, the levels in both SMA1-1 and 
SMA2-1 remain lower even after the full recovery of patients when compared to 
levels in the healthy CC1-1 and 2-1 groups (Fig. 5.2B). Plasma Hp levels at 
recovery in the SMA 1-1, SMA 2-1 and SEVM2-1 groups are significantly lower to 
those of the CC1-1 and CC2-1 groups (Fig. 5.2B and D).
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Figure 5.2 Levels of Hp phenotypes in the A) controls; CC and DC; B) SMA;
C) CM; D) SEVM and E) UM
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Graphs are presented as median interquartile range with 10-90 percentile. Outliers beyond 10-90 
percentile are indicated as round black dots on the graph. Non-parametric un-paired t-test was 
used to compare two groups while Non-parametric ANOVA was used to make comparison
between the three groups.
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The black = SMA; Brown = DC; Red = SMA; Orange = CM; Purple = SEVM and Blue = UM. 
Figures 5.2 B-E are presented as median interquartile range with 10-90 percentile. Points beyond 
10-90 percentile are indicated as round black dots on the graphs. An unpaired nonparametric 
Mann-Whitney test was used to compare data between two non-paired groups such as data at 
recovery and the CC. A paired nonparametric Wilcoxon test was used for paired data within each
disease group such as paired PDO and PD28 
These data are based on the numbers of subjects in table 5.1.
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5.5 SMA2-2 and UM2-2 have low plasma fHb level at acute onset
Both SMA2-2 and UM2-2 groups have lower fHb levels at onset compared 
to CM2-2, SEVM2-2 (Fig. 5.3D), SMA1-1 and UM1-1 (Fig. 5.3B-D). The plasma 
fHb levels in both SMA2-2 and UM2-2 groups are essentially the same both at 
onset and recovery and are not different to CC2-2 group (Fig. 5.3D).
Within the control groups, the fHb levels in the entire phenotypes are not 
statistically different, however, the level in both the CC2-2 and the DC2-2 groups 
show higher median; the level in the DC2-2 is statistically higher to both DC1-1 
and DC2-1 (Fig. 5.3A). The higher fHb level in the DC2-2 is accompanied by lower 
Hp level (Fig. 5.3A and 5.2A). Both fHb and Hp levels are stable in the UM2-2 
group (Fig. 5.2E and 5.3D). In the SMA2-2 group the levels of fHb at onset and 
recovery are the same, however its Hp level is low at onset but high on recovery 
(Fig. 5.2B and 5.3D) and appears not to be associated with fHb scavenging at 
onset. The plasma fHb levels in both the CM2-2 and SEVM2-2 are higher at 
onset but lower at recovery compared to the levels in the SMA2-2, UM2-2 and 
CC2-2 groups (Fig. 5.3D).
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Figure 5.3 Levels of fHb associated with each Hp phenotype group in the A) 
controls, CC and DC; and levels associated with the malaria syndromes in 
subjects with B) Hp1-1; C) Hp2-1 and D) Hp2-2
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*= Statistically different to CC (*=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001). Data are 
presented as median interquartile range with 10-90 percentile. Points beyond 10-90 percentile are 
indicated as round black dots on the graphs. Non-parametric Mann Whitney test was used to 
compare between two groups while ANOVA with multiple comparison testing was used to compare 
more than two groups. Pvalue <0.05 was considered as statistically significant. F=effect size and 
do indicate differences in mean values. The numbers of subjects in each group are as indicated in
table 5.1.
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5.6 Severe malaria groups with Hp1-1 have stable sCD163 levels
The levels of sCD163 are not statistically different in the entire Hp 
phenotypes within the CC group (Fig. 5.4A). However, Hp1-1 individuals within the 
severe malaria groups have stable levels of sCD163 that are not different to levels 
in the CC1-1 group at both onset and recovery (Fig. 5.4B). On the other hand, the 
level of sCD163 in the UM1-1 group at onset is significantly higher than the level in 
the healthy CC1-1 group and those within the severe malaria groups (Fig. 5.4B).
The levels of sCD163 at onset are not statistically different in the entire 
malaria groups with both Hp2-1 and Hp2-2 phenotypes (Fig.5.4C-D). However, 
malaria recovered patients with Hp2-1 phenotype, particularly the SMA2-1 and 
CM2-1 groups have lower levels of sCD163 in their healthy state compared to the 
levels in the disease state and the CC2-1 group (Fig 5.4C).
While the sCD163 level in the CM2-2 group is lower at recovery to the level 
in the CC2-2 group (Fig. 5.4D), the level in the SMA2-2 group is higher at recovery 
to the levels at onset and the CC2-2 groups (Fig. 5.4D).
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Figure 5.4 Levels of sCD163 associated with each Hp phenotype. A) Levels 
in the control; and levels associated with B) Hp1-1; C) Hp2-1; D) Hp2-2
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the graphs. Non-parametric Mann Whitney test was used to compare between two groups while 
ANOVA with multiple comparison testing was used to compare more than two groups, p-value 
<0.05 was considered as statistically significant. F=effect size and do indicate differences in mean 
values. The numbers of subjects in each group are as indicated in table 5.1.
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5.7 Plasma Hpx levels recovered in the entire malaria and Hp phenotypes 
unlike plasma Hp levels.
In the two control groups, the level of HPx associated with Hp2 allele 6:is 
not statistically different to the CC2-1 group, the level in the CC2-2 group is 
significantly lower than the levels in both CC1-1 and CC2-1 groups (Fig. 5.5A). On 
the other hand, plasma HPx level in the DC2-1 group is significantly lower than the 
DC1-1 group while the level in the DC2-2 group is lower than the DC2-1 group (Fig 
5.5A).
Unlike in the control groups, the plasma HPx levels in individuals with Hp1- 
1 phenotype and presenting with severe forms of malaria (SMA1-1, CM1-1 and 
SEVM1-1) are all the same at acute onset and are significantly lower than the 
levels in the UM1-1 and the healthy CC1-1 groups (Fig.5.5B). However, the levels 
at recovery are not statistically different in the entire disease groups (Fig. 5.5B). 
HPx levels are lower at acute onset in both SMA2-1 and CM2-1 groups compared 
to the level in the healthy CC2-1 group (Fig. 5.5C), however the levels are not 
statistically different at recovery (Fig. 5.5C).
The plasma HPx levels in both the SMA2-2 and CM2-2 groups are 
statistically lower at onset compared to the level in the CC2-2 group (Fig. 5.5D). 
However, HPx levels in the entire Hp2-2 phenotype with malaria are the same at 
recovery and are higher than the levels in the CC2-2 group (Fig. 5.5D).
While the plasma HPx levels, particularly in both the Hp2-1 and Hp2-2 
phenotypes show distinct differences and appear to be discriminatory among the 
malaria groups at acute onset (Fig. 5.5A-D), levels all returned to the same point 
on recovery of the patients irrespective of the differences in both the Hp and 
malaria phenotypes (Fig.5.5B-D).
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Figure 5.5 Levels of HPx in each Hp phenotypes A) in the controls; B) Hp1-1;
C) Hp2-1 and D) Hp2-2
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in table 5.1
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Figure 5.6 Plasma levels of markers of oxidative stress and inflammation
associated with Hp phenotypes in A) SMA; B) CM; C) SEVM and D) UM
groups
Sample Groups HP Sample Groups HP
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CC 2 2
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The experiment was performed on individual crude plasma samples and numbers in each disease 
groups are as shown in table 5.1. The data were normalized by dividing each data point by the 
column total and the values obtained were then summed up by row and each data point is again 
divided by the row total. The control groups were normalized alongside with each disease groups 
to avoid bias and ensure comparison within each group. Hence, slight but not significant variations 
in levels across the control groups exist when comparing between groups. This is because values 
used for normalization within each group are different. After normalization, we analyzed the data by 
multiple comparison testing. The colour scale shows the intensity or level of expression within each 
protein group on the heatmap. The levels of significance are as indicated on the colour scale, 
which reflect the colour intensity that are significantly different within each group.
A p<0.05 was considered as statistically significant.
HP=Haptoglobin; LDH=Lactate dehydrogenase; SOD-1 =Superoxide dismutase; CRP=C-reactive
protein; CLU=clusterin.
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Figure 5.7 Plasma levels of cytokines associated with Hp phenotypes in the
A) SMA; B) CM; C) SEVM; D) UM
Sample Groups 
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The experiment was performed on individual crude plasma samples. The number of subjects in 
each disease group is as shown in table 5.1. Normalization was performed by dividing each data 
point by the column total and the values obtained were then summed up by row and each data 
point is again divided by the row total. The control groups were normalized alongside with each 
disease groups to avoid bias and ensure comparison within each group. Hence, slight but not 
significant variations in levels across the control groups exist when comparing between groups 
because values used for normalization within each group are different. The colour scale shows the 
intensity or level of expression within each protein group on the heatmap. After normalization, we 
analyzed the data by multiple comparison testing. The levels of significance are as indicated on the 
colour scale, which reflect the colour intensity that are significantly different within each group.
A p<0.05 was considered as statistically. IL= Interleukin; IFN-y = Interfron gamma; MCP- 
1=Monocyte chemoattractant protein-1; MlP-1 (3= Macrophage Inflammatory protein-1 (chemokine 
c-c motif ligand 4; CCL4); G-CSF=Granulocyte-colony stimulating factor; GM-CSF=Granulocyte
macrophage colony stimulating factor
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5.80 Plasma levels of the markers of oxidative stress, inflammation and 
cytokines are dependent on both malaria and Hp phenotypes
The plasma level of SOD-1 differs with both Hp and malaria phenotypes 
(Fig. 5.6A-D). There is null SOD-1 level in the SMA2-2 group at acute onset and 
high level of IL-10:IL-6. Aside the null SOD-1 level in the SMA2-2 group at acute 
onset, the rest of the malaria groups with Hp2-2 phenotype have either higher 
level of SOD-1 at acute onset or levels that are not different to that at both PD28 
and the CC as well as null or stable levels of IL-10:IL-6 (Fig. 5.6A-D; Table 5.4).
On the other hand the higher levels of SOD-1 in the SMA1-1 and 2-1 are 
accompanied by null IL-10:IL-6 ratio (Fig. 5.6A and 5.7A; Table 5.4), while the 
stable to depleted level of SOD-1 in subjects with Hp1 allele and presenting with 
CM, SEVM and UM are associated with stable and high IL-10:IL-6 at acute onset; 
PDO (Fig. 5.7A-D; Table 5.4).
Furthermore, the level of CRP in the SMA2-2 at PD28 is higher than CC 
unlike the rest of malaria groups with Hp2-2 while the CRP levels in SMA1-1 and 
2-1 at PD28 are not different to CC but level in the rest of malaria groups with 
Hp1-1 and/or 2-1 have higher levels of CRP at PD28 compared to the CC (Fig. 
5.6A-D and Table 5.4).
Both the levels of Hp and Clusterin (CLU) are largely depleted in the entire 
severe malaria groups at acute onset (Fig. 5.6A-C).
There are higher levels of LDH in the CM groups at acute onset compared 
to other malaria groups, except the SEVM2-1 group (Fig. 5.6C; Table 5.4).
The levels of CRP are slightly lower in the Hp2-2 phenotype with malaria, 
except in the SEVM2-2 group (Fig. 5.6A-D).
While the level of LDH is higher in the DC1-1, its SOD-1 level is lower 
compared to the DC2-1 and the DC2-2 (Fig. 5.6D). There are higher levels of both
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CLU and Hp in the DC2-1 group compared to the DC1-1 and DC2-2 groups (Fig. 
5.6A-D).
The levels of IL-8 are depleted at acute onset (PDO) in the entire CC, UM 
and SMA groups independent of Hp phenotypes. However, at recovery, both 
SMA2-2 and UM2-1 groups have high plasma levels of IL-8 compared to levels in 
the CCs (Fig. 5.7A and D).
Levels of IL-17 is slightly higher in SMA2-2, DC2-2 and subjects with Hp2 
allele in the CM and UM groups compared to levels in Hp1 allele and controls (Fig. 
5.7A, B and D).
Higher levels of GM-CSF compared to that of the control are found in 
SMA2-2 and CM2-2 (Fig. 5.7A-B). Levels of macrophage-associated chemokines 
such as MCP-1 and M IP -ip  are as described in the summary table 5.4.
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5.9 Discussion
Hp phenotypic frequencies in malaria as observed in our data have been 
previously reported (Atkinson et al., 2007, Elagib et al., 1998, Minang et al., 2004, 
Quaye et al., 2000b), but without satisfactory explanation for the observed 
association and whether the observation could be found with other disease. The 
claimed susceptibility of Hp1-1 to malaria is difficult to comprehend as it’s 
expected to be protective (selected) against malaria due to its high frequency in 
the malaria holoendemic sub-Saharan Africa (Quaye et al., 2006, Teye et al., 
2006, Elagib et al., 1998). While the high and low Hp phenotypic frequencies 
appear to be associated with susceptibility and protection in malaria syndromes, 
the same frequencies are present in the DC group. This implies that the 
associations are not only restricted to malaria infection neither are they a 
consequence of the infection. More so, that the populations were at Hardy- 
Weinberg equilibrium. We propose that though malaria is one of the major 
selective pressures and evolutionary driving forces (Kwiatkowski, 2005, Cox et al., 
2007), Hp phenotypes could be selective for something other than malaria despite 
its role in malaria pathophysiology.
The role of Hp in malaria could be more associated with the levels of the 
protein than the frequencies of the phenotypes. The phenotypes could be capable 
of modulating response to infection. The result indicated that the susceptibility of 
Hp1-1 to SMA is not unconnected with the generally low and stable plasma Hp 
level associated with the phenotype (Fig. 5.2B). Levels of PD and Hp measured 
independent of malaria disease groups indicated that Hp levels could either 
decrease or increase together with PD in the subjects with Hp1 allele but not in the 
Hp2-2 group (Table 5.3) and these differences could be important in the 
pathological processes.
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The Hp2-2 phenotype could be more protective against the severe forms of 
malaria than the Hp1-1 phenotype. The negative correlation between age and PD 
in the Hp2-2 phenotype (Table 5.3) could indicate decrease in parasite load with 
increase in age and vice versa. It could also be due to the anti-parasitic activity of 
Hp2-2 (Imrie et al., 2004). Previous reports have also showed that the Hp2-2 sera 
agglutinate Streptococcus Pyrogenes carrying a T4 antigen at higher agglutination 
titre compared to the Hp2-1 sera, while the Hp1-1 sera exhibited anti-agglutination 
function (Prokop et al., 1979, Gunther et al., 1979).
Hp phenotypes modulate response to malaria syndromes and appear to be 
an underlying factor for the differences in malaria pathophysiology among 
individuals presenting with the same or different malaria syndromes. Plasma Hp 
levels as well as levels of other plasma proteins of importance in malaria 
pathophysiology such as the marker of oxidative stress; intravascular haemolysis; 
chemokines and cytokines appear to be dependent on Hp phenotypes. As a result, 
individuals with different Hp phenotypes and the same malaria syndrome could 
mount different responses to the infection.
It is not clear why the levels of Hp and HPx are low in the SMA2-2 (Fig.
5.2D and 5.5D) in the absence of high fHb levels in the group (Fig. 5.3D). These
low Hp and HPx levels in the SMA group with Hp2-2 (SMA2-2) are unlikely to be
congenital as both the levels of Hp and HPx in the group recovered to normal at
PD28 (Fig. 5.2D and 5.5D). It’s likely that both The HPx and Hp levels in the SMA
subjects with Hp2-2 (SMA 2-2 group) are involved in some other functional activity,
which is likely to be responsible for their low levels in the face of low fHb. The low
levels of plasma Hp at PDO and PD28 in both SMA2-1 and SMA1-1 groups are
likely to be congenital and account for the low Hp level through convalescence to
full recovery in the SMA group as observed in the previous chapter (Fig. 4.1 A and
5.2B). These observed congenitally low Hp levels are likely caused by certain Hp
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variants known to be associated with high Hp levels but are of lower frequency in 
the SMA groups compared to the CC as further discussed in Chapter 6. In the 
event of a congenitally low level of Hp the level of plasma HPx is unaffected 
(Delanghe et al., 1998b), but this is only possible in the absence of underlying 
haemolysis. Therefore, the normal levels of HPx in the face of low Hp levels in 
both SMA1-1 and SMA2-1 groups at recovery are rather indicative of congenitally 
low plasma Hp levels.
The high plasma levels of both fHb and LDH in the CM2-1 and CM2-2 
groups reflect higher IVH and nitric oxide scavenging than the SMA group. The 
CM group is characterized with mild anaemia coupled with impaired 
consciousness or coma (Mishra and Newton, 2009, Janka et al., 2010), 
characteristics that are directly or indirectly connected with elevated level of LDH. 
High LDH plasma levels have been linked to low NO and organ vasculopathy via 
impairment of blood flow (Kato et al., 2006, Gladwin et al., 2003, Reiter et al., 
2002, Minneci et al., 2005), a proposed mechanism of CM (Idro et al., 2010). LDH 
is a biomarker of intravascular haemolysis (Kato et al., 2006, Balias, 2015, Balias, 
2013, Tabbara, 1992) as well as Nitric Oxide (NO) bioavailability (Kato et al., 
2006).
Though sCD163 is a marker of macrophage activation (Burdo et al., 2011b, 
Burdo et al., 2011a, Stilund et al., 2014, Chua et al., 2013b) with anti-inflammatory 
function (Adly et al., 2015, Frings et al., 2002), the stable levels of sCD163 from 
onset to recovery in the SMA1-1 group (Fig. 5.4B) are likely to be linked to null/low 
Hp level in the group and failure in the homeostatic scavenger-receptor pathways 
rather than impaired macrophage activation (Fig. 5.3B). Impaired macrophage in 
the SMA1-1 group is highly unlikely as a result of high level of MIP-1p (CCL4) in 
the group at both onset and recovery. On the other hand, the depleted levels of
156
sCD163 at recovery in the CM2-2 and CM2-1 groups (Fig. 5.4C-D) could indicate 
a yet unknown additional function of sCD163 during the recovery phase.
The null level of SOD-1 is indicative of absence of oxidative stress (Liu et 
al., 2016). Oxidative stress as indicated by high SOD-1 level and cytokine 
imbalance as indicated by low/stable IL-10:IL-6 appears to be the major underlying 
pathophysiology associated with malaria subjects with Hp2-2 except the SMA2-2 
group, which is without oxidative stress and cytokine imbalance. However, 
inflammation in the SMA2-2 subjects appears to be poorly managed. On the other 
hand, cytokine imbalance and oxidative stress appears to be the underlying 
pathophysiology in the SMA1-1 groups unlike in other malaria subjects with Hp1-1. 
However, while inflammation was quickly managed in the SMA1-1 and 2-1 groups, 
it appears to persist in all other non-SMA malaria subjects with Hp1-1 and/or Hp2- 
1 phenotypes. We propose that cytokine balance and absence of oxidative stress 
proffers a better prognosis in SMA2-2 and non-SMA groups with Hp1 allele while 
persistent inflammation proffers a worse prognosis in these groups. Therefore, 
inflammation, cytokine imbalance and oxidative stress that are proposed as 
underlying factors for onset of severe malaria (Helleberg et al., 2005, Perkins et 
al., 2011) or progression from mild to severe forms of malaria (Burte et al., 2013, 
Kurtzhals et al., 1998) are not typical in all individuals but are rather dependent on 
Hp phenotypes.
The duration from the onset of the disease to recovery appears to be 
associated with Hp phenotypes; inflammation as indicated by CRP levels appear 
to have been effectively resolved at PD28 in the SMA1-1, 2-1 and Hp2-2 subjects 
in the non-SMA groups but not in the SMA2-2 and Hp1-1 subjects in the non-SMA 
groups (Fig. 5.6A-D, Table 5.4). While the 28th day post treatment might be 
sufficient for recovery of the patients based on clinical parameters such as PCV
and symptoms resolution, there might still be some degree of ongoing
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inflammatory response in the recovery phase in some subjects. This is evident by 
the higher level of CRP in both the SMA2-2 and Hp1-1 non-SMA subjects (Fig. 
5.6A-D, Table 5.4).
Hp phenotype appears to explain the disparity in the levels of IL-10 reported 
in the SMA (Lyke et al., 2004, Burte et al., 2013). IL-6 is reported to act as an anti­
inflammatory cytokine alongside IL-10 (Burte et al., 2013) but it also functions as a 
pro-inflammatory cytokine (Scheller et al., 2011, Prakash et al., 2006).
IL-8, which is produced by epithelial cells, muscle cells and endothelial cells 
(Hedges et al., 2000, Wolff et al., 1998, Utgaard et al., 1998) is likely to play some 
role during sporozoites invasion through the cells as with other invading parasites 
(Eickhoff et al., 2003, Li et al., 1998). The different pattern of IL-8 expression in the 
malaria groups at onset and recovery indicates a likely role in malaria; IL-8 might 
have a similar biologic function in both UM and SMA groups and another similar 
function in both CM and SEVM groups at onset (Fig. 5.7 A-D). Early IL-8 response 
is thought to confer protection but late production could be linked to disease 
severity (Lyke et al., 2004, Barnwell, 2006). However, this also appears to be Hp 
phenotype dependent.
Both IL-17 and IFN-y have a synergistic role in inflammatory disease 
(Savarin et al., 2012, Teunissen et al., 1998), therefore, the depleted level of 1L-17 
and IFN-y might constitute a worse prognosis. IL-17 might protects from SMA 
through its involvement in granulopoiesis, infiltration of neutrophils and recruitment 
of T-cell into peripheral tissue (Weaver et al., 2007). However, high IL-17 in the 
CM might be a disadvantage. Neutrophil infiltration enhances the sequestration of 
monocytes in the brain and could lead to cytokine imbalance (Che et al., 2000).
Plasma levels of MCP-1 are indeed independent of the anemic status as 
previously reported (Fernandes et al., 2008, Wilson et al., 2010) but are rather 
dependent on Hp and malaria phenotypes. The levels of both MCP-1 and IL-10
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are high at acute onset and could be as a result of the migration and infiltration of 
IL-10 secreting monocytes to the site of active inflammation through MCP-1 signal 
(Deshmane et al., 2009).
The circulatory levels of GM-CSF are indicative of monocyte and 
granulocyte participation and bone marrow activity; GM-CSF is thought to have an 
active defensive role in malaria through IL-12 production (Trinchieri, 1998, Mosser 
and Karp, 1999). It is also involved in the promotion of erythropoiesis (Liehl et al., 
1994). The low level of GM-CSF in the UM with Hp1 allele could be indicative of 
poor monocyte participation. On the other hand, the high level of GM-CSF 
associated with SMA2-2 group indicates absence of bone marrow suppression 
and offers a better prognosis for the group. Hence, the claimed bone marrow 
suppression (Perkins et al., 2011), is dependent on Hp phenotype rather than 
being restricted to severe forms of malaria as was reported (Stoiser et al., 2000).
In conclusion, our results show that inflammation, oxidative stress and 
cytokines imbalance in clinical malaria syndromes are divided along the lines of 
Hp phenotypes and are unlikely to be entirely involved at the same time in malaria 
pathophysiology. Hp phenotypes in clinical malaria seem to modulate the plasma 
levels of markers of intravascular haemolysis, oxidative stress, macrophage- 
associated chemokines and both pro/anti-inflammatory cytokines. The levels of 
these plasma proteins are likely to explain the differences in malaria 
pathophysiology; our data suggest that oxidative stress and cytokine imbalance is 
unlikely in malaria subjects with Hp1 allele with the exception of SMA1-1 while 
malaria subjects with Hp2 allele with the exception of SMA2-2 have high oxidative 
stress and cytokine imbalance. Hp phenotypes could indeed modulate the balance 
between pro/anti-inflammatory cytokines and could partly explain the inter­
individual response to inflammatory disease associated with haemolysis.
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CHAPTER 6: RESULT 3 
6.0 HIGH THROUGHPUT SEQUENCING OF HAPTOGLOBIN 
(Hp) GENE REVEALS ASSOCIATION BETWEEN Hp 
SEQUENCE VARIANTS, PLASMA Hp LEVEL 
AND DISEASE
6.1 Background
Haptoglobin (Hp) phenotypes showed distinct frequencies from one 
population to another as mentioned in the Introduction. Aside from this, the plasma 
Hp level differs from one population to another and also varies among normal and 
diseased persons. The acute phase responsiveness of Hp shows wide differences 
in inflammatory disease. Furthermore, and as mentioned in the Introduction, 
different studies have reported association between Hp and disease, and different 
structural variants of Hp protein have been described (Carter and Worwood, 2007, 
Bier, 1967, Connell and Smithies, 1959, Quaye et al., 2006, Quaye, 2008). All of 
these are indications that certain as yet unknown but important sequence variants 
in the Hp gene could be an underlying factor responsible for these variations in Hp 
frequency, level, structure and association with disease.
The ‘cause and effect’ relationship between Hp gene sequence variants, Hp 
plasma level, Hp frequency and association with malaria are both unknown and 
poorly described. Previous studies on the Hp gene reveal different structural 
variants but their effect and clinical association are either poorly defined or not 
studied at all. Most Hp associated variants in the dbSNP, dbVar and ClinVar 
databases are designated as having unknown function. Aside from the upstream 
variant reported as the ‘A-61C’ no other variant of the Hp gene has been
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described to be of clinical relevance, even the A-61C at ‘-61’ was wrongly ascribed 
(Oliviero et al., 1987).
One of the major controversies is that, on one hand 
ahaptoglobinaemia/hypohaptoglobinaemia (null/low Hp level) have been described 
as consequences of malaria infection and are used as metrics of effective malaria 
therapy or prevention and control (Imrie et al., 2012, Imrie et al., 2006), while on 
the hand they have been described as having a genetic origin.
Plasma Hp levels were measured at enrollment, during convalescence and 
following patient recovery to ascertain whether the null/low level could be reversed 
following malaria treatment. Results presented in Chapter 4 indicate that the 
null/low Hp level in the SMA group is stable all through convalescence to full 
recovery. Results in Chapter 5 examining Hp phenotypes and Hp plasma protein 
levels further indicate that stable and low levels of Hp in the SMA group are mostly 
associated with the Hp1-1 phenotype.
So far, the results indicate that stable and low Hp levels do not recover in all 
the population, particularly in the SMA group. Based on this observation, we 
proposed earlier that this stable and low plasma Hp all through convalescence to 
recovery could be genetic and a predisposing factor for onset of SMA, particularly 
in SMA1-1, rather than being the consequence of the disease.
To test this idea further, a high throughput sequence analysis of the Hp 
gene, ensuring good coverage beyond the 5’UTR and the supposed promoter 
region was performed on a MiSeq illumina machine. Reads were aligned to the 
reference gene using BWA and the data analyzed for the location of variants, as 
described in the methodology chapter. The aim was to investigate whether or not 
there is any genetic basis for low/null plasma Hp level and association between Hp 
gene sequence variants and malaria illness within the population.
The results presented here indicate that certain Hp sequence variants are
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associated with Hp plasma levels as well as severe malaria. Interestingly, certain 
deletions at sites distal and proximal to the translational start site in the 5’ flanking 
region of the Hp gene are strongly associated with severe forms of malaria. The 
result also indicates that sequence variants upstream of the translation start site of 
the Hp gene (Fig. 2.2) are not only important in disease but also in population 
genetics as well.
6.2 The nomenclature for human gene variants
It is important to understand some of the nomenclature used in the 
description of sequence variants in accordance with the Human Genome Variation 
Society (HGVS) recommendations (v2.0).
For example, a sequence variant designated as g.-43A>G means 
nucleotide A as reference and G as the variant at position 43, counting to the left 
(5’ direction; upstream) of the ATG translational start site, hence the negative sign. 
The letter ‘g’ indicates the type of reference sequence used for the description of 
the variant, which in this case is the genomic reference sequence.
It is important to mention that more than one genotype combination is 
possible within a given sequence variant. Therefore, we will be using terms such 
as genotypes for ‘a given sequence variant’ or simply mentioning the genotypes 
within a given variant. For example, the possible genotype combinations for g.- 
43A>G include, HOM_REF, that is homozygous for reference allele A/A (an ‘A’ in 
both alleles) at that -43 position; HOM_VAR means homozygous for a variant 
allele G/G; and HET genotype for the variant is A/G, meaning one allele has the 
same nucleotide as the reference while the other allele has the variant nucleotide. 
In the Variant Call Format (.VCF) file this position is assigned a ‘0’ when the 
nucleotide in one allele is the same as the reference and a T  for the variant. 
When there is more than one possible variant at a given position such as g.-
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1203GCCC>ACCC,GCCT, the VCF file will assign a ‘1’ for the first variant (ACCC) 
and a ‘2 ’ for the second variant (GCCT) at that position, etc. In line with this, A 
HOM_REF could be designated as 0/0; HOM_VAR as 1/1 and 2/2; HET_VAR as 
1/2; and HET as 0/1 and 0/2. Alternatively, the 0/0 or HOM_REF genotype could 
be represented as g.-1203GCCC/GCCC.
In addition, a g.-2189delT/C is used to designate a single point 
heterozygous or homozygous deletion at nucleotide position 2189 upstream of the 
translational start site. A g.-2189delT/C implies either both T and C are deleted or 
both TT and CC deleted depending on the genotype combination at that position.
6.3 Cluster of variants are present at some regions on Hp gene
The variant pattern in the Hp gene may reveal regions under more genetic 
pressure. Sequence variants and deletions appear to be more concentrated at 
certain positions on the gene. Both homozygous and heterozygous deletions are 
common at both distal and proximal upstream regions (16:72085496-72086460) 
from the translational start. Clusters of variants are also present at the upstream 
region from the translational start site at positions 16:72086460-72087324 and 
16:72088159-72088467 (Fig. 6.1, Appendix 2). There are also variants at the 
intronic region. However, sequence variants within the exons are rare (Fig. 6.1).
6.4 Some yet unknown variants on Hp gene
The variant call analysis reveals known and unknown sequence variants in
the Hp gene (Appendix 2, Fig. 6.2). These variants include Single Nucleotide
Polymorphisms (SNPs) and insertion and deletions (indels). Some of the variants
designated as unknown are sometimes an additional or extended deletion or
insertion (indels) at previously described variant positions or the occurrence of an
unknown SNP in close proximity to the known (Fig. 6.2), which are sometimes
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called together as a single variant by the software. In such cases, both the 
reference and the alternative allele are represented by more than one nucleotide 
as shown in appendix 2.
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Figure 6.1 variants locations on Hp gene
c *
Visualizing the .VCF file in Integrative Genome Viewer (IGV) reveals sites on Hp gene with 
variations. The light and deep blue dotted colours indicate whether the variation is heterozygous or 
homozygous with the reference or alternative allele. The arrow on the vertical axis points to sample 
ID while the horizontal axis points to the reference gene. The variants were visualized on IGV by 
aligning the .VCF file to the human Hp reference gene on Chr 16:72084980-72098624.
Figure 6.2: Hp sequence variants in the population shows different pattern to
known variants in other population
Genes, NCBI Home sapiena A n n o ta tio n  Heleaae 105 
dbSN'P 144 (Home sapiens A n n o ta tio n  Release 105) a l l  aata
rs765836392 -/IT  rs553438812 -/CRCflCfiCfl
rs555900817 -/TCfiC rs774133623 =  C/6
rs749268185 B  fi/T rs556S42077 S Z * =  -/CfiCfl
rs75326878 B  fi/T
v a r ia n ts .v c f
NC J00016.9: 72,086... ZZ  NCJ00816.9: 72,086...
1 I
7. Unknown Variant 8. Unknown Variant
The red colours represent SNP while the purple represent an insertion/deletion (indels). Both have 
a unique identification number (rs) and correspond to a specific position on Hp gene. The 
nucleotide sequence corresponds to position in the Hp gene where the variants occur. The black 
bars are an example of an unknown variant, numbered 7 and 8; as was previously described in 
chapter 2. Variants that extend beyond one or two previously known variants are considered as 
unknown. Some of the un-known variants identified in the population extend beyond a known 
variant or across combination of variants. This shows that different deletion parttern could exist
within a population.
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Figure 6.3. The algorithm for mapping Hp variants to both Hp levels and
disease
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Malaria parasite (MP) positive subjects that were sequenced include 153 patients with UM; 24 with 
SEVM; 66 with CM; 82 with SMA and 37 with CM+SMA (Table 3.1) while malaria parasite negative 
subjects include 55 in the DC and 99 in the CC groups (Table 3.1). Sequences in all of these 
groups were aligned to the reference genome using BWA. Variants were called with SamTools. 
Only the variants upstream of the translation start site (proximal and distal promoter) and with 
population allele frequency ranging from 0.1 to 0.8 were considered out of a total of 118 variants 
detected (both known and unknown; Appendix 2). Association between Hp variants and levels 
were considered only in the CC groups while the association between the variants (being SNPs or 
indels) and disease were computed in the entire disease groups but interpreted relative to the 
controls (Tables 6.1 and 6.2). The DC group consists of subjects with mostly bacterial infection, 
particularly typhoid fever. Multiple comparison testing was used to compute for the association 
between Hp levels and the variants while odds ratio (OR) was computed to determine the 
association between the variants and disease. Example of one of the variant, g.-1203G>A found to 
be associated with Hp level is as shown in this figure. The AA genotype (HOMO-VAR) has normal 
levels while the GA genotype (HET) and the GG genotype (HOMO-REF) have medium and low Hp
levels respectively.
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6.5 Hp gene sequence variants and association with both the disease and 
plasma Hp levels
The association between Hp variants and levels were only determined in
the CC group (Fig. 6.3). Only the variants (indels and SNPs) at both the proximal 
and the distal region and with the frequency of 0.1-0.8 were analyzed out of the 
known and unknown 118 variants detected (Appendix 2; Fig. 6.3). This is because 
the numbers of subjects with variant having frequencies that are less than 0.1 are 
few and cannot be considered for further analysis.
6.51 Deletions at the distal region upstream from the translational start site 
protects from severe malaria, particularly SMA.
A strong protection from SMA is associated with the g.-3014delG/T [OR= 
0.35 (0.188-0.657), p=0.001]; g.-2949delT/A [OR = 0.44 (0.226-0.870), p=0.018]; 
g.-2605delT/G [OR =0.40 (0.185-0.872), p=0.021]; g.-2209delG/A [OR=0.34 
(0.139-0.779), p=0.011]; g.-2189delT/C [OR=0.34 (0.139-0.779), p=0.011] and 
the g.-(2050_2052)delT/TTC [OR=0.36 (0.162-0.799), p=0.012]. These deletions 
protect from SMA to the same magnitude as evident from the OR, Cl and the p- 
values (Table 6.1A-G).
Both the g.-3014delG/T and g.-(2050_2052)delT/TTC significantly 
[OR=0.37 (0.141-0.976), p=0.045 and OR=0.11 (0.015-0.876), p=0.037] confer 
protection from respiratory distress and hypoglycaemia; the SEVM group (Tables 
6.1A and F).
The g.-2806del I I I IC /T specifically and significantly [OR=0.47(0.218- 
0.990), p=0.047] confers protection from the CM (Table 6.1 E).
The frequencies of these deletions are about 50% lower in severe malaria 
syndromes compared to the controls, the DC and CC groups (Table 6.1 A-G).
There are several homozygous deletions at distal locations upstream of the 
translation start site and corresponding to positions 16:72085496-72086460. The
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deletions occur in close proximity to one another at 3 different positions; -2050 to - 
2209, -2605 to -2806 and -2949 to -3014 and are about 200bp long (Fig. 6.8) and 
are identified as g.-3014delG/T, g.-2949delT/A, g.-2806delTTTTC/T, g.- 
2605delT/G, g.-2209delG/A, g.-2189delT/C and g.-(2050_2052)delT/TTC (Table
6.1 A-G).
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6.52 Variants at both distal and proximal regions upstream from the 
translational start site are associated with malaria
Both the odds ratio (OR) and genotype frequency were computed to 
determine the association between variants and disease in line with the algorithm 
(Fig. 6.3). The HOM-VAR (1/1) genotype for the variant, g.-2949T>A significantly 
predisposes to both CM and SMA (Table 6.2A) while the HET (0/1) genotype for 
the g.-(1203_1206)GCCC>ACCC,GCCT variant is associated with low risk of SMA 
(Table 6.2D).
The HET (0/1) for the variants, g.-1976A>T and g.- 
92TGAC>AGAC,TGAG,TTAC are associated with reduced risk of UM (Tables 
6.2B and F). The HET (0/1) for the variant, g.-1976A>T is also associated with a 
significantly [OR=0.35 (0.168-0.747), p=0.0064] reduced risk of CM while the 
HOM-VAR (1/1) is associated with an increased risk of CM [OR=2.79 (1.347- 
5.790), p=0.0057] and fever of bacterial aetiologies (OR=2.17 (1.034-4.566), 
p=0.041); the DC group (Table 6.2B). Also associated with an increased risk of 
CM is the HET-VAR (1/2) genotype for the g.-92TGAC>AGAC,TGAG,TTAC 
variant (Table 6.2F). Furthermore, while the HET genotype for the variant, g.- 
1452T>C is strongly and uniquely associated with protection from fever of 
bacterial etiologies, the DC group (Table 6.2C). The HET genotype for g.-283T>C 
variant is uniquely and significantly [OR=2.17 (1.025-4.580), p=0.042] associated 
with the DC group (Table 6.2E).
Though the allele frequency (AF) of the variant, g.-49A>C is very low (Table
6.2G), it appear to have an important role in infection. The HOM-REF (0/0)
genotype for this variant is associated with an increased risk of both the
uncomplicated (UM) and the severe forms (CM and SMA) of malaria while the
HET (0/1) genotype is associated with reduced risk of developing both severe and
uncomplicated malaria (Table 6.2G). Interestingly, the HET (0/1) genotype for this
171
variant do not only protect from malaria but appear to be associated with 
protection from a number of bacterial infection in the DC group (Table 6.2G).
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6.53 Sequence variants at proximal and distal regions upstream of 
translation start site are associated with plasma Hp levels
Multiple comparison testing was performed in order to determine the 
association between the levels of plasma Hp associated with the different 
genotypes in the CC groups as described in fig. 6.3.
Plasma Hp levels are associated with the g.-1203G>A, g.-1955T>C, g.- 
(1811_1806)GCCTGA>ACCTGG, g.-49A>C and g.-43A>G variants (Table 6,3). 
Normal plasma Hp levels are found in >70% of the population that are HOM-VAR 
for g.-1203G>A, g.-1955T>C and g.-(1811_1806)GCCTGA>ACCTGG and HOM- 
REF for g.-49A>C and g.-43A>G (Fig. 6.3; Table 6.3). Those that are HET for 
these variants have lower than normal plasma Hp levels. On the other hand, 
presence of HOM-VAR for g.-49A>C and g.-43A>G and HOM-REF g.-1955T>C  
and g.-(1811_1806)GCCTGA>ACCTGG and including either the homozygous or 
heterozygous deletions at these positions are associated with low plasma Hp level 
(Table 6.3).
Both the g.-1203G>A and the g.-49A>C also show association with 
disease. However, the g.-49A>C showed association with the UM, CM, SMA and 
DC and is not restricted to only malaria syndromes while the g.-1203G>A is 
restricted to only the SMA (Tables 6.2D and G). While the g.-1203G/G confers 
susceptibility to SMA, the g.-1203G/A confers protection, considering their 
frequencies in the disease groups compared to the CC and the OR (Table 6.2D; 
Table 6.3). The g.-49A/A which is associated with high levels appears to confer 
susceptibility to malaria while the g.-49A/C which is associated with suboptimal 
plasma Hp levels appear to confer protection to malaria and bacteria infection 
(Table 6.2G; Table 6.3).
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6.54 Deletions at the proximal upstream sites on Hp gene do not affect
plasma Hp levels
The g.-3014delG/T, g.-2949delT/A, g.-2806delTTTTC/T, g.-2605delT/G, g.- 
2209delG/A, g.-2189delT/C and g.-(2050_2052)delT/TTC deletions covering 
16:72085496-72086460 (Table 6.1A-G) as earlier mentioned do not affect plasma 
Hp level. Hp levels are not associated with any of these deletions found at 
positions 16:72085496-72086460 (Fig. 6.4). Plasma Hp levels in individuals with 
any of these deletions are not statistically different to those without any of the 
deletions (Fig. 6.4). While the deletions are associated with severe malaria, they 
do not appear to be associated with plasma Hp levels. However, long or short 
homozygous or heterozygous deletions downstream of positions 16:72085496- 
72086460 are more associated with plasma Hp levels rather than malarial illness 
(Table 6.3).
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Figure 6.4 Upstream deletion spanning 16:72085496-72086460 do not affect
plasma Hp level.
1500000-1
p = 0.12721000000-
E
500000-
-!*
de le tions at 16 :72085496-72086460 
are not associa ted w ith  p lasm a Hp leve ls
Mann Whitney test was used to compare between the two groups. The data points in the graph 
consist of 15 subjects in the CC group with either of the deletions and 12 subjects without the
deletions.
6.55 The genotypes that are associated with Hp plasma levels also 
determine Hp phenotype susceptibility to SMA.
The SMA1-1 group have lower frequencies of 1/1 genotypes from the g.- 
1203G>A; g.-1955T>C and g.(-1811_-1806)GCCTGA>ACCTGG variants that are 
associated with normal plasma Hp levels and a higher frequency of 0/0; A/A 
genotype from the variant, g.-43A>G also known to be associated with normal 
plasma Hp level (Table 6.4).
Unlike the SMA1-1 group, the SMA2-2 (SMA group with Hp2-2) have higher 
frequencies of the variants that are associated with normal plasma Hp levels 
compared to the CC; the frequencies of 1/1 genotypes for the g.-1203G>A; g.- 
1955T>C and g.(-1811_-1806)GCCTGA>ACCTGG; 0/0 genotype for the g.- 
43A>G are higher in the SMA2-2 group. The frequencies of the 0/1 genotypes 
across the entire variants with Hp2-2 are lower in the SMA compared to the CC 
(Table 6.4).
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While the entire 0/1 genotypes are of lower frequencies in the SMA2-2 
group compared to those of the CC group, only the 0/1 genotype from the g.- 
49A>C shows lower frequency compared to that of the CC group in the Hp1-1 
subjects with SMA (SMA1-1) (Table 6.4).
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6.6 Long Hp gene deletions
There is a rare homozygous deletion of the entire Hp gene in the 
population. A homozygous deletion of the entire Hp gene (Fig. 6.5) was seen in 
one (B-0368) out of 523 samples. Both the VCF and BAM files mapped to the 
reference gene in the IGV indicate a complete deletion of both alleles in the 
patient. The deletion in the VCF file is indicated as grey colour in the direction of 
the arrow while that of the BAM file is shown by the zero coverage and the 
absence of reads (Fig. 6.5).
Another deletion of both alleles spanning from a distant upstream position 
of the translational start site to position beyond exon 6 of Hp2 allele or exon 4 of 
Hp1 allele (16:72093742) but not including exon 7 of Hp2 and exon 5 of Hp1 allele 
was seen in one sample, A-0751 (Fig. 6.6). Both B-0368 and A-0751 have null 
plasma Hp levels, lower than normal plasma HPx levels but normal plasma fHb 
levels.
Another long heterozygous deletion (deletion on one allele) as well as short 
homozygous deletions occur from the 5’UTR to the intronic region between exon 6 
and 7 and spanning region 16:72088231-72093725 were present in only sample 
E-0988 (Fig. 6.7), a patient presenting with gastroenteritis as one of the DC group. 
The plasma Hp and HPx levels in this sample are normal, 0.5g/L and 1.1 g/L but 
with a very high plasma fHb level unlike in samples B-0368 and A-751.
The Hp phenotypes and genotypes for both B-0368 and A-0751 could not 
be determined by western blot and PCR methods. Aside of these 3 samples, 
entire long deletions of the Hp gene appears to be rare in the population. Samples 
with very good coverage and without any of these deletions are as shown (Fig. 
6.8).
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Figure 6.5: Homozygous deletion of entire Hp gene
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The figure shows both the .VCF and .BAM files aligned to the Hp reference gene as visualized in 
Integrative Genome Viewer (IGV). The different colours indicate different variants in the subjects as 
found in the .VCF file. The gray colour in the direction of the arrow indicates complete deletion of 
the gene in the subject, B-0368. Below the .VCF file is the .BAM file uploaded for the same subject 
and showing complete disappearance of the coverage and reads, which indicates complete
deletion across the entire Hp length.
Figure 6.6: Homozygous deletion of Hp gene from the promoter to the intron
between exon 5 and 6
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The figure shows both the .VCF and .BAM files aligned to the Hp reference gene as visualized in 
Integrative Genome Viewer (IGV). The different colours indicate different variants in the subjects as 
found in the .VCF file. The gray colour in the direction of the arrow indicates deletion of the gene 
that extends from the promoter to the intronic region just before the last exon. Below the .VCF file 
is the .BAM file and showing complete deletion of the reads and zero coverge. However, a very 
short region in the promoter and the last exon was spared as indicated by the small read coverage
areas.
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Figure 6.7 A heterozygous deletion on Hp gene from the promoter to exon 5 
and other short homozygous deletion between exon 1 and 5
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The figure shows both the .VCF and .BAM files aligned to the Hp reference gene as visualized in 
Integrative Genome Viewer (IGV). The different colours indicate different variants in the subjects as 
found in the .VCF file. The gray colour in the direction of the arrow indicates deletions. The 
disappearance of the reads/coverage between the promoter and the last exon as shown in the 
.BAM file is indicative of the deletion. Looking at the .BAM file, it is also obvious that there are 
some few reads in-between the promoter and the last exon, indicating a likely heterozygous
deletion (deletion on one allele).
Figure 6.8 A typical example of reads alignment without any deletion in the
promoter and the entire Hp gene
rife 72.03S.OSS- 72.11
I I I  I f> n 8 i i smil i i  
I ! II
lit III IIII I I I I III III Ki  mill I ' l i i i us
it Hi!!!!NISI l i t III
in
I
III
h
The figure shows both the .VCF and two (2) .BAM files aligned to the Hp reference gene as 
visualized in Integrative Genome Viewer (IGV). The different colours indicate different variants in 
the subjects as found in the .VCF file. There are no deletions in these subjects; the BAM files have 
both good coverage and overlapping reads across the entire Hp region.
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6.7 Population associated Hp sequence variants
Some variants in the Hp gene are found to be common in the entire 
population such as the HET; CT/C (rs576218458) SNP occurring at position 
16:72089044-72089045. The occurence of this SNP is independent of the 
disease, race or individual variations. The entire population also has a ‘slow’ and a 
‘fast’ (f-s) but not f-f or/and s-s sub-phenotypes of Hp (Connell et al., 1966, Koch et 
al., 2003).
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6.8 Discussion
The study of human genetic variation has both evolutionary and health 
significance. For example, Single Nucleotide Polymorphisms (SNPs) have been 
reported to affect protein function and level (Griffiths et al., 2008). Genetic 
variations are associated with diversity; susceptibility to diseases; individuality and 
response to medicine (Shastry, 2002).
Results from the previous chapters have indicated that low plasma Hp 
levels are likely to be of genetic aetiology. The Hp gene appears to have been 
very prone to genetic pressure; malaria was reported to be responsible for the 
copy number variation (CNV) in the Hp gene that gave rise to the Hp2 allele 
(Rodriguez et al., 2012). As a result, the Hp2 allele is generally considered to be 
protective from malaria. The frequency of Hp2 allele is lower in malaria patients 
compared to Hp1 as we had observed and as was reported (Atkinson et al., 2007, 
Elagib et al., 1998). However, the result in Chapter 5 shows that the Hp 
frequencies in the control groups (DC and CC) are of the same trend and not 
different to the malaria groups. Hence, we earlier suggested that the Hp gene 
could be under selective pressure for something other than malaria but could 
confer a selective advantage or disadvantage to malaria and other diseases. 
Whatever the case might be, variants in the Hp gene play some roles in malaria.
The result shows that sequence variants at the distal and proximal regions 
upstream from the translational start site of the Hp gene are associated with both 
protection and susceptibility to malaria syndromes and do indicate the roles of Hp 
gene in malaria. Hp sequence variants at both the distal and proximal upstream 
region, be it indels or SNPs are strong determinants as to whether a child infected 
with Plasmodium falciparum could go on to develop either of the severe forms of 
malaria.
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The deletions at the distal upstream regions are strongly associated with 
protection from SMA while variant-associated genotypes have been shown to 
either predispose or protect from different malaria syndromes as well as mild and 
severe bacterial infections, which indicates that the Hp gene could also confer 
selective advantage or disadvantage to other diseases aside from malaria.
We propose that the distal regions of the Hp gene where the deletions 
occur are spatially close and could interact with the promoter due to DNA looping 
(Fig. 6.9) that could possibly allow interaction between the proximal promoter and 
the distal region through DNA binding proteins such as transcription factors and 
could be important in gene expression.
The close proximity of the 3 different 200bp long regions of deletion also 
suggests that the sites might have some regulatory functions as proposed in the 
model (Fig. 6.9). Regions distal to the translational start site are reported to 
contain some cis-acting regulatory sequences called upstream activation 
sequences (UASs) or enhancers (Fig. 6.9) that could interact with the promoter- 
proximal elements (Griffiths et al., 2008). These UASs are thought to be about 
200bp long in immunoglobulin genes and could occur in more than a single 
position (Cooper, 2000, Griffiths et al., 2008) as has also been observed with the 
Hp gene (Fig. 6.9). Furthermore, the UASs are thought to contain clusters of 
binding sites for more specific translational factors (Cooper, 2000, Griffiths et al., 
2008) as well as some negative and positive regulatory elements such as 
repressors and activators of translation (Cooper, 2000).
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Figure 6.9. The looping model to illustrate possible interaction between the 
distal and proximal promoter sites on Hp gene
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Distal upstream sites on Hp gene could interact with the proximal promoter sites through DNA 
looping. This looping mechanism could bring both the distal and proximal promoter sites in close 
proximity. As a result, proteins that are capable of binding to the promoter could also interact with 
the distal sites. These proteins could either activate or prevent gene expression on binding to the 
activator or the repressor sites on the gene. We have earlier shown that a deletion of about 200bp 
long were found at 3 sites at the distal upstream region that correspond to 2050 to 2209, 2605 to 
2806 and 2949 to 3014 and designated as C, B and A respectively. These distal upstream 
deletions were shown to protect from severe malaria (Tables 6.1A-G). As a result, we propose that 
certain protein-DNA interactions are likely at these designated sites and could enhance disease 
severity had the deletion not occurred. We considered these regions to have some possible 
repressor function, as the deletions are likely to prevent certain protein-DNA associations that 
could enhance disease severity. On the other hand, variants at position designated as D and E 
protect from both mild and severe forms of malaria (Fig. 6.2B and D). We again proposed that 
certain interactions at these positions are likely to activate the observed protection. Hence, both D 
and E are designated as activator sites. The ATG, 5’ UTR, TATAA, CCAAT box and the GC-Rich 
elements are as show in the figure. The Hp sequences corresponding to the ATG, the TATAA box, 
CCAAT box and the GC-rich sites are as shown in this figure. The proximal promoter region that 
could possibly interact with the activator and repressor site is as indicated by the horizontal arrow.
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In line with the above and the fact that there are normal plasma Hp levels 
despite these deletions, we proposed that certain DNA-protein interactions at 
those 3 regions of deletion (Fig. 6.9) are involved in enhancing disease 
severity/resolution through as yet unknown mechanism(s). Therefore, the 
deletions confer protection to the severe forms of malaria by preventing such 
interactions. Example of such possible interaction is that of Hp and prostaglandins 
that was reported to elicit harmful oxidation processes (Lange, 1992). The 
protection or susceptibility associated with the observed genotypes might be due 
to some kind of interactions at the upstream regions of the gene.
The Hp gene promoter lies within -43 to -400 nucleotides upstream of the 
translation start site (Pelletier et al., 1998, Lee et al., 2002, Oliviero et al., 1987) 
and some of the variants shown to have association with the disease and plasma 
Hp levels are within these regions, which are also thought to be the binding sites 
for hormones and cytokines released during acute phase response (Quaye, 2008).
The CCAAT sequence within the Hp promoter is required for the activation 
of Hp gene expression (Oliviero et al., 1987, Pelletier et al., 1998, Lee et al., 
2002). Induced mutations at the promoter region have been reported to reduce 
plasma Hp level. Furthermore, a SNP within the promoter has also been reported 
to decrease the Hp responsiveness to IL-6 (Grant and Maeda, 1993). Therefore, it 
is more likely that the effect of these promoter associated sequence variants on
plasma Hp levels could be tightly linked to their ability to enhance or inhibit gene
/
expression.
Genotypes associated with Hp levels could determine the susceptibility of 
Hp phenotypes to SMA. Some genotypes that are associated with normal Hp 
levels are of lower frequency in the SMA1-1 and 2-1 groups compared to the CC  
such that normal Hp levels are rarely found in these groups while genotypes that 
are associated with normal Hp level are of higher frequencies in the SMA2-2 group
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compared to the CC. We have earlier shown that while the Hp levels recover in the 
SMA subjects with Hp2-2, levels do not recover in the SMA subjects with both 
Hp2-1 and 1-1.
While we suggested that the low levels of Hp could be a risk factor for onset 
of SMA, the presence of the variant, g.-49A>C, could change the entire 
pathological equation between Hp levels and disease. Though low Hp level is a 
risk factor for onset of SMA, it does not appear so in individuals with the g.-49A/C 
variant, which is shown earlier to be associated with suboptimal Hp levels. On the 
other hand, high plasma Hp does not appear to protect from SMA in individuals 
with the g.-49A/A wild type. While the g.-49A/A is associated with high plasma Hp 
level it significantly predisposes to malaria; UM [OR=1.80(1.041-3.112), 
p=0.0035]; CM [OR=2.45(1.179-5.99), p=0.016] and SMA [OR=1.96(1.014-3.778), 
p=0.045] and its frequency is higher in the SMA group with Hp1-1 than Hp2-2. The 
g.-49A/C variant is observed to be associated with low plasma Hp and protection 
to malaria; UM [OR=0.55(0.314-0.969), p=0.0386]; CM [OR=0.38(0.176-0.824), 
p=0.014]; SMA [OR=0.434(0.216-0.874), p=0.02] as well as other bacterial 
infections; the DC group [OR=0.38(0.166-0.869), p=0.022]. A previous report that 
low Hp levels are associated with protection from malaria (Cox et al., 2007) could 
be due to the effect of the g.-49A>C variant.
This genetic effect and the differences associated with Hp levels within the 
major Hp phenotypes might be responsible for the different responses elicited in 
the malaria groups by individuals with different Hp phenotypes as mentioned in the 
previous chapter.
The variant, g.-49A>C is the same as the A -61C ’ that was previously
reported (Oliviero et al., 1987, Cox et al., 2007) because the nucleotide sequence
flanking the g.-49A>C is the same as those around the A-61C position (Oliviero et
al., 1987, Cox et al., 2007). Aside from this g.-49A>C that has been wrongly
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reported as the A-61C none of the variants that we have shown to be associated 
with plasma Hp level have been reported.
Our result agree with the previous observation that the g.-49A>C (A-
61C) is associated with reduced plasma Hp level (Cox et al., 2007).
While low/null levels of plasma Hp could occur as a consequence of 
haemolysis (Delanghe et al., 1998b), we have established that a situation whereby 
the level remains low following treatment and through convalescence is rather due 
to genetic factors.
The controversy regarding the aetiology of hypohaptoglobinaemia (low) and 
ahaptoglobinaemia (null) has not been properly addressed; sequence variants 
such as SNPs and short indels appear to be the major cause of 
hypo/ahaptoglobinaemia in this population rather than the long heterozygous and 
homozygous deletions on Hp gene that was previously reported (Koda et al., 
2000, Koda et al., 1998b) Different variants of the Hp gene could be responsible 
for ahaptoglobinaemia and hypohaptoglobinaemia in different populations as 
evident from this study and the previous report in Ghana (Teye et al., 2003, Teye 
et al., 2004).
Long homozygous and heterozygous deletions of the Hp gene as 
previously described (Koda et al., 2000, Koda et al., 1998b) are found in only two 
out of the 519 subjects that were successfully sequenced. Both heterozygous 
and/or homozygous deletions of an entire Hp gene are rare in African populations 
(Koda et al., 2000). This long homozygous deletion of the Hp gene observed in 2 
out of 519 patients in this population do not affect the removal of fHb from 
circulation. The reduced levels of HPx in these individuals are likely to indicate its 
role in the removal of fHb from the circulation in the absence of Hp. On the other 
hand, the high plasma fHb level in the face of normal Hp and HPx levels in a 
patient with heterozygous deletion from exon 1 to 6 alongside other short deletions
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of the intact allele indicate that the binding sites for fHb may have been deleted on 
the Hp gene. This implies that certain short deletions in the Hp gene that might not 
affect plasma Hp level could affect its ability to scavenge fHb.
The variants described in this study are different from those reported in 
previously in Ghana (Teye et al., 2003, Teye et al., 2004) and other populations 
(Koda et al., 2000, Koda et al., 1998b). Hence, the Hp gene appears to be subject 
to different genetic pressure in different populations. These differences in genetic 
pressure with geographical locations could partly explain the presence of some of 
the unknown variants that are seen in this population as well as the marked 
differences in the frequencies of Hp phenotypes in different geographical 
locations. Furthermore, aside the role of Hp gene in disease, it could be of 
importance in population genetics since some of the variants are common to the 
entire population.
In this study we show that some yet unknown variants of the Hp gene are 
associated with protection and susceptibility to malaria, whether or not they are 
associated with plasma Hp levels. Furthermore, the genotypes that are associated 
with Hp plasma levels could also determine the susceptibility rate of Hp 
phenotypes to SMA. The Hp gene could be useful as a promising genetic marker 
for studying disease susceptibility and/or protection among individuals within a 
given population and it have been implicated in several diseases. Though the 
results of some mechanistic studies are already in line with our observation; there 
is a need to carry out a more mechanistic study to investigate some of the 
observations in this association-based study. Associations between Hp variant and 
both Hp levels and disease need to be validated in other populations.
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CHAPTER SEVEN: RESULT 4 
7.0 POTENTIAL BIOMARKERS FOR CLINICAL MALARIA
SYNDROMES
7.1 Background
As mentioned in Chapter 3, P. falciparum malaria illness is associated with 
different clinical presentations. Accurate diagnosis to differentiate between these 
malaria syndromes and from other causes of fever is important for effective patient 
management. Aside from general administration of anti-malarial drugs, each 
malaria syndrome requires different patient care. Malaria syndromes overlap with 
several illnesses. For example, CM has been defined as generalized convulsion in 
the presence of asexual forms of the P. falciparum parasite. However, in a malaria 
holoendemic region, there are other causes of convulsion such as meningitis and 
one could not completely rule out the presence of malaria parasites in such 
subjects (Aipit et al., 2014). There is therefore the need for a specific biomarker for 
CM to differentiate it from other causes of convulsion in malaria holoendemic 
regions.
Furthermore, most fever-associated illnesses have been mistaken and 
treated as malaria (Moreno-Caballero et al., 2016, Decuypere et al., 2016), 
particularly in non-malarial paediatric fever (Al-Harthi, 2015) and could place 
higher demand on antimalarial therapy leading to drug resistance. It is therefore 
important to search for biomarkers that could differentiate among the malaria 
syndromes and between malaria syndromes and other causes of fever.
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Effective diagnosis alongside appropriate treatment remains the main malaria 
control strategy beside any effective preventive measures. The most commonly 
recommended methods of malaria diagnosis are microscopy, Malaria Rapid 
Diagnostic Test (MRDT) and clinical observation.
Despite these recommendations, the diagnosis of clinical malaria is still 
complicated as a result of its different clinical manifestations; symptom overlap 
with other causes of fever; concurrent malaria parasite and bacteria co-infection 
and the need for trained specialist in the areas of microscopy and molecular 
techniques.
There are also some downsides to the use of MRDTs that are designed to 
detect Parasite Histidine-rich Protein2 (pHRP2) and/or Plasmodium Lactate 
Dehydrogenase (pLDH), (Mbabazi et al., 2015). For example, HRP2 can persist in 
circulation for several weeks after parasite clearance (Kyabayinze et al., 2008, 
Mbabazi et al., 2015, Swarthout et al., 2007). Therefore, the use of MRDT for 
HRP2 detection and diagnosis is not effective in regions where malaria is 
holoendemic and for patients with recent malaria episodes, which may lead to 
false positive results (Mbabazi et al., 2015). On the other hand, the pLDH-based 
assay can provide a false negative result at low parasite density (Mbabazi et al., 
2015). More importantly, both pHRP2 and pLDH target parasite products, and are 
not useful for differentiating the onset of clinical malaria.
Microscopic examination of giemsa stained blood is useful for detection and
in differentiating between parasites species or stages in the life cycle such as
distinguishing between clinically important asexual forms of the parasite and
gametocytes, and for quantifying parasite density. However microscopy cannot be
used to differentiate among the clinical malaria syndromes. Both molecular and
serology-based methods of diagnosis are also limited in this regard. While PCR
based methods can be important in detecting co-infection with other pathogens
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(Ben-Zvi et al., 2012), they cannot differentiate among the clinical malaria types, 
and they are also technically demanding and costly (Ansah et al., 2013). Serology- 
based methods of detection are limited in diagnosing onset of malaria; this is 
because detectable parasite specific antibody may only appear several days into 
the infection and will persist after treatment.
The most commonly used method of diagnosis in a district laboratory in 
sub-Saharan Africa is based on clinical signs and symptoms (Font et al., 2001, 
Aidoo, 2013). Resources and trained personnel are scarce in most areas where 
malaria is holoendemic. As a result, presumptive clinical diagnosis is predominant, 
and may result in the administration of anti-malarial drugs to individuals that do not 
need them (Olivar et al., 1991, Allen et al., 2013). The considerable symptom 
overlap between, for example, respiratory tract infection and malaria can lead to 
misdiagnosis and over-use of anti-malarial drugs (Redd et al., 1992, Aipit et al., 
2014).
Efforts in the past to improve the specificity of presumptive clinical 
diagnosis have been limited (Smith et al., 1994). The WHO Integrated 
Management of Childhood Illnesses (IMCI) recommended that every child living in 
a high transmission malaria holoendemic region, where 5% of febrile children are 
parasitaemic, should be considered to be infected and treated for malaria (WHO, 
1997). However, this is likely to produce a significant rate of malaria over­
diagnosis.
In a bid to further understand differences in the plasma proteome of 
children presenting with different malaria symptoms, we observed some potential 
biomarkers that could discriminate among the malaria cases at onset and could be 
of importance in the disease prognosis.
The results in this chapter describe the plasma levels of HPx, sCD163 and 
clusterin in malaria syndromes. We show that the plasma HPx levels varies among
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the malaria groups at acute onset. In addition, an sCD163 level also varies during 
the early stages of the infection and could be useful to monitor the onset of the 
recovery phase in response to treatment. Importantly, we have found that plasma 
Clusterin (CLU) level is a specific biomarker of CM and it’s likely to have a 
protective role at the onset of the disease. The results here were obtained using 
the cohort described previously in table 3.1.
7.2 Plasma HPx and free-haem levels
7.2.1 Plasma HPx levels vary among malaria syndromes at onset and 
increases sensitively following treatment.
Plasma HPx levels among the disease groups are significantly different at 
onset (Fig. 7.1A-B). The plasma HPx level is statistically higher in the UM group 
than that of the severe malaria groups at onset (Fig 7.1A-B). Circulatory HPx 
levels among the severe forms of malaria are significantly different with distinct 
differences in median and mean values (p<0.0001, F= 10.08) in spite of the closely 
related pathophysiology in some groups such as CM+SMA, CM and SMA (Fig 
7.1A).
More importantly, the HPx levels in the malaria groups are different to that 
of the malaria negative DC group of mostly children presenting with fever of 
bacterial aetiology (Fig. 7.1 A).
However, as found for other clinical biomarkers, there is some degree of 
overlap in levels but the level within each group has a distinct median and mean 
through convalescence (Fig. 7.1 B).
The SMA group has a lower level of HPx at onset and all through convalescence 
to full recovery (Fig. 7.1 B). Both the SEVM and CM groups show peak values at 
PD14 that are not statistically different to the level at recovery; PD28 (Fig. 7.1 B).
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It is obvious that there is a gradual increase in HPx levels following drug 
treatment (Fig. 7.1 B). Examination of the early time points (day 0-3) in the CM 
group shows that the plasma HPx level immediately begins to increase on 
commencement of treatment, indicating a quick response (Fig. 7.1C).
The levels of Hp at onset through convalescence to full recovery are 
unlike the levels of HPx (Fig. 7.1 B and E). Levels of Hp in the malaria groups are 
low and stable through convalescence (Fig. 7.1E).
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7.2.2 Plasma HPx levels correlate with parasite density and sCD163 level at 
onset
The plasma HPx level in the SMA group correlates positively with parasite 
density (PD) and negatively with sCD163 level at onset (Table 7.1a and d). There 
are negative correlations between HPx and sCD163 levels in both the UM and 
SEVM groups but not in the CM group (Table 7.1d). There is no correlation 
between Hp and HPx in the SMA and CM+SMA groups unlike the positive 
correlation in other malaria groups (Table 7.1c). None of the malaria groups show 
correlation between HPx and fHb (Table 7.1b).
7.2.3. There are significant differences in plasma free-Haem levels among 
malaria phenotypes at onset.
The levels of plasma free-haem in the malaria groups are significantly 
different at onset (Fig. 7.1 D). Levels fall drastically in the early convalescence 
phase between PDO to PD7 (Fig. 7.1 D). Levels at PD7 and PD14 are not 
statistically different in all the malaria groups (Fig. 7.1D). There is an increase in 
plasma free-haem from PD14 to recovery (PD28). The plasma free-haem levels at 
recovery in the malaria groups are not statistically different to one another (Fig. 
7.1D).
The level of free-haem in the SEVM group at onset is higher than other 
groups but its plasma HPx level is not as low as might be expected (Fig. 7.1D and 
A_B). However, there are decreasing levels of free-haem along with increasing 
levels of HPx at the convalescence phase in all malaria groups (Fig. 7.1 B and D). 
Both CM and SMA groups have lower plasma HPx levels that are not statistically
different to other malaria groups at recovery (7.1 B and D). While the UM group
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shows a significant negative correlation (r=-0.3229; p=0.0063) between plasma 
HPx and free-haem levels, the severe malaria groups do not show any significant 
correlation. Free-haem levels show no correlation with either fHb or PD in all 
malaria groups.
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7.3 Plasma levels of sCD163 in malaria groups
7.3.1 Plasma sCD163 levels in the UM group show changes not observed in 
other malaria groups
The plasma sCD163 level in the UM group increases significantly from PDO 
to PD7; peaked at PD7 and thereafter decreases significantly to PD14 and then 
PD28. Level at PD28 is the same as that of CC group (Fig. 7.2A). The UM group 
has significantly higher plasma sCD163 level than other malaria groups at onset 
(Fig. 7.2E). The sCD163 levels in the SEVM group follow similar pattern as the UM 
group but levels at PD14 were not different to PD28 but normalized at PD14 to the 
same level as in the CC group (Fig. 7.2B).
Unlike in both the UM and SEVM groups, plasma sCD163 levels in the 
SMA group are stable through convalescence (Fig. 7.2D)
Interestingly, the plasma sCD163 level at recovery in the CM group is 
significantly lower to levels in other disease groups and the CC (Fig. 7.2C and F). 
Aside from the reduced sCD163 levels in the CM at recovery, levels at both onset 
and recovery are the same in the entire severe malaria groups (Fig. 7.2E-F).
7.3.2 Correlation between sCD163, parasite density, fHb and Hp
Plasma Hp and sCD163 levels correlate negatively only in the DC group 
(Table 7.2b). No correlation between sCD163 and Hp is observed in the malaria 
groups (Table 7.2b). The plasma sCD163 and fHb levels show significantly 
negative correlation in the DC group and a significant positive correlation in the 
SMA group (Table 7.2a). There are no significant correlations between sCD163 
and fHb levels in the rest of the malaria groups (Table. 7.2a). Plasma sCD163 and 
PD show significantly positive correlations in both the SMA and UM groups (Table 
7.2c).
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Figure 7.2 Plasma levels of sCD163 with convalescence in the A) UM; B)
SEVM; C) CM; D) SMA; and in the different disease group at E) PDO
and F) PD28
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Graphs are shown as median and interquartile range with 10-90 percentile. The data is based on 
the general cohort table in fig. 3.1. Non-parametric ANOVA and Mann Whitney tests were used to 
analyze the data. Fig 7.2 E and F are to allow comparison of levels at PDO and PD28 within the 
different malaria groups. p<0.05 was considered as significant. *= Statistically different to CC 
(*=p<0.05; **=p<0.01; ***=p<0.001; ****=p<0.0001). $=Statistically different to UM ($=p<0.05; 
$$=p<0.01). &= Statistically different to CM (&=p<0.05; &&=p<0.01).
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7.4 Plasma clusterin (CLU) levels in the malaria groups
Studies on CLU levels were performed on a separate paediatric cohort to 
those previously described. A total of 194 samples were used and consist of 
samples from each malaria disease group and those that died following CM attack 
(CM dead subjects) and including samples at both acute onset (PDO) and at 
recovery; PD28 (Table 7.3). The DC groups in this cohort consist of subjects with 
syndromes that closely mimic that of CM and include children with convulsion, mild 
anaemia and coma of other etiologic cause that include meningitis. A trained 
laboratory scientist not part of this study group confirmed the DC and the CC 
groups to be malaria parasites negative. The clinical characteristics of subject in 
the CLU cohort are shown in table 7.3 below. The plasma CLU level was assayed 
using a monoclonal anti-human CLU antibody.
7.4.1 Lower CLU level is associated with onset of CM
The plasma CLU level in the CM group is significantly lower than the levels 
in all other clinical groups at onset aside the levels in CM dead subjects (Fig. 
7.3A). CM dead subjects have the least plasma CLU level, significantly lower than 
level in the CM group. CM dead subjects could not survive till day 28 (Fig. 7.3A).
Plasma CLU in the SMA group at onset shows a non-significant lower 
median to those of the UM, DC and CC groups (Fig. 7.3A). On recovery, the 
plasma CLU level in the CM and the rest of the malaria groups are not statistically 
different to the levels in the CC group (Figure 7.3B).
7.4.2 Plasma CLU level in the entire CM group increases with recovery
The circulatory CLU levels in the entire CM patients increase steadily from
onset to recovery and appear not to be affected by individual variability in the
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population (Fig. 7.3C). The mean level at recovery is significantly higher 
(p=0.0001) to levels at onset (Fig. 7.3C).
Plasma CLU levels in the SMA patients vary from onset to recovery; some 
decreases, others increases while some are stable (Fig. 7.3D). In the UM group, 
levels at onset are not statistically different to those at recovery. However, there is 
a slight increase from PDO to PD28 in the majority of the patients (Fig. 7.3E).
7.4.3 Specificity and sensitivity of clusterin levels in discriminating among 
malaria syndromes
The area under the ROC curve termed as Area in the table below each 
ROC curve (Fig. 7.4A-F) is the measure of how well CLU level can distinguish 
between two disease groups; CM versus CC or CM versus SMA or UM groups.
Plasma CLU at acute onset (PDO) significantly discriminates CM from CC in 
approximately 91% of the subjects; Area 0.9087, P<0.0001 (Fig. 7.4A). The ROC 
analysis of levels at day 28 in the CM group does not show significant difference to 
the CC group (Fig. 7.4B). Plasma CLU levels significantly differentiate CM dead 
from healthy CC in 87% of the subjects considering the area under the curve; 
0.8667, p<0.0001 (Fig. 7.4C). The ROC analyses further show that plasma CLU 
levels discriminates CM from DC, SMA and UM at acute onset (Fig. 7.4D-F).
7.4.4 Plasma CLU levels correlate differently with IL-6 and IL-10
Plasma CLU level shows significant negative correlation with the levels of 
IL-10, IL-6 and IL-8 only in the CM group at onset (Table 7.4). At recovery, both 
plasma CLU and IL-10 levels show significant positive correlation in the CM group 
and a significant negative correlation in the SMA group (Table 7.4).
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The plasma IL-6 level correlates negatively with CLU level only in the SMA 
group at recovery (Table 7.4). There are no correlations between plasma CLU and 
these cytokines in the UM group (Table 7.4)
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Figure 7.3 Plasma Clusterin levels at A) PDO; B) PD28 and at onset and
recovery in the C) CM; D) SMA and E) UM
0.3-
0 .2 -
0.1 M ■
O.O-1 r
0.3-1
0 . 2 -
B
p=0.5298
O  0.1 Mi i
0 .0 J  1-
P<0.00010 .20-1
0 . 10-
0.00
0 .20-1
0.15-
'fe 0-10-1 
m
°  0.05-
0.00
<r
D
p=0.0115
aj
<nJ3
o
0.25-1 p=0.1915
0 . 2 0 -
0.15-
0 . 10-
0.05-
0.00
Fig. 7.3A-B) Data are presented as median interquartile range with 10-90 
percentile. Non-parametric AN0VA and AN0VA with multiple comparison testing were
used to analyze the data.
Fig. 7.3C-E) Plasma Clusterin levels in the CM, SMA and UM at both PDO and 28. 
Data are presented as point graph from PDO to PD28 and analyzed by paired non- 
parametric t-test. p<0.05 is considered as significant. The numbers of subjects in each
group are as indicated in table 7.3.
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Figure 7.4 ROC curve analysis of plasma CLU levels
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Plasma Clusterin level discriminate CM from other malaria syndromes and the DC in a ROC curve 
analysis. (A) ROC curve compares CM at PDO to CC; B) CM at PD28 with CC; C) Dead CM 
subjects with CC; D) CM at PDO with CC; E) CM at PDO with SMA at PDO; F) CM at PDO with UM 
at PDO. Under each curve is a statistical table showing the Area under the curve (Area), Standard 
error, 95% Confidence Interval (Cl) and p-values. The area under curve quantifies the overall 
ability of the test to discriminate between two groups. For example, an area of 0.9087 or 90.87% as 
in the CM PDO vs CC (Fig. 2A) means, the probability that a randomly selected CM patient will 
have lower clusterin level compared to the CC is 90.67% or 0.9067. Sensitivity indicates true 
positive rate while 1-specificity indicate false positive rate. p-value<0.01 was considered to be
statistically significant.
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7.5 Discussion
7.5.1 Plasma HPx levels significantly varies among the clinical malaria 
syndromes at acute onset
The management of malaria patients largely depends on the syndrome or 
clinical manifestation. Discriminating between the different clinical presentations of 
malaria at onset is important for appropriate therapy and to avoid unnecessary 
anti-malarial drug use.
The varying levels of plasma HPx in subjects with clinical malaria 
syndromes at acute onset in spite of related pathophysiology could be useful in 
assessing the severity of the disease. The rapid increase in plasma HPx level 
following appropriate treatment also makes it a valuable prognostic maker for 
effective malaria therapy.
More importantly, plasma HPx levels were able to discriminate between the 
UM and DC groups. This is important to discriminate between UM associated 
fever and fever of bacterial origin.
HPx is a better marker for diagnosis and prognosis in clinical malaria compared to 
Hp, particularly in a population with congenitally low Hp levels. The congenitally 
low level of Hp hampers its usage as a biomarker in haemolytic inflammatory 
disease.
The plasma HPx is recycled and never completely depleted unlike plasma 
Hp. HPx has a longer half-life of about 7 days in circulation, allowing for more 
precise measurement compared to the few minutes half-life of Hp (Langlois and 
Delanghe, 1996, Delanghe and Langlois, 2001, Echeverry et al., 2016). 
Furthermore, the HPx level is not influenced by extravascular haemolysis unlike 
other markers of haemolysis and its level is not influenced by 
ahaptoglobinaemia/hypohaptoglobinaemia in healthy subjects (Langlois and
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Delanghe, 1996, Delanghe and Langlois, 2001). All of these make HPx a better 
marker in the diseased subjects. This finding is important in African populations 
with high frequency of a/hypohaptoglobinaemia as observed in this study and in 
line with previous reports (Delanghe and Langlois, 2001, Constans et al., 1981, 
Allison et al., 1958, Carter and Worwood, 2007).
The absence of correlation between HPx and free-haem in the severe 
malaria disease groups could be due to the proposed endothelial sequestration of 
haem (Balia et al., 1993, Balia et al., 2005, Camus et al., 2015).
An inverse correlation between HPx and free-haem that only exists in the UM 
group and the direct correlation between HPx and Hp in the UM, SEVM and CM 
groups that are absent in the SMA group is due to the naturally low Hp and 
suboptimal HPx level in the SMA group. This lower than normal levels of both Hp 
and HPx predisposes to SMA.
The significant positive correlation between HPx and PD in the SMA is an
indication that they both increase together. We propose that the increase in PD
triggers HPx expression via the release of free-haem by parasite action on the
erythrocytes. However, the suboptimal level of HPx in the SMA group exacerbates
the pathological process. The increasing PD also seems to trigger the expression
of CD 163 receptors, which could accounts for the significant positive correlation
between both of them in the UM and SMA groups. The CD163 receptors are also
likely to be involved in the direct endocytosis of both free-haem and fHb
particularly in the event of low Hp level as in the SMA group. Both the uptake of
free-haem and fHb by CD163 receptors leads to subsequent shedding of the
receptor as sCD163. The sCD163 released is also involved in the binding of fHb
(Madsen et al., 2004), which could again account for the observed positive
correlation between fHb and sCD163 in the SMA group. The correlation between
sCD163, fHb and Hp in the DC group reveals the supposed homeostatic
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mechanism and the deviation from this as observed in malaria contributes to 
disease severity.
The increasing level of free-haem at the recovery phase as HPx levels 
returns to normal could be due to erythrocyte turnover rather than a consequence 
of the pathology.
A more precise way of malaria diagnosis and monitoring response to 
treatment is to measure the levels of HPx in tandem with free-haem levels. This 
approach could also be used in parallel with MRDTs, microscopy and clinical 
observation in a district laboratory in order to properly discriminate among the 
clinical malaria syndromes at acute onset.
7.5.2 Plasma sCD163 as a marker for malaria prognosis
Plasma sCD163 level is a useful measure to monitor macrophage activation 
in inflammatory conditions (Dige et al., 2014, Kjaergaard et al., 2014). The 
expression of CD 163 on the surface of monocytes is accompanied by increasing 
sCD163 (Cunnington et al., 2012).
The high level of sCD163 in the UM group at onset and the increase in 
levels from PDO to PD7 in both the UM and the SEVM groups during treatment 
might likely indicate an onset of the recovery phase and appropriate response to 
the treatment. Treatment appears to reactivate the action of the macrophages 
during the recovery phase through an as yet unknown mechanism. However, the 
immunomodulatory effects of anti-malarial drugs have been reported (Zhao et al., 
2012). The recruitment of monocytes and macrophage activation are essential for 
the clearance of malaria parasites (Chua et al., 2013a), which probably include 
those parasites that are killed by drug action.
Furthermore, sCD163 is known to have anti-inflammatory and cytokine-like 
functions and was reported to be associated with the healing phase of
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inflammatory process (Zwadlo et al., 1987, Van Gorp et al., 2010, Sulahian et al., 
2004, Moestrup and Moller, 2004, Frings et al., 2002). Therefore the stage at 
which it is expressed at a higher level could mark the onset of an anti-inflammatory 
response and the recovery process rather than disease progression. Therefore, 
day 7 when the sCD163 level peaked is the onset of the recovery phase in the UM 
and the SEVM groups unlike PD14 in the CM group following drug treatment. The 
subsequent decrease of sCD163 to normal level in the UM group post PD7 is a 
sign of disease resolution and recovery. This reduced level post PD7 after the 
initial increase may be considered as a marker of effective malaria therapy.
Unlike the pattern in the other malaria groups, the lower level of sCD163 in 
the CM group at recovery could be a predisposing factor to CM. This low level in 
CM is neither due to fHb or Hp level. As proposed earlier in chapter 4, we 
considered the level at full recovery as comparable to the levels prior to the 
disease. The stable levels of sCD163 at onset and through convalescence to 
recovery in the SMA groups indicate poor macrophage activation and it is likely to 
be a predisposing factor for the onset of SMA.
An elevated level of sCD163 is associated with protection from malaria and 
delay of disease onset (Perdijk et al., 2013, Kusi et al., 2008). Therefore, the more 
drastic CM episode as reported (Pasvol, 2005, Idro et al., 2010) could be tightly 
linked to the suboptimal sCD163 level.
7.5.3 Plasma CLU level is a specific marker for CM at onset.
We show that low plasma CLU is tightly associated with the 
pathophysiology of CM at acute onset and discriminates CM subjects from other 
malaria syndromes and those with closely related syndromes such as convulsion, 
anemia and coma: the DC. We propose that high levels of plasma CLU are 
needed to enhance the recovery process in the CM group. Furthermore, the
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depleted plasma CLU level in the CM group at onset discriminates this group from 
other severe malaria groups. Its increasing level with patient recovery is indicative 
of a better prognosis in the CM group.
The protective role of plasma CLU at the onset of CM may be linked to its 
functions that are tightly related to the pathophysiology of CM. One major CM 
pathophysiology is thought to be due to mechanical obstruction of the cerebral 
microvasculature by infected red blood cells (RBC) and neurological dysfunction 
due to blood-brain barrier permeability that allows parasite product access to the 
brain (Polimeni and Prato, 2014). Hence, CM is characterized by neurological 
dysfunction and encephalopathy-like syndrome such as psychosis, headache, 
seizure and coma (Newton and Warrell, 1998, Gitau and Newton, 2005, Polimeni 
and Prato, 2014).
Plasma CLU has been reported to accumulate at fluid-tissue boundaries 
where it carries out a cyto-protective role. It could act either as a surface bound or 
diffusible form to protect membranes (Wilson and Easterbrook-Smith, 2000). As a 
result of this, its biologic function at the blood brain barrier and regions of 
membrane attack due to parasitized RBC cytoadherence and sequestration is 
more likely.
Plasma CLU is known to prevent neurodegenerative disorder, a hallmark of 
CM. CLU’s primary source of secretion is neural cells (Nuutinen et al., 2009, 
Sokolowski and Mandell, 2011), and it is involved in repair and replacement of 
nervous system cells that have lost the ability to regenerate (Jones and Jomary, 
2002, Nuutinen et al., 2009, Sokolowski and Mandell, 2011).
The primary function of CLU is to promote cell clustering (Shafie et al., 2014), 
which could be important in the recruitment of cells such as phagocytic cells to 
sites of parasite sequestration. CLU itself is known to have phagocytes like 
function in cells exposed to cellular debris (Bartl et al., 2001). It also functions as a
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chaperone, plays a role in maintaining stressed protein in a stable folded state, 
serves as an extracellular heat shock protein and protects cells from heat and 
other stressful stimuli (Wilson and Easterbrook-Smith, 2000, Michel et al., 1997, 
Luo et al., 2005).
Plasma CLU is reported to function as an anti-oxidant and is likely to 
prevent cellular apoptosis and enhance viability (Wang et al., 2014b, Luo et al., 
2014, Zhang et al., 2014). Its antioxidant role is closely linked to the prevention of 
cellular senescence caused by cellular stress and induced DNA damage (Luo et 
al., 2014).
Conditions of stress such as hypoxia and cellular damage that are typical of 
CM (Clark et al., 2006) are known to induce the expression of CLU to prevent 
cellular apoptosis (Jones and Jomary, 2002, Trougakos and Gonos, 2009, Reddy 
et al., 1996, Wang et al., 2014b, Luo et al., 2005) through its interaction with the 
pro-apoptosis protein, Bax (Zhang et al., 2005, Kim et al., 2012b). CLU gene 
knock out in human cells causes a significant reduction of cellular growth and a 
higher rate of apoptosis (Trougakos et al., 2004).
CLU also plays a role in the prevention of inflammation: mice deficient in 
CLU are reported to have severe inflammation (McLaughlin et al., 2000). 
Complement deposition is known to be involved in clearance of infected RBC in 
CM (Eisenhut, 2015, Poh et al., 2014) and plasma CLU is known to function as a 
complement inhibitor (Nuutinen et al., 2009, Sokolowski and Mandell, 2011, Jenne 
etal., 1991, Jenne and Tschopp, 1992).
Interestingly, recent studies have implicated Matrix Metalloproteinases
(MMPs) in the pathology of CM. These MMPs play several roles in the
development of CM, for example they bind to a large repertoire of substrates and
induce an imbalance between homeostatic molecules, increase pro-inflammatory
responses, and enhance blood brain barrier permeability by disrupting the
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endothelial junction (Polimeni and Prato, 2014). Several antimalarial drugs, such 
as chloroquine and artemisinin and its derivatives are known to either reduce 
expression or circulatory levels of several MMPs (Lesiak et al., 2010, Buommino et 
al., 2009, Wartenberg et al., 2003, Polimeni and Prato, 2014). At present, broad 
spectrum and/or specific MMP inhibitors are being sought as an adjunct therapy in 
CM (Polimeni and Prato, 2014). CLU is known to act as an MMP inhibitor. It binds 
very strongly to MMP-9, MMP-2, MMP-3 and MMP-7 and inhibits their enzymatic 
activity (Jeong et al., 2012).
The low plasma level of CLU correlates with the high IL-6 level at onset 
while the high CLU level at recovery correlates with IL-10 level. We therefore 
propose that the late expression of IL-10 and continuous expression of both IL-6 
and IL-8 could exacerbate the pathology of CM by decreasing the level of CLU. 
The correlation between IL-6, IL-10 and plasma CLU levels in the CM group is 
opposite to that in the SMA group and both appear to be regulated over time. This 
result is consistent with reports that the roles of cytokines in malaria are tightly 
regulated (Burte et al., 2013, Xu et al., 2013, Noone et al., 2013, Robinson et al., 
2009).
In conclusion, we show that HPx levels discriminate between all the clinical 
malarial disease groups and between clinical malaria syndromes and the DC 
group at onset. Changes in the levels of HPx and free-haem through 
convalescence may be used as a prognostic marker during appropriate treatment. 
Plasma sCD163 levels can also be considered as a prognostic marker in malaria 
as well as the marker for effective malaria therapy, particularly in the UM group. 
We suggest that low and stable level of sCD163 could predispose to CM and SMA  
respectively. Importantly, we show that low plasma CLU level is a specific marker 
for CM and therefore suggest that parenteral administration of CLU may enhance 
recovery from CM and prevent its associated neurological sequelae such as
severe neurological injury (McGuire et al., 1994), and epilepsy (Christensen and 
Eslick, 2015, Serghides et al., 2014).
Finally, we show that insight into malaria disease progression and recovery 
can be achieved by monitoring underlying differences that are associated with the 
pathophysiology of UM in comparison to those of severe malaria syndromes.
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CHAPTER EIGHT
8.0 FINAL DISCUSSION
Malaria illness exhibits different clinical syndromes at presentation. While 
some develop just UM, others develop more severe forms such as SMA, CM, 
respiratory distress and hypoglycemia. In this study we showed the likely 
underlying pathophysiology and genetic factors that are associated with the acute 
or insidious onset of SMA.
As earlier mentioned in the Introduction, several mechanisms underlying 
the pathophysiology of SMA have been suggested. Though there are 
controversies regarding the appropriate models to test for these mechanisms 
(Craig et al., 2012), they appear to be linked to the pathology of severe malaria in 
general. However, there is no distinction as to which of the mechanism(s) is (are) 
commonly associated with a given severe malaria syndrome and whether these 
mechanisms are dependent on individual host factors or differences.
Most often than not, general mechanisms underlying the pathophysiology of 
severe malaria are presented without a drill down to specifically understand the 
pathophysiology of a given malaria syndrome such as SMA. This generalization 
could lead to wrong assumptions. For example, malaria associated intravascular 
haemolysis could be linked to low plasma Hp level but it is not right to assume that 
low plasma Hp level is a consequence of intravascular haemolysis.
Lack of properly stratified and clinically defined syndrome-specific based 
study could be linked to some failure or poor assessment of adjunct therapy in 
terms of benefit or harm (Cunnington et al., 2013). The different responses to 
malaria infection that manifested as syndromes could be the result of certain 
individual or host factors. Hence, stratification along such lines could be important.
In this study, samples are collected based on specific malaria syndromes.
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In addition, we stratified samples based on Hp isoforms; a protein that is tightly 
linked to inflammatory and haemolytic disease such as malaria. This is because 
Hp is one of the important proteins expressed early in the pathophysiology of 
malaria that could set the stage or regulate other downstream homeostatic 
processes. Apart from its immunomodulatory functions as previously mentioned in 
the Introduction, it appears to set the stage for other proteins that might be 
implicated midstream and downstream in the infection stages such as markers of 
oxidative stress, CD163, HO-1, HPx, bilirubin, ferritin and cellular signals.
Importantly, we hypothesized that insight into acute onset and malaria 
disease progression and/or recovery can be achieved by monitoring the underlying 
pathophysiology of UM in comparison with those of other severe malaria 
syndromes at acute onset and through convalescence to recovery.
8.1 Likely mechanism(s) that could restricts infection to the UM.
Understanding the pathophysiology that could restrict malaria infection to 
the UM is important in order to understand the anomalies that are associated with 
the onset of the severe forms.
Aside from the genetic differences, these studies have shown that early 
response of Hp, HPx and sCD163 is very important and could restrict the infection 
to UM. The parallel increase in plasma levels of Hp, HPx and sCD163 and an 
effective homeostatic process between both Hp/fHb and HPx/free-haem could 
protect from severe forms of malaria. This is because low levels of both HPx and 
Hp could cause impairment in the scavenger-receptor pathways as well as other 
downstream homeostasis processes that are important towards recovery. The 
level of sCD163 could also be important in limiting disease progression but more 
effectively in the presence of Hp and HPx. This is because the protective role of
sCD163 is enhanced and supported by both Hp and HPx. The null or low level of
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plasma Hp affects the capacity of HPx to scavenge the free-haem overload. This 
becomes more complicated in individuals with suboptimal levels of both sCD163 
and HPx as determined by ELISAs.
Furthermore, enhanced and early clearance of both fHb and free haem by 
scavenger-receptor mediated endocytosis has both anti-inflammatory and anti­
oxidant effects as a result of the downstream by-products of the process such as 
sCD163, bilirubin, Fe2+ and CO. The sCD163 has anti-inflammatory roles that 
could restrict the infection; the Fe2+ is important in red cell iron turnover and 
erythropoiesis while the Fe2+/ferritin confers cytoprotection (Otero et al., 2009, 
Lanceta et al., 2015). Interaction between sCD163 and IgG protects against the 
oxidative effect of Hb as recently suggested (Subramanian et al., 2013).
Finally, low parasite biomass or density could restrict the infection to UM 
rather than the severe forms except when there are other underlying conditions 
such as genetic factors and low or dysfunctional Hp and HPx level. The parasite 
density and pfHRP in this cohort are higher in the severe malaria groups than the 
UM.
8.2 Low plasma levels of Hp, HPx, CLU and sCD163 predisposes to severe 
malaria
Pathological conditions and/or genetic factor as with plasma Hp levels could 
cause low levels of plasma proteins such as HPx, CLU, sCD163 and Hp. The 
varying levels of Hp, sCD163, HPx and CLU are the common denominator among 
the entire malaria syndromes in this study.
The level of HPx and Hp in the SMA are suboptimal and it’s likely to be 
responsible for the absence of correlation between HPx, free-haem, Hp and fHb in 
the SMA group. We have observed that intravascular haemolysis in the SMA 
group is not higher than in UM and other severe forms of malaria. However,
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clearance of fHb seems to be impaired by low/null Hp and suboptimal HPx level in 
the SMA group. Results from the previous chapters have shown that this low level 
of Hp through convalescence and in the absence of higher haemolysis in the SMA 
group as compared to other malaria groups are likely to be genetic. The lower 
level of Hb in the SMA is not attributable to higher intravascular haemolysis but 
could be rather due to an enhanced clearance of both infected and uninfected 
erythrocytes by the spleen as previously mentioned in chapter 4. However, the 
reason behind this enhanced erythrocyte clearance in the SMA group compared to 
other disease groups is as yet not clear but previous reports had suggested that it 
could be linked to certain types of complements proteins as mentioned previously 
in the Introduction.
HPx is known to be recycled during haem metabolism and it’s not expected 
to be depleted. Though high PD is a contributory factor to the development of 
severe forms of malaria, it appears not to be responsible for the suboptimal levels 
of HPx in both the CM and the SMA group. For example, the PD in the CM and 
SMA are not different to that of the SEVM group. Also, both CM and SMA have 
lower free-haem levels compared to the SEVM group yet their HPx levels are 
lower compared to levels in the SEVM group at PD28 (Fig. 7.1 B and D). The lower 
level of HPx with convalescence in the SMA group does not appear to be 
associated with age. Therefore, the suboptimal HPx level in the SMA and CM 
groups at PD28 could constitute a risk factor rather than being a consequence of 
haem overload.
The expression of both Hp and HPx upstream of the infection process is 
determinant factor as to how the infection progress. Impairment of both Hp and 
HPx leads to accumulation of fHb; free haem; tissue damage; organ failure 
(Ferreira et al., 2008) and impaired sCD163 and HO-1 functions, which are tightly
linked (Cunnington et al., 2004, Cunnington et al., 2012).
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Furthermore, the stable level of sCD163 with convalescence in the SMA 
and the lower than normal level of sCD163 associated with the CM at PD28 
constitute poor prognosis in both the SMA and the CM respectively,
The low plasma CLU level uniquely associated with the CM at acute onset 
not observed in other malaria syndromes might likely explain the development of 
CM in some subjects instead of SMA.
8.3 Haptoglobin phenotypes modulate response to malarial infection
The differences in the pathophysiology of severe malaria syndromes are 
linked to differences in Hp phenotypes and could be accountable for some 
contradictory reports in the studied subjects.
In this study, aside from clinically defined syndromes of malaria, we further 
sub-classified each syndrome into the 3 sub-categories based on the major Hp 
phenotypes. Both the ‘slow and fast’ Hp sub-phenotypes as previously described 
(Connell et al., 1966, Koch et al., 2003), were not considered, as the entire 
population have the same sub-phenotype of Hp.
Hp phenotypes have been reported to be associated with several non- 
infectious and infectious diseases including malaria. But it was not known if 
malaria associated pathophysiology are dependent on Hp phenotypes.
Plasma level of Hp and HPx tend to decrease with increase in PD in 
individuals with the Hp1 allele but increase with increase in PD in the Hp2 allele. 
Also, the low level of Hp in the SMA is more pronounced in the Hp1-1 phenotype. 
These are important in determining the pathological equation of the disease. The 
duration from the onset of the disease to recovery appears to be associated with 
Hp phenotypes; inflammation as indicated by CRP levels is easily resolved in SMA  
subjects with Hp1-1 and Hp2-1 but not Hp2-2 and subjects with Hp2-2 but without 
SMA and vice versa. Inflammation, oxidative stress and cytokines imbalance in
clinical malaria syndromes are divided along the lines of Hp phenotypes and are 
unlikely to be entirely involved at the same time within a given malaria 
pathophysiology.
Hp phenotypes appear to modulate the plasma levels of markers of 
intravascular haemolysis, oxidative stress, macrophage-associated chemokines 
and both pro/anti-inflammatory cytokines in clinical malaria. The levels of these 
plasma proteins are dependent on both the malaria and Hp phenotypes and are 
likely to explain the differences in malaria pathophysiology and disease severity.
Individuals with different Hp phenotype and presenting with the same 
malaria syndrome elicit different responses and vice varsa. Some likely 
physiological pathway to disease progression from mild to severe malaria or onset 
of severe syndromes within a given Hp phenotype could be deduced from the 
difference between the mild malaria to severe malaria syndromes as highlighted 
below.
8.3.1 Comparing UM to severe forms in Hp1-1 subjects
The depleted circulatory levels of Hp, IL-6 and higher circulatory levels of LDH, IL-
8 and MIP-p (CCL4) in the SEVM subjects compared to the UM subjects are the
major pathophysiology difference between uncomplicated malaria and respiratory
distress in subjects with Hp1-1 phenotype. Elevated plasma CCL4 was reported in
severe malaria (Perkins et al., 2011) while another report indicated that the level
is also elevated in mild malaria as well (Ochiel et al., 2005). However, we
observed that the level of CCL4 in malaria seems to vary with both Hp and malaria
phenotypes rather than being restricted to either the UM or the severe forms.
While the plasma CCL4 is high in the SEVM group with Hp1-1 and 2-2, its levels is
lower in the SEVM subjects with Hp2-1 as in the mild or uncomplicated malaria.
Depleted circulatory plasma levels of Hp, stable MCP-1, higher LDH, early and
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stable IL-8, high and stable level of fHb and low and stable level of sCD163 are 
found in the CM compared to the UM in subjects with Hp1-1 phenotypes. Several 
reports have associated high IL-8 with disease severity (Lyke et al., 2004, Bostrom 
et al., 2012, Mahanta et al., 2015), but it rather seems to be tightly linked to Hp 
phenotypes.
Null/low and stable levels of Hp, depleted level of CLU and lower IL10:IL-6 
at onset in the SMA differentiates it to UM in subjects with Hp1-1. The imbalance 
between pro-inflammatory and anti-inflammatory cytokines through excessive 
production of IL-6 and IL-10 is more associated with Hp1 allele in the SMA group. 
The UM group have lower plasma Hp, SOD-1, IFN-y and higher plasma LDH, 
CRP, IL-6, IL-10, and MCP-1 compared to the CC in subjects with Hp1-1.
8.3.2 Comparing UM to severe forms in Hp2-1 subjects
❖ Higher levels of LDH and low IL-10:IL-6 ratio differentiate SEVM from the 
UM in Hp2-1 subjects. However, the UM2-1 has higher CRP compared to 
the SEVM2-1.
❖ Depleted Hp, CLU, higher LDH and continuous expression of both IL-6 and 
IL-10 (low IL-10:IL-6) at onset differentiate CM from UM in Hp2-1 subjects.
❖ The SMA subjects with Hp2-1 have a very high level of SOD-1, G-CSF and 
low IL-10:IL-6 ratio at acute onset compared to UM subject with the same 
phenotype.
❖ Lower levels of IL-6, IL-10, and higher plasma IL-10:IL-6 and IFN-y 
differentiate UM from CC in subjects with Hp2-1 phenotype.
❖ High plasma level of CLU and lower plasma levels of MCP-1, IL-6, and IL- 
10 in the UM differentiate them from the CC.
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8.3.3 Comparing UM to severe forms in Hp2-2 subjects
❖ Lower Hp, IL-10:IL-6, IL-17 and higher levels of LDH, CRP and MIP-1B are 
associated with SEVM at onset compared to the UM in Hp2-2 subjects.
❖ Lower Hp, CLU, IL-10:IL-6 and higher LDH and CRP are associated with 
CM at onset compared to the UM in subjects with Hp2-2.
❖ Lower Hp, SOD-1 and CLU at acute onset and high IL-8 and GM-CSF at 
recovery differentiate SMA from the UM in subjects with Hp2-2.
Importantly, while the plasma proteins in the CC group do not show any
major difference with Hp phenotypes that of the DC does. High plasma level of IL- 
17 and GM-CSF are associated with DC2-2 and high plasma level of both G-CSF 
and Hp are associated DC2-1 group while high LDH level is a hallmark of DC1-1 
group.
Oxidative stress and cytokine imbalance appear not to play a role in the 
pathology of SMA in Hp2-2 patients unlike SMA in patients with Hp1 allele as was 
previously discussed in chapter 5.
8.4 Differentiating SMA from other severe haemolytic anaemia
We observed that the pathophysiology of severe anaemia in malaria is 
different to that of parasite negative severe anaemia of other aetiology (DC). While 
the low level of Hp in the DC is a consequence of haemolysis that of SMA is 
majorly congenital and could be a risk factor for acute onset of SMA. Also, there is 
a likely receptor-mediated uptake of fHb by CD163 in the DC while the process 
seems impaired in the SMA group. While low Hb level in the DC could be linked to 
intense intravascular haemolysis; that of SMA could be due to enhanced 
clearance of both infected and uninfected erythrocyte by the spleen.
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8.5 Host genetic factors and severe malaria
Host genetic factors can confer susceptibility or protection to severe 
malaria. As earlier mentioned in Chapter 6, sequence variants at both distal and 
proximal upstream regions of the translational start site on Hp gene could confer 
susceptibility or protection to severe forms of malaria. Some of these variants 
determine the progress of the disease more than any anomalies in the 
pathological process. For example, the low plasma Hp level predisposes to SMA 
but the presence of the g.-49A/C genotype for the variant, g.-49A>C, which is 
associated with the reduced level of Hp protects from SMA. The g.-49A>C variant 
is linked to the contradictory report (Cox et al., 2007) regarding the plasma Hp 
levels and susceptibility or protection to malaria. The g.-1203 is also associated 
with severe malarial anaemia and plasma Hp levels.
We observed that several deletions at the distal upstream region of the Hp 
gene confer significant protection to SMA. Genotypes from variants at both the 
proximal and distal upstream regions of Hp gene show significant association with 
the various malaria syndromes.
Genotypes that are associated with Hp levels determine the susceptibility 
rate of Hp phenotypes to SMA. Congenitally low/null plasma Hp level as reported 
in this study is a predictor of whether or not a child with uncomplicated malaria will 
go on to developing an SMA episode in the clinic.
We have shown that the pathology of malaria, particularly the severe forms 
are tightly linked to Hp gene sequence variants despite indications that it could be 
equally important in other diseases. Hp genotypes show different frequencies with 
geographical region and ethnic groups. It therefore appears that these differences 
in Hp genotype with geographic location could be responsible for the contradictory 
report on malaria pathophysiology in different regions.
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8.6 Potential biomarkers of clinical malaria syndromes
Biomarker discovery is very important in order to enhance quick and 
accurate diagnosis and prognosis. A major problem in biomarker discovery, 
particularly in severe malaria is due to overlapping pathophysiology manifested as 
syndromes.
Plasma CLU, a protein that is rarely reported in malaria could have 
application as a biomarker of CM. CLU levels in CM subjects are uniformly low at 
acute onset independent of the individual Hp phenotypes unlike in the SMA, UM 
and SEVM groups. Low levels of CLU appear to be linked to onset of CM.
The steady rise in plasma HPx levels in clinical malaria as earlier stated in 
Chapter 7 could have an application as a prognostic biomarker in malaria in 
predicting response to treatment. Changes in the levels of sCD163 at early time 
points during treatment could mark the onset of recovery.
8.7 Concluding remarks
This study was able to address the research questions as mentioned in 
Chapter 1. We show that intravascular haemolysis in the SMA is not higher than in 
other malaria syndromes and low/null Hp level is likely to be a risk factor for 
malaria and its severe forms rather than being a consequence of haemolysis. 
Furthermore, previously unknown variants at the proximal and distal upstream 
region of Hp gene were shown to have association with plasma Hp levels and/or 
disease.
The pathophysiology and response to malaria infection is modulated by Hp 
phenotypes. Individuals presenting with the same malaria phenotypes could mount 
different responses that are based on their Hp phenotypes. Therefore, difference 
in Hp phenotypes could explain some of the contradictory reports on the 
pathophysiology of malaria.
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Hp is one of the important proteins elicited upstream of the infection stage 
in the pathology of malaria and appears to indirectly regulate the role of other 
midstream and downstream proteins.
This study further reveals the association between low plasma CLU level 
and CM at acute onset and the potential of HPx in predicting response to 
treatment.
The findings described here are particularly important in district clinics in the 
sub-Saharan region of Africa where malaria is holoendemic and both trained 
physicians and clinical scientists are largely absent.
8.8 Future Work
❖ We hypothesized that some kind of interaction at the distal and proximal 
upstream region of the Hp gene (~3.4kb) are involved in susceptibility to 
severe malaria, which needs to be investigated in a mechanistic study. 
There is a need to further understand the expression of Hp gene in terms of 
studying the transcription factors and some likely proteins that could interact 
with the proximal and the distal promoter region of the gene.
❖ Since Hp appears to modulate response to malaria infection, there is need 
to further study the immunomodulatory functions of the different Hp 
phenotypes in malaria. The association between Hp phenotypes and 
cytokines at acute onset of malaria needs to be studied in all the clinical 
presentations of malaria. Plasma cytokine levels, inflammation and 
oxidative stress appear to be divided along the lines of Hp phenotypes and 
are likely to be important for protection or susceptibility to severe forms of 
malaria.
❖ A mechanistic study is required to further investigate the role of plasma 
CLU in malaria particularly CM. Further study is required to test for the
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biologic functions of CLU in line with the proposed mechanisms underlying 
the pathology of CM as proposed in this study. The therapeutic value of 
CLU in malaria also needs further investigation.
❖ There is need to investigate the possible glycosylation pattern and its role in 
malaria in both the (3 and a-chains of Hp. In Fig. 3.1C-D, four spots labeled 
as 3, 4, 5 and 6 with slightly different PI and molecular weight were 
identified as Hp (Fig. 3.2C) and two spots, 9 and 10 were identified as Hp 
a-2 chains (Fig. 3.2D). We observed that spot 3 (Fig. 3.2C) is very faint in 
the entire clinical groups while spot 6 appears to be more expressed in the 
UM than the CC. Both spots 9 and 10 of the a-2 chain are depleted in the 
SMA group but only spot 10 is depleted in the CM group (Fig. 3.2D). All 
these spots were identified as Hp by mass spectrometry (Table 3.2). We 
proposed that glycosylation is more likely to explain the slight differences in 
the pi and molecular weight of the Hp spots and their different levels of 
expression could likely indicate different roles in malaria. A study in Non­
small Cell Lung Cancer patient had reported similar spots of a-2 chain with 
a isoelectric point (pi) of about 5.95 and 5.65, which gave a strong positive 
signal with fluorescein labeled WGA (Wheat Gel Agglutinin) and could 
indicate possible glycosylation with sialic acid and/or N-Acetylglucosamine 
(Everaert et al., 1998a). Hp is widely reported in many diseases and its 
functions are likely to be affected by their glycosylation pattern. Sialylated 
glycoprotein has been reported to mediate binding between Hp and mature 
B-cell expressing CD22 (Powell et al., 1993, Hanasaki et al., 1995).
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